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Abstract 
 Non-Hodgkin’s lymphoma is the fifth most common cancer in the UK, 
accounting for 4% of all new cases. The control of lymphomagenesis still remains a 
challenge. Early growth response gene (Egr) 2 and 3 are zinc finger transcription 
factors. Egr2 plays an important role in the development of both central nervous 
system and lymphocytes. However the mechanism of action in lymphocytes is still 
unknown.  
 In order to fully understand the function of Egr2, in lymphocytes, we 
developed Egr2 and 3 double knockout mice (Egr2-/-Egr3-/-) by crossbreeding 
lymphocyte specific Egr2 knockout mice (CD2-Egr2-/-) with Egr3 knockout mice 
(Egr3-/-), as previous reports suggested that Egr3 compensates for the role of Egr2. 
In the absence of Egr2 and 3, the homeostasis of T cells is dysregulated with hyper-
homeostatic proliferation of effector like phenotype cells. More importantly the 
development of spontaneous B and T cell lymphoma was found in more than 70% 
of Egr2-/-Egr3-/- mice. The lymphoma cells from Egr2-/-Egr3-/- mice were highly 
proliferative and metastatically spread into other non-lymphoid organs, such as 
lung, liver and kidney. In additional to this lymphoma development the Egr2-/-Egr3-/- 
mice showed signs of chronic inflammatory disorder. This inflammatory disorder 
was characterised by glomerulonephritis and an increase in serum cytokines, which 
may provide the microenvironment for the lymphoma development. 
To explore the molecular mechanism of tumour development in 
Egr2-/-Egr3-/- mice, the transcriptional profile of Egr2 was studied by microarray and 
ChIP-on-chip. We found firstly that Egr2 directly binds to the promoter regions of 
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Ikaros and FOXO3. The deletion of Egr2 and 3 in lymphocytes led to the 
downregulation of Ikaros, Aiolos and FOXO3 expression. The impaired expression 
was found to be associated with proliferative disorder and the development of T 
and B cell lymphoma. Secondly Egr2 strongly inhibits STAT3 transcriptional activity 
by regulating SOCS3, which is a known inhibitor of STAT3. The breakdown of this 
regulation could be an important mechanism in lymphomagenesis. 
 A model is proposed which defines Egr2 and Egr3 as the backbone of 
important tumour suppressor genes that control cell fate decision and regulates 
homeostasis in the lymphoid system. Thus, our results suggest that Egr2 and 3 are 
important regulators of lymphocyte function by their involvement in multiple cell 
signalling pathways, which could potentially be key genes for future cancer therapy. 
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Cancer is one of the most common diseases in the world. In the UK around 
424,128 new cases of cancer were diagnosed in year 2010, and more than 1 in 3 
people will develop some form of cancer during their lifetime (CancerResearch 
2011). The incidence rate for cancer in Great Britain, alone, has increased by 26% 
between 1979 and 2008.  There are many types of cancers, around 200 different 
types, but five of them – breast, lung, colorectal, prostate and non-Hodgkin’s 
lymphoma  account for over half (58%) of all new cases (CancerResearch 2011). 
  
1.1  Hallmarks of Cancer 
In the past 20 years an enormous progress has been seen in our 
understanding of cancer at molecular level; resulting in a large number of exciting 
new targets for the development of efficient therapies for treatment. Every cancer 
has different features, which depend on the origin of the cancer cell. However the 
end result is the same. In 2000, Hanahan and Weinberg defined six hallmarks of 
most if not all cancers, which established the logical framework for understanding 
the astonishing diversity of cancer development (Hanahan and Weinberg 2000). A 
decade later, Hanahan and Weinberg proposed further four emerging hallmarks 
(Hanahan and Weinberg 2011), that further explained other factors contributing 
towards cancer growth (Figure 1.1).  
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Figure 1.1: Hallmarks of Cancer, adapted from (Hanahan and Weinberg 2000). 
The six hallmarks of cancer are illustrated here in conjunction with two enabling 
characteristics. Activation of oncogene, suppression of tumour suppressor genes, 
destruction of apoptosis, limitless replication, metastasis and angiogenesis were proposed 
by Hanahan and Weignberg in 2000. In 2010 they added a further two hallmarks, 
destruction of cell metabolism and the evading of the immune destruction. The two 
enabling characteristics are indicated as tumour promoting inflammation and genome 
instability. 
 
Cancer has long been known as a genetic disease. In 1951, Muller suggested 
that a cell must comprise more than one mutation in order to transform into a 
neoplasm (Muller 1951). Since then a number of findings have described that 
cancer is a step-wise process, where the cell acquires different qualities at each 
step, initiating the neoplasm. This has also supported the clonal expansion theory 
of tumour development by Nowell in 1970s, stating that a normal cell which 
acquires a somatic mutation will achieve a growth advantage over adjacent normal 
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cells which eventually leads to clonal expansion (Nowell 1976; Nowell 2002; Sarasin 
2003). 
The normal process by which normal cells become progressively transformed to 
malignancy is known to require the sequential mutations, which arise as a 
consequence of damage to the genome (Bertram 2000). Mutations in the context of 
carcinogenesis can occur in a number of different ways, but using the extensive 
classification these include:  
 
 Point mutations, resulting in an amino acid substitutions; frame-shift 
mutations or mutations to stop codons which either truncate the protein 
product or ascent its sequence. 
 Chromosomal instability or imbalance, resulting in amplification, over-
expression or inappropriate expression of a particular gene. 
 Loss of a gene or its fusion with another gene as a result of chromosomal 
breakage and rearrangement resulting in a chimeric protein with altered 
functions. 
 Epigenetic modifications to DNA of which the most important is the 
methylation of cytosine in CpG islands leading to gene silencing.  
 
Mutations within developing cancer cells have two basic functions: mutations 
which increase the activity of the protein that encourage proliferation, these are 
called oncogenes; or mutations which inactivate genes that suppress cell 
proliferation and growth, hence referred to as tumour suppressor genes. 
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1.2  The Cell Cycle and Cancer development 
1.2.1  Cell Cycle Regulation 
During the life of a cell, it will undergo cell proliferation, which involves the 
reproduction of a cell to form two identical daughter cells. The daughter cells will 
further reproduce themselves into two more daughter cells, and so on. This cyclic 
process is a sequence of stages through which a cell passes between one cell 
division and the next is called the cell cycle (Figure 1.2). The phases of the cell 
growth are the same whether in a tumour cell or in a normal cell. 
  
 
Figure 1.2: Cell Cycle Control. 
There are four stages to the cell cycle; gap phase (G1) before the DNA replication (S phase), 
followed by another gap phase (G2) and the mitotic phase (M phase). The cell cycle process 
is regulated by cyclin dependent kinases (CDK) and cyclin genes. (Taken from: National 
Institute of Health, Appendix A: Early Development. In Stem Cell Information)  
 
  Chapter 1 – Introduction 
 
6 
 
The cell cycle for the eukaryotic cells is composed of four stages; the gap 
phase before the DNA replication (G1), the DNA synthesis phase (S Phase), the gap 
phase after DNA replication (G2), and the mitotic phase, which leads the cell to 
divide (M phase) (Hartwell and Weinert 1989). In addition to the four phases, there 
is a G0 phase, which is an inactive phase outside of the cell cycle. During this phase 
the cells are known to be quiescent, which plays a major part of non-growing, non-
proliferating cells (Vermeulen, Van Bockstaele et al. 2003). Most of the cells in an 
adult are not in the process of cell division but can enter the cell cycle at G1 due to 
mitogens or growth factors. At G2 checkpoint, preceding mitosis, there is also a 
quality control of the cell material, checking the newly synthesised DNA is identical 
to the original DNA and that division occurs equally between the daughter cells 
(Hickman, Moroni et al. 2002). 
The cell cycle is a complex process, which requires a coordination of a 
variety of macromolecular synthesis, assemblies and movement. This shift from one 
cell cycle phase to another is carefully regulated before replication the quality of 
the DNA is checked (G1 phase) (Sandal 2002).  
The cell cycle is mainly regulated by cyclin-dependent kinases (CDK). There 
are a number of regulation mechanisms for the CDKs which ensures that the correct 
timing of kinase activity occurs during the cell cycle. CDKs alone cannot regulate the 
cell cycle but are only active once they have formed a complex with their 
associates, cyclin (Table 1.1). Cyclins were so named due to their expression levels 
oscillating throughout the cell cycle. As the CDKs function at different phases of the 
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cell, they are both negatively and positively regulated during the cell cycle and 
hence provide the driving force for the cell cycle progressions (Sandal 2002). 
 
CDK Cyclin Cell Cycle Phase 
CDK1 (cdc2) Cyclin A G2/M phase transition 
CDK1 (cdc2) Cyclin B Mitosis 
CDK2 Cyclin E G1/S phase transition 
CDK2 Cyclin A S phase 
CDK4 Cyclin D1, D2, D3 G1 phase 
CDK6 Cyclin D1, D2, D3 G1 phase 
 
Table 1.1: CDK/cyclin complexes at different phases of the cell cycle Adapted from 
(Sandal 2002). 
 
1.2.2  Inhibitors of CDK 
The regulation of the CDK/cyclin complexes is highly monitored due to the 
proteins expressed at different stages of the cell cycle. The CDKs and the cyclins are 
regulated by many different proteins, such as CDK inhibitors (CKI), some of which 
are p21CIP/KIP, p27cip/kip and p16INK4a. The CKI mediate cell cycle arrest in 
response to several anti-proliferative signals (Kaldis, Pitluk et al. 1998).  
The cell cycle control is also maintained by other genes known as the proto-
oncogenes and tumour suppressor genes. The activation of one and the evasion of 
the other, respectively are key hallmarks of cancer development. 
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1.2.3  Self-Sufficiency in Growth Signals 
The most fundamental trait of cancer cells involves their ability to sustain 
chronic proliferation. Normal tissues maintain homeostasis of cell number by the 
careful production and release of growth promoting signals that instruct entry into 
and progression through the cell growth and division cycle. Proto-oncogenes are 
involved in the process of regulating proliferation, cell cycle progression and 
apoptosis. The proto-oncogenes become activated (oncogenes) by one of the 
means of mutations described earlier, which leads to the deregulation of cell 
growth. Distinct oncogenes have been specifically associated with the different 
subtypes of non-Hodgkin’s lymphoma (Anderson, Reynolds et al. 1992). Table 1.2, 
summarises the oncogenes activated in some of the non-Hodgkin’s lymphoma. 
 
Oncogene/Pathway NHL subtype. 
Bcl-2 
Follicle Lymphoma, Diffuse large B-cell 
lymphoma 
Cyclin D1 Mantle cell lymphoma 
c-Myc Burkitt lymphoma 
NF-kB 
MALT lymphoma, diffuse large B-cell 
lymphoma 
Bcl-6 
Diffuse large B cell lymphoma, follicular 
lymphoma 
 
Table 1.2: Oncogenes which are activated in different types of  lymphoma 
Adapted from Hachem, A and Gartenhaus, R.B 2005 (Hachem and Gartenhaus 
2005). 
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1.2.4  Evading Growth Suppressors 
In addition to the cell capability of inducing and sustaining positively acting 
growth stimulatory signals, cancer cells must also evade powerful programs that 
negatively regulate cell proliferation, which depend on tumour suppressor genes. 
Tumour suppressor genes are normal genes that negatively regulate the cell 
division, repair DNA damage or direct the cells to undergo apoptosis. The 
inactivation of tumour suppressor genes deregulated the cell cycle control and 
leads to cancer. The first tumour suppressor gene discovered was the human 
Retinoblastoma protein (pRb) by Alfred Knudson (Knudson 1971; Knudson, 
Meadows et al. 1976). Over the years many such tumour suppressor genes have 
been identified. The most famous is the p53 gene, known as the “Guardian of the 
Genome” (Lane 1992), where the inactivation of the gene is an almost common 
step in the development of over 50%  of human cancers (Hollstein, Sidransky et al. 
1991).  The tumour suppressor genes are usually defected when the gene is 
inactivated on both alleles, “two-hit” theory (Knudson 1971). Table 1.3 shows a 
number of tumour suppressor genes affected in lymphoma. 
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Tumour Suppressor Gene NHL subtype. 
BRCA1 Diffuse large B cell lymphoma 
BRCA2 T-cell Non-Hodgkin’s lymphoma 
TP53 
Burkitt’s lymphoma, Chronic 
myelogenous leukemia, B cell lymphoma 
IKZF1 
T Cell lymphoma, Acute lymphoblastic 
leukemia, T Cell leukemia 
IKZF3 
B Cell lymphoma, Chronic lymphocytic 
leukemia 
 
Table 1.3: Tumour Suppressor Gene which are deactivated in different types of  
lymphoma Adapted from Skibola, C.F., et al 2007 (Skibola, Curry et al. 2007). 
 
 
1.2.5  Evasion of Apoptosis 
Tissue homeostasis is characterised by the balance between proliferation 
and cell growth versus the cell death. In response to stressful stimuli, the cell 
usually supports a cellular stress response to ensure survival (Kultz 2005; Lockshin 
and Zakeri 2007). Apoptosis, also known as programmed cell death is the cell’s 
intrinsic death program that regulates various physiological as well as pathological 
processes. Apoptosis was initially described by its morphological characteristics, 
including cell shrinkage, membrane blebbing, chromosome condensation and 
nuclear fragmentation (Wyllie, Kerr et al. 1980; Kerr, Winterford et al. 1994; Lowe 
and Lin 2000). There are two major apoptosis signalling pathways, that is, the death 
receptor (extrinsic) pathway and the mitochondrial (intrinsic) pathway (Figure 1.3)  
(Hengartner 2000). 
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The extrinsic pathway is initiated by the binding of an apoptotic-inducing to 
the cell surface death receptors associated with Fas-associated death domain 
(FADD) or tumour necrosis factor (TNF) receptor, respectively (Debatin and 
Krammer 2004). The well-studied death ligands are Fas ligands and TNF ligands, 
which binds to the transmembrane death receptors such as Fas receptor or TNF 
receptor, respectively. Upon ligand binding the FADD become activated and 
interact with initiator enzymes of the caspase cascade, mostly caspase 8 and 10, 
resulting in downstream activation of caspase 3 and 7 (effector caspases) and 
ultimately programmed cellular destruction through proteolytic cleavage of caspase 
substrates (McKenzie and Kyprianou 2006).  
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Figure 1.3: Apoptotic extrinsic and intrinsic pathways (Tait and Green 2010). 
There are two apoptotic pathways; extrinsic pathway, which is initiated by the activation of 
death receptors. The intrinsic pathway is mitochondrial mediated. The permeabilisation of 
the mitochondria releases the cytochrome C into the cytoplasm, activating the caspases. 
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The intrinsic pathway is initiated by internal stress, such as DNA damage, 
lack of growth factors (Okada and Mak 2004). The internal stress signals 
subsequently targets the mitochondrial membrane, leading to mitochondrial outer 
membrane permeabilisation (MOMP). This causes the release of cytochrome c 
(Newmeyer and Ferguson-Miller 2003). The release of cytochrome c into the 
cytosol results in the activation of apoptotic protease activating factor-1 (APAF-1) 
and caspase 9, which form a functional apoptosome that activates the effector 
caspase cascade, resulting in programmed cellular destruction (McKenzie and 
Kyprianou 2006) (Figure 1.3). 
As Hananah and Weinberg defined the characteristics of cancer 
development, they proposed the evasion of the apoptosis as one of the key 
hallmarks and this has been observed in many human cancers. In principle, the 
apoptosis pathways can be blocked at different levels of the signalling cascade by 
upregulation of anti-apoptotic proteins and/or downregulation or dysfunction of 
pro-apoptotic proteins (Fulda 2009). Examples of altered apoptosis signalling 
pathways that contribute to stress resistance in human cancers are: 
Impairment of death receptors is via downregulation of receptor surface 
expression as part of the adaptive stress response. For example, in chemotherapy 
resistance leukaemia, the CD95 expression was downregulated (Friesen, Fulda et al. 
1997). TRAIL is a death receptor which binds to CD95 ligand to induce apoptosis. 
Deletions or mutations, resulting in loss of both copies of TRAIL-R1 or TRAIL-R2 
were detected in small percentage of NHL (Fulda 2009).  
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Caspase 8 has been shown to be transcriptionally regulated by splicing in 
leukaemia and neuroblastoma. The alternative splicing of intron 8 of the caspase 8 
gene results in the generation of caspase-8L, which lacks the catalytic site (Miller, 
Karacay et al. 2006). 
An increase in the ratio of anti- to pro-apoptotic Bcl-2 proteins has been 
detected in a number of cancers and has been related to tumour cell survival and 
apoptosis resistance. For example, overexpression of BCL-2 is a key feature of 
human follicular lymphoma and is caused by the chromosomal transclocation of the 
BCL-2 oncogene into the immunoglobulin heavy chain gene locus (Tsujimoto, Finger 
et al. 1984). 
 
1.2.6  Telomere Length – Limitless Replication 
Telomeres are long stretches of noncoding DNA located at the end of all 
eukaryotic chromosomes (Figure 1.4). In vertebrates the telomeres are composed 
of simple, repetitive non-coding DNA sequences. In human and mouse the 
telomeres contain a six base pair sequence TTAGGG, repeated many thousands of 
times. However, the length of the telomere varies from one chromosome to 
another. The telomere length also varies greatly between species, from 
approximately 300 to 600 bp in yeast (Shampay, Szostak et al. 1984) to kilo bases in 
humans. 
The discovery of chromosomal integrity was proposed by Barbara 
McClintock in 1941. She studies the telomeres in chromosomes from the maize 
plants. She proposed that if the chromosomes ends were broken by various means, 
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then it resulted in adhesion and fusion of their ends, with the consequent 
formation of dicentric chromosomes (McClintock 1941).  
 
 
Figure 1.4: Telomeres located at the ends of all eukaryotic chromosomes. 
The telomere repeats (TTAGGG)n are present at the ends of all eukaryotic chromosomes. 
These telomeres shorten after each cell division. 
 
Two years previous to this finding a young American geneticist Hermann J. 
Muller noticed that the ends of the irradiated chromosomes were different to other 
genome and could not recover terminal deletions from the Drosophila chromosome 
ends. He suggested that the chromosome ends are specialised structures and 
  
  
TTAGGG TTAGGG TTAGGG TTAGGG TTAGGG (TTAGGG) n 
AATCCC AATCCC AATCCC 
Telomere 
Telomere 
Centromere 
Telomere 
DNA repeats 
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named them Telomeres from a Greek term “telos” (End) “meros” (Part)(Greider 
1996).  
A number of scientists have used molecular techniques to confirm the initial 
finding by McClintock, that telomeres are essential for chromosome stability. In 
addition to this finding it has also been shown that telomeres have many other 
critical functions such as: 
 Telomeres also participate in nuclear processes such as chromosome 
positioning in the nucleus (Ferguson and Fangman 1992; Brewer and 
Fangman 1993; Luderus, van Steensel et al. 1996). 
 Regulation of gene expression and transcriptional repression (Sandell and 
Zakian 1993). 
 Cellular senescence (Holt, Wright et al. 1996; Shay and Wright 2005). 
 
The inability of the conventional DNA polymerase to replicate to the end of the 
chromosome during lagging strand synthesis results in 50-200 base pairs to be lost 
from the end of the linear chromosome, during each cell division (Hastie, Dempster 
et al. 1990; Lindsey, McGill et al. 1991). This telomere shortening occurs because 
during DNA replication, the DNA polymerase synthesis DNA in the 5’ to 3’ direction 
with the aid of RNA primers. The leading strand is synthesised continuously and the 
lagging strand to be synthesised discontinuously. The RNA primers are degraded by 
RNase H and the Okazaki fragments are ligated with DNA ligase. However this 
process leaves the 3’ end of the chromosome as a single stranded DNA, called “end 
replication problem” (Olovnikov 1973). If the 3’ end is incompletely replicated, the 
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single-strand DNA is unstable, and this leads to the loss of telomere repeats after 
each replication (Weng, Palmer et al. 1997). 
Therefore telomeres have an important role to play to protect the 
chromosomes from erosion. A study by Olovnikov in 1972 showed that erosion of 
the chromosome ends lead to the loss of essential genes and an exit from the cell 
cycle (Olovnikov 1973). In 1990 it was demonstrated by Harley, C.B, et al , that 
telomere shortening accounts for the process of a ‘cellular ageing’ (Harley, Futcher 
et al. 1990). 
The telomere shortening happens with age or with cell division. It also occurs in 
other types of somatic cells including hematopoietic stem cells, leukocytes, 
endothelial cells (Harley, Futcher et al. 1990; Hastie, Dempster et al. 1990; Lindsey, 
McGill et al. 1991; Chang and Harley 1995). However in contrast, the germ line and 
malignant cells do not appear to undergo telomere shortening with cell division 
(Allsopp, Vaziri et al. 1992). Earlier studies also demonstrated that a significantly 
shorter telomere length in most cancers compared with noncancerous tissue from 
the same patient (Hastie, Dempster et al. 1990). This suggests that human cancers 
and germ line cells have developed a mechanism to overcome the telomere loss 
during cell division. 
 
1.2.6.1 Telomerase 
The telomere stabilisation is achieved by reactivation or upregulation of the 
ribonucleoprotein enzyme telomerase  (Greider and Blackburn 1989). Telomerase is 
an RNA-dependent DNA polymerase, which utilises its RNA as a template for the 
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addition of TTAGGG repeats to the 3’ ends of the chromosomes, therefore 
compensating for losses due to the end-replication problems. It was first discovered 
in Tetrahymena by Elizabeth Blackburn and Carol Greider (Greider and Blackburn 
1985).  
Initially it has been proposed that telomerase is expressed in germ-line and 
malignant cells but not in most somatic cells (Wright, Piatyszek et al. 1996), based 
on the immortality of the germ-line and of malignant cells (de Lange 1994). 
However a number of studies then indicated that telomerase activity is also 
detected in normal somatic cells that have the potential to self-renew themselves, 
such as hematopoietic stem cells (Morrison, Prowse et al. 1996), lymphocytes 
(Weng, Levine et al. 1996; Weng, Granger et al. 1997; Hathcock, Weng et al. 1998; 
Weng 2002) and skin epithelial cells (Harle-Bachor and Boukamp 1996). 
One of the hallmarks proposed by Hanahan and Weinberg in 2000 was the 
limitless replication potential of a cancer cells. Studies have found that cancer cells 
have shorter telomere length due to their capability of intense cell proliferation, 
however this short telomere lengths is maintained with the activation of 
telomerase enzyme. This was supported by Shay and Bacchetti, who observed an 
increase in telomerase activity in majority of human cancers (Shay and Bacchetti 
1997). 
 
1.2.7  Inflammation and Cancer  
A decade after the proposal of hallmarks of cancer by Hanahan and 
Weinberg, they proposed to include two more hallmarks of cancer, with enabling 
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characteristics of tumour promoting inflammation and genome instability and 
mutation (Hanahan and Weinberg 2011). 
Inflammation is a physiological process in response to tissue damage 
resulting from microbial pathogen infection, chemical irritation, and/or wounding 
(Philip, Rowley et al. 2004). In the initial stages of inflammation the neutrophils are 
the first to migrate to the inflammatory site under the regulation of the molecules 
produced rapidly responding macrophages and mast cells in tissues (Nathan 2002). 
As inflammation progresses, various types of leukocytes, lymphocytes and other 
inflammatory cells are activated and attracted to the inflamed site by a signalling 
network involving a great number of growth factors, cytokines, and chemokines 
(Nathan 2002). 
There are also control mechanism in place that prevent inflammation, a 
number of molecules in the body play dual roles of both promoting and suppressing 
inflammation, such as transforming growth factor-β (Lu, Ouyang et al. 2006). The 
balance between promoting and suppressing inflammation is strictly regulated, if 
however the inflammation process is dysregulated and becomes favoured towards 
promoting inflammation, then the cellular response changes to the pattern of 
chronic inflammation. 
However the link between inflammation and cancer was observed as early 
as 1863 by Virchow, who indicated that cancers tended to occur at sites of chronic 
inflammation (Balkwill and Mantovani 2001). Epidemiologic studies have also 
supported that chronic inflammatory diseases are frequently associated with 
increased risk of cancers (Lu, Ouyang et al. 2006). The development of cancers from 
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inflammation might be a process driven by inflammatory cells as well as a variety of 
mediators, including cytokines, chemokines, and enzymes, which altogether 
established an inflammatory microenvironment (Coussens and Werb 2002). 
Cytokines, including interleukins (IL), TNF-α, growth factors, and 
differentiation factors (co-stimulating factors), are secreted molecules or 
membrane-bound molecules that play a regulatory role in the growth, 
differentiation, and activation of immune cells (Dranoff 2004). One of the major 
tumour promoting mechanism is the production of tumour-promoting cytokines by 
immune/inflammatory cells that activate transcription factors, such as NF-κB, 
STAT3, and AP-1, in premalignant cells to induce genes that stimulate cell 
proliferation and survival (Figure 1.5) (Grivennikov, Greten et al. 2010).  
 
 
Figure 1.5: Role of inflammation in tumour promotion (Grivennikov, Greten et al. 
2010). 
This schematic representation shows the production of tumour-promoting cytokines by 
immune/inflammatory cells that activate transcription factors, such as NF-κB, STAT3, and 
AP-1, in premalignant cells. These factors induce genes that stimulate cell proliferation and 
survival. 
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Among these transcription factors, NF-κB and STAT3 are activated in the 
majority of cancers and act as oncogenes, whose activation in malignant cells is 
rarely the result of direct mutations and instead depend on signals produced by 
neighbouring cells, such as IL-6, IL-10 and IL-23 (Yu, Pardoll et al. 2009). 
Proteins from the STAT family can both inhibit and promote cancer. Anti-
tumour responses are increased by the activation of STAT1, which induces IL-12 
production leading to the activation of STAT4 by IL-12 receptor engagement, 
promoting Th1 responses to produce IFN-γ. IFN-γ stimulate macrophages, natural 
killer cells and CD8+ T cells, mediating cytolytic activity (Darnell 1998; Takeda and 
Akira 2000; Chang, Han et al. 2009) (Figure 1.6). 
 
Figure 1.6: The role of STAT proteins in regulation of cancer adaptive immunity 
(Yu, Pardoll et al. 2009) 
The STAT family can both inhibit and promote cancer. The activation of STAT1 in T cells 
produces IFN-γ, which stimulate macrophages, natural killer cells and CD8+ T cells, 
mediating cytolytic activity. However, STAT3 has the ability to inhibit STAT1 and promote 
tumour progression. 
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However, STAT3 has the ability to antagonise STAT1 (Kortylewski, Kujawski 
et al. 2005). Both STAT3 and STAT5 are involved in the expansion of T regulatory 
cells, which promote tumour progression by inhibiting anti-tumour immune 
responses that are mediated by Th1 type CD4
+ T cells and CD8+ T cells (Figure 1.6) 
(Kubo, Hanada et al. 2003). 
A number of literature publications have associated chronic inflammatory 
conditions with lymphoid malignancies, one example is provided by mucosa-
associated lymphoid tissue (MALT) lymphomas. MALT lymphoma occurs in the 
context of chronic inflammation caused by infectious agents such as Helicobacter 
pylori, Borrelia burgdorferi (Ferreri, Ernberg et al. 2009). Other studies have also 
shown an increase risk of cancer development in patients with systemic lupus 
erythematosus, a systemic autoimmune disease with chronic inflammation and 
tissue damage (Pettersson, Pukkala et al. 1992). Association is also been recorded 
in other autoimmune disease and Non-Hodgkin’s lymphoma, such as Burkit 
lymphoma occurs in only X-linked lymphproliferation, T-cell tumours occur in 
ataxia-telangiectasia and Diffuse large B-cell lymphomas occur in rheumatoid 
arthritis (Baecklund, Iliadou et al. 2006; Grulich, Vajdic et al. 2007).  
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1.3  Lymphoma 
Lymphoma is defined as a cancer in the lymphatic system. Lymphoma is a 
solid tumour of the lymphoid cells. It represents about 4% of the new cases of 
malignant disorders diagnosed in the UK and US each year, making it the fifth most 
common cancer diagnosed and is the cause of malignant disorder death (Jemal, 
Tiwari et al. 2004; Illes, Varoczy et al. 2009; CancerResearch 2011). The incidence of 
most malignant disorders is decreasing, whereas the lymphomas are increasing in 
frequency; the cause of this is unknown as the classification of lymphoma is difficult 
due to its diverse group of malignant diseases that vary in immunophenotype, 
genotype, clinical presentation, treatment and prognosis (Illes, Varoczy et al. 2009). 
The World Health Organisation (WHO) have classified lymphoma on the 
basis of morphology, immunophenotype, genetic features, clinical features, and a 
normal counterpart cell is hypothesised for each cancer (Jaffe 2009; Ishida and 
Ueda 2011) 
There are two types of lymphoma; Hodgkin’s lymphoma (HL) and non-
Hodgkin’s lymphoma (NHL). There are more than 35 types of lymphoma, of which, 
30 are classified as non-Hodgkin’s lymphoma.  
 
1.3.1 Non-Hodgkin’s Lymphoma (NHL) 
Over the years the understanding of genetic abnormalities has improved. 
The classification of NHL has steadily evolved as the understanding of the biology of 
the immune system has advanced (Harris, Jaffe et al. 1994; Armitage 2005; Vose 
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2008; Jaffe 2009). This has led to the development of the WHO classification of 
lymphoma. The WHO classification is presented in Table 1.4. It subdivides tumours 
into B cells and T/NK- cell origin and those with an immature or blastic appearance 
compared to those that are developing from more mature stages of lymphoid 
development (Armitage 2005).  
 
 
Table 1.4: World Health Organisation Classification of Lymphoid Neoplasms 
(Armitage 2005) 
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1.4  Immune System 
The immune system is the body’s defence system against infections caused 
by pathogenic microorganisms and viruses. The immune system is a critical system 
within the body and this is demonstrated by the severity of the 
immunodeficiencies, hence the complex array of protective mechanisms to control 
and eliminate the foreign bodies. The immune system defence is provided in two 
ways; innate and adaptive system. The innate immune system provides a generic 
and an immediate defence against a toxin or a pathogen, whereas the adaptive 
immune system manifests exquisite specificity for its target antigens. Even though 
the innate and adaptive immune systems are described as contrasting separate 
arms, they generally act together (Chaplin 2010).  
The adaptive immunity also plays an important role in immunologic memory 
and the capacity for the rapid response in the event of re-exposure. The vital cells 
of the adaptive immune system include the effectors of cellular immune responses, 
the T lymphocytes and B lymphocytes (will be referred to as T cell or B cell), which 
are highly mobile. The characteristic of the adaptive immunity is the use of antigen 
specific receptors on T and B cell to initiate targeted effector responses in two 
stages. Firstly the antigen is presented to and recognised by the antigen specific T 
or B lymphocyte leading to cell priming, activation, and differentiation, all of which 
is carried out within the lymphoid tissues. This is followed by the second effector 
response, which takes place either due to the activated T cell or due to the release 
of antibody from activated B cell (Figure 1.7) (Parkin and Cohen 2001).   
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The ability of both B and T cells to generate antigen receptor diversity 
provides the immune system the potential to eliminate a vast variety of foreign 
pathogens. 
 
 
 
Figure 1.7: The role of T and B lymphocytes in Adaptive Immunity, adapted from 
(Parkin and Cohen 2001). 
T and B cell initiate targeted effector responses in two stages. Firstly the antigen is 
presented to and recognised by the antigen specific T or B lymphocyte leading to cell 
priming, activation, and differentiation, all of which is carried out within the lymphoid 
tissues. This is followed by the second effector response, which takes place either due to 
the activated T cell or due to the release of antibody from activated B cell.  
 
 
1.4.1 Generation of Antigen Receptor Diversity 
The lymphoid arm of the immune system has evolved to respond and 
protect against a diverse set of antigens, encountered by the host. This is achieved 
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by the limitless diversity of antigen receptors. The generation of unique receptor 
type for each cell occurs during the development process of both B and T cells. The 
DNA sequences that present antigen specificity to these B cell receptors (BCRs) and 
T cell receptors (TCRs) are assembled at seven different loci (three for the BCR; one 
immunoglobulin heavy chain plus a κ or λ light chain; four for the TCR [α, β, γ and 
δ]) (Cedar and Bergman 1999). The generation of the antigen-binding diversity is 
assembled at the variable domain exons of the antigen receptors expressed on B 
and T cells, which are generated via somatic assembly of component variable (V), 
diversity (D), and joining (J) gene segments in a process called V(D)J recombination 
(Lieber 1991).   
V(D)J recombination is a site-specific recombination process, which is 
directed by recombination signal sequences (RSS). Each RSS consists of a conserved 
heptmer and nonamer sequences, with respective consensus sequences of 
CACAGTG and ACAAAAACC, separated by intervening spacer sequence that is either 
12bp or 23bp in length (van Gent, Ramsden et al. 1996). The V(D)J recombination 
process is initiated by the recombination activating genes 1 and 2 (RAGs) proteins, 
which induces double-strand breaks (DSB) between the RSS and variable region 
gene-coding segment (Jung and Alt 2004). The DSB are repaired by ubiquitously 
expressed nonhomologous end joining (NHEJ) proteins, forming precise signal and 
joints and imprecise coding end joints (Bassing, Swat et al. 2002).  
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1.4.2 Lymphoid Haematopoiesis 
Both T and B cells, which are like all leukocytes, are derived from pluripotent 
hematopoietic stem cells (HSC), within the bone marrow. HSCs are defined as 
primitive cells which are capable of both self-renewal and differentiation into any of 
the hematopoietic cell lineages (Oguro and Iwama 2007). Once the HSCs receive a 
signal to undergo differentiation, the first biological change in the HSCs is the 
gradual loss of self-renewal; hence onwards the developmental sequence begins. It 
is the specialised microenvironment of the bone marrow that provides the signals 
both for the development of the lymphocytes progenitors from hematopoietic stem 
cells and for the further differentiation of the B cells. These signals regulate the 
expression of key genes that direct the control the development program.  
The HSCs first differentiate into multipotent progenitors cells (MPPs), which 
have the ability to produce both myeloid and lymphoid cells. These cells express a 
cell surface receptor tryrosine kinase (also known as FLT3), which is required for the 
cells to differentiate to the next stage as either common lymphoid progenitors 
(CLP) or Common Myeloid progenitors (CMP). The stromal cells provide the FLT3 
ligand to the FLT3 receptor to signal the MMP cells to differentiate into CLP.  The 
progenitor cells can differentiation into any leukocyte, which can be separated into 
two major lineages: the lymphoid lineage, which includes the T, B, and natural killer 
(NK) cells. The second myeloid lineage is comprised of erythrocytes, 
megakaryocytes, granulocytes, and monocytes/macrophages (Lai and Kondo 2008; 
Slavov, Gimenes Teixeira et al. 2010).  
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The process by which lymphocytes are developed is named lymphopoiesis 
or otherwise formally called lymphoid haematopoiesis.  
 
1.5  B Lymphocyte Development 
In mouse, B cells are generated from pluripotent HSCs in the liver during 
mid-to-late foetal development and in the bone marrow after birth (hence the 
name B cells) (Hardy and Hayakawa 2001). In the mid- 1960s B cells, were 
discovered and characterised with the aid of experimental animal models, clinical 
evaluation of patients with immunodeficiency diseases and the characterization of 
cell surface molecule (Good and Zak 1956). During lymphocyte development, cells 
first become committed to the lymphoid, opposed to the myeloid, lineage and then 
to either B or T cell lineages. In mice the development of B cells initiates with the 
stromal cells secreting the cytokine IL-7, which is essential for the growth and 
survival of developing B-lineage cells (Ray, Stoddart et al. 1998).  
The B cell development rise from the common lymphoid progenitor, and 
differentiate during a number of different stages, the earliest being pro-B cells, 
followed by late pro-B cells, large pre-B cell, small pre-B cell, and eventually the 
mature B cells (Figure 1.8). As mentioned previously the generation of unique and 
diverse antigen receptors (in B cells known as the immunoglobulin) for each B cell 
occurs during these developmental stages by DNA recombination. The VH, DH, and 
JH, rearrangement of the heavy chain (H-chain) together with VL-JL rearrangement 
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of the light chain (L-chain) gene segments generate a B cell repertoire expressing 
antibodies.  
 
 
Figure 1.8: B cell development stages (Meffre, Casellas et al. 2000). 
B cells are developed in the bone marrow from stem cells. During B cell development the 
V(D)J rearrangement occurs, regulated by a number of genes. The initial immunoglobulin 
(Ig) gene rearrangement begins at the early pro-B cell stage, with the joining of the DH to 
the JH segments, resulting in the development of late pro-B cells, followed by further 
rearrangement of VH to DJH. The immature antigen specific B cells are released into the 
periphery where they are exposed to antigens and matured. 
 
The initial immunoglobulin (Ig) gene rearrangement begins at the early pro-
B cell stage, with the joining of the DH to the JH segments (Alt, Yancopoulos et al. 
1984). This leads the cell to become a late pro-B cell, where the second 
rearrangement of VH gene segment to the DJH. The successful rearrangement of the 
VH to DJH leads to the production of the intact µ heavy chain, resulting in the 
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expression of Igµ chain in complex with the surrogate light chain (consisting of λ5 
and VpreB chains). The Igµ chain is also associated with two other proteins chains, 
Ig-α (CD79α) and Ig-β (CD79β).  The immunoglobulin-like complex is known as the 
pre-BCR cell receptor (pre-BCR) (Melchers 2005).  
The pre-BCR plays a critical role in B cell development as suggested in a 
number of studies where deficient mice were created for the components of the 
pre-BCR, either the µ heavy chain or the λ5 protein (Kitamura, Roes et al. 1991; 
Kitamura, Kudo et al. 1992). In both of the studies B cell development was found to 
be severely impaired at the transition from the pro-B cell stage to the large pre-B 
cell stage, which resulted in no or poor generation of mature B cells.  
The assembly of the pre-BCR mediates a number of signals so that the following 
process can be performed (Martensson, Almqvist et al. 2010).  
 
 The cellular transition from the large pre-B cell stage to the small pre-B cell 
stage. 
 The Igµ heavy chain allelic exclusion and the down-regulation of the 
recombination by deactivating the recombination-activating genes (RAG). 
 
Allelic exclusion is a process that ensures when one of the two µ heavy chain 
alleles has achieved a functional rearrangement at the pro-B cell stage and 
produced the Igµ heavy chain the V(D)J rearrangement at the other allele is 
inhibited to avoid the generation of B cells with double specificity and a B cell 
expressing a unique B cell receptor with monospecificity (Karasuyama, Nakamura et 
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al. 1997). It has been demonstrated that the expression of RAG-1 and RAG-2 genes 
was down-regulated in the large pre-B cells (Grawunder, Leu et al. 1995). In 
contrast, the expression of RAG-1 and RAG-2 were highly expressed in pro-B cells 
and small pre-B cells, where the rearrangement of the heavy chain and the light 
chain occurs, respectively. 
As cells transit from large pre-B cell stage to small pre-B cell stage, the pre-BCR 
induces signals for proliferation expansion of large pre-B cells, which undergo two 
to five rounds of cell division (Rolink, Winkler et al. 2000).  
As the cells transit into small pre-B cells the expression of RAG1 and RAG2 genes 
is induced, resulting in the rearrangement of the light chain locus, expanding the 
population of the cells with a successful IgH chain, ultimately resulting in a more 
diverse antibody repertoire, which later in development will recombine with and 
express a unique light chain. 
In line with the monospecificity of the heavy chain, the light chains are also 
enforced with allelic exclusion. The rearrangement at the light chain does not 
include the D segment, only joining the V to J segment. Like the heavy chain the 
rearrangement is initiated on only one allele, of which if the VJ rearrangement fails 
to produce a functional light chain, then the rearrangement is repeated on the 
other allele. As well as allelic exclusion, light chains also undergo isotypic exclusion, 
meaning that they express either κ or λ Light chain. However, the expression of κ or 
λ is not represented equally on the B cells or in the serum Ig (Chen, Trounstine et al. 
1993). 
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The successfully rearranged light chain goes on to pair with the Igµ chain, which 
transforms the cells from small pre-B cells to immature B cells. Immature B cells are 
the first B lineage cells that express BCRs, they display surface IgM (Meffre, Casellas 
et al. 2000). The immature B cells are positively and negatively selected based on 
their antigen specificity and migrate from the bone marrow to the secondary 
lymphoid organ, spleen and lymph nodes.  
 
1.5.1 B cell maturation and subset development 
Loder, et al (1999) was first to refer Immature B cells as “transitional” (T1 
and T2) based on their phenotype and ontogeny and were characterised primarily 
in the mouse (Chung, Silverman et al. 2003) and since then a number of groups 
have confirmed and further characterised the distinct subsets. The early transitional 
B cells exit the bone marrow and enter the peripheral circulation. On arriving in the 
spleen, the cells  pass through a series of transitional stages prior to developing into 
mature follicular(FO), marginal zone (MZ) or B-1 B cells (Allman and Pillai 2008) 
(Figure 1.9).  
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Figure 1.9: Characteristics of the three peripheral B cell subsets (Pillai, Cariappa et 
al. 2004). 
 
Mature FO B cells are always found adjacent to T cell zones. This 
arrangement allows activated FO B cells and activated T helper cells to migrate 
towards each other and interact. Therefore FO B cells participate in T cell-
dependent germinal centre-based immune responses to protein antigens. FO B cells 
also occupy a second niche; they also recirculate through the bone marrow and are 
known to respond to T cell-independent manner to blood borne pathogens (Pillai 
and Cariappa 2009). 
In contrast to FO B cells, MZ and B-1 B cells  respond in a T cell-independent 
manner and can develop into antibody producing plasma cells upon antigen-
stimulation (MacLennan, Toellner et al. 2003). MZ B cells are considered to be like 
innate-like cells that can be induced to differentiate into short lived plasma cells in 
the absence of BCR ligation (Allman and Pillai 2008). B-1 B cells are the majority B 
cell subpopulation in pleural and peritoneal cavities (Baumgarth 2011).  
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1.5.2 B cell Tolerance 
The development and the maturation process of B cells are tightly regulated 
by testing the antigen receptor for tolerance to a self-antigen. There are two 
processes of B cell tolerance; central tolerance, where the antigen receptor of the 
immature B cell is tested in the bone marrow. The second process is peripheral 
tolerance, where self-reactive B cells have escaped the central tolerance and 
become mature B cells; hence the name peripheral tolerance as the process occurs 
in the secondary lymph node organs.  
Understanding the tolerance mechanisms and the identification of the 
developmental stages of B cell tolerance has been difficult. But the recent 
availability of transgenic mice in which majority of lymphocytes express an immune 
receptor against a given antigen has enabled the identification of several 
mechanisms.  
 
1.5.2.1 Clonal Deletion 
During the B cell development, the immune system generates potentially 
harmful self-reactive B cells that must be distinguished from useful lymphocytes. 
These self-reactive B cells are eliminated from functional repertoire during the 
transition from the pre-B to mature B-cell stage in the bone marrow, even low-
affinity interactions can lead to central deletion (Nemazee and Burki 1989; Chen, 
Nagy et al. 1995), by the process of BCR ligation.  
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1.5.2.2 Clonal Anergy 
Clonal anergy was first proposed in the 1980s by Pike and Nossal, when they 
found that B-cell precursors cultures with high levels of antibody against surface 
IgM impeded any B-cell development (Pike, Boyd et al. 1982). Anergic lymphocytes 
persist in tolerant animals, but are functionally inactivated. Goodnow group 
demonstrated clonal anergy in vivo using transgenic B-cell receptor (BCR) against 
hen-egg lysozyme (HEL). They found that when these mice were crossed with mice 
expressing a soluble form of HEL, the transgenic B cells became Anergic (Goodnow, 
Crosbie et al. 1988). 
 
1.5.2.3 Receptor Editing 
Although many self-specific B cells undergo clonal deletion, some of them 
can undergo further somatic recombination to make new VH and VL combination 
that are not specific, which is known as receptor editing. The ability of receptor 
editing to rescue some self-specific B cells by changing their specificity was 
demonstrated by the Nemazee and Weigert groups, with the aid of mice carrying Ig 
transgenes encoding self-MHC-specific BCR. They found that total B cell numbers 
were greatly reduced in the periphery, but of these few B cells that were produced 
in the mice were not self-specific because they have been able to make new 
recombination of both heavy and light chains in the V region (Gay, Saunders et al. 
1993; Tiegs, Russell et al. 1993). 
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1.5.3 Homeostatic proliferation of B cells 
When B cells emerge from bone marrow into the periphery, they are still 
functionally immature. Due to the high expression levels of surface IgM and low 
levels of IgD, not many immature B cells survive to develop into mature B cells, 
however majority of peripheral B cells are long-lived (Gaudin, Rosado et al. 2004). 
The failure of most of the newly formed B cells to survive for more than a few days 
is due to the access of follicles in the secondary lymphoid organs.  The follicles 
cannot accommodate all the B cells that are generated, hence if the new immature 
B cells do not enter the follicles, and then they cannot survive due to the 
competition for entry. Hence the follicles provide signals necessary for B cell 
survival, one particular signal is from B-cell-activating factor (BAFF, also known as 
BLyS) belonging to the TNF family (Schneider, MacKay et al. 1999).  
BAFF and a proliferating-inducing ligand (APRIL) are related members of the 
TNF family. BAFF binds to the BAFF receptor (BAFFR, also known as BR3) with high 
affinity. In the absence of BAFF, B cell maturation proceeds normally in the bone 
marrow, however splenic B cell are reduced, especially transitional T2, mature and 
MZ B cells (Schiemann, Gommerman et al. 2001; Bossen, Tardivel et al. 2011). 
Hence BAFF, upon binding to the receptor BR3 enhances survival of semi-mature 
and mature B cells and it has been reported that this occurs by promoting 
expression of BCL-2 family members (Harless, Lentz et al. 2001). BAFF also mediates 
longevity of mature B cells. This was observed when treatment with soluble BAFF 
receptors resulted in the rapid loss of most of the mature peripheral B cells (Gross, 
Dillon et al. 2001).  
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Fitness of survival of naïve B cells does not only rely on competitive 
processes but are also dictated by BCR specificity. Continuous signalling through B 
cell receptor also has a positive role in the maturation and continued recirculation 
of peripheral B cells. This is supported by the existence of more restricted 
immunoglobulin (Ig) variable region gene repertoire in mature B cells than that 
seen in their immature precursors (Levine, Haberman et al. 2000).  
 
1.6  T Cell Development 
T cells arise from hematopoietic stem cells that migrate to the thymus 
(Starr, Jameson et al. 2003). The thymus is an organ that supports the 
differentiation and selection of T cells (Takahama 2006). Figure 1.10 shows the 
overall scheme of the T cell development within the thymus. 
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Figure 1.10: Overall summary of T cell development in the Thymus (Germain 
2002). 
T cells development occurs in the thymus. The hematopoietic stems cells migrate to the 
thymus were they differentiate and mature into specialised T cell.  
 
 
Lymphoid Progenitors arise in the bone marrow and migrate to the thymus. 
In the thymus these cells lose the potential for B cell and natural killer cell 
development (Michie, Carlyle et al. 2000). During T cell development in the thymus 
the T cell precursors, called thymocytes, lack expression of CD4 and CD8 and are 
called double negative (DN). DN thymocytes can be subdivided further into four 
sequential stages of differentiation, which are known by their surface expression of 
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CD44 and CD25: DN1, CD44+CD25-; DN2, CD44+CD25+; DN3, CD44-CD25+; and 
DN4;CD44-CD25- (Godfrey, Kennedy et al. 1993). As the cells progress from DN2 to 
DN4 stages, they express the pre-T cell receptors (pre-TCR), which is composed of 
the non-rearranged surrogate pre-Tα Chain and a rearranged TCR β-chain, forming 
a pre-TCR complex (von Boehmer and Fehling 1997). Both TCRα and β genes have 
variable (V) and joining (J) segments, while β genes also have diversity (D) 
segments. The rearrangement of these genes follows the same mechanism as B cell 
developments, with the aid of RAG 1 and RAG 2. Only the cells that succeed in a 
functional in-frame rearrangement of the gene encoding the TCR β-chain are 
selected for further differentiation beyond this DN3 stage. The selection events are 
required to select only those cells that are able to weakly recognise self-MHC 
molecules loaded with self-peptide (Michie and Zuniga-Pflucker 2002). The cells 
that have a functional β chain and recognise self-peptide/MHC molecules are 
termed as β-selection. 
 
1.6.1 Positive Selection and Negative Selection 
In the thymus cortex, the successful expression of the pre-TCR complex on 
the cell surface, along with Delta-Notch interaction, initiates the signals to progress 
the development to double positive (DP) thymocytes that express the TCRαβ 
antigen receptors (Takahama 2006). During the transition of DN4 to DP the RAG 
proteins expression is switched off and the pre-TCR expression leads to substantial 
cell proliferation. 
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At the DP stage of the thymocyte differentiation, the RAG genes are once 
again expressed and the cells will undergo the rearrangement of TCR Vα and Jα, 
producing a new rearranged TCRα chain that can pair with the existing rearranged 
TCRβ chain, which allows the surface expression of TCRαβ-CD3 complex (Goldrath 
and Bevan 1999). 
  From the large number of DP thymocytes, the ones that are best suited to 
function in the host environment are permitted to mature and migrate to 
peripheral lymphoid tissues. This selection is characterised by four processes; death 
by neglect, Negative selection, positive selection and lineage-specific development 
(Figure 1.11) (Germain 2002).  
 
 
Figure 1.11: Positive selection process, negative selection process and death by 
neglect (Takahama 2006) 
The double positive (DP) thymocytes undergo both positive and negative selection to 
delete any auto-reactive lymphocytes. Those thymocytes that have receptors that bind 
strongly to self-antigens are removed by the induction of apoptosis of the auto-reactive 
cells.  
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Death by neglect is initiated when there is too little signalling between the 
TCR and the self-peptide-MHC ligands, which result in delayed apoptosis. Too much 
signalling can promote acute apoptosis, which is caused in negative selection. 
Positive selection occurs when the signalling is at an intermediate level, where TCR 
signalling initiates effective maturation (Germain 2002).  
Positively selected DP thymocytes are induced to differentiate into single 
positive (SP) thymocytes, which are CD4-CD8+ (MHC class I reactive) or CD4+CD8- 
(MHC class II reactive) (Hollander and Peterson 2009). These thymocytes spend 
approximately 12 days in the medulla before travelling to the thymus. During this 
period the SP thymocytes go through a maturation process. This is accompanied by 
further deletion of self-reactive thymocytes that have escaped negative selection in 
the cortex. This process is particularly important in central tolerance to tissue 
specific antigens (Kyewski and Derbinski 2004).   
As well as the deletion mechanism that ensures self-tolerance, it is also 
thought that the medulla is the place for the production of regulatory T cells (Treg) 
(Takahama 2006). Treg cells have emerged to play a critical role in suppressing the 
response of the immune system to self-antigen (Kuhn, Beissert et al. 2009). 
 
1.6.2 T cell Maturation and T Cell Tolerance  
After completing their maturation in the thymus, the T cells migrate to the 
periphery. Although these T cells are mature, they are termed immunologically 
naïve T cells, as they have not been activated in the periphery. Naïve T cells express 
molecules such as CD62L (Gallatin, Weissman et al. 1983; Resino, Navarro et al. 
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2001) that enables their circulation through the blood and secondary lymphoid 
organs such as lymph nodes and the white pulp area of the spleen. During the 
circulation it enables them to come in contact with thousands of antigen presenting 
cells (APC) in the lymphoid tissues and interact with peptides on MHC-molecule. 
APC are cells that present antigen peptide associated MHC molecule to inactivate T 
cells and activate them for the first time, such as macrophages, dendritic cells and B 
cells.  
The level of stimulation that the T cell receives upon contact with the APC 
presenting peptide-MHC molecules governs the response of that T cell. Only those 
T cells that bind and receive a strong signal upon interaction with an APCbecome 
activated and induce an immune response.  
The outcome of a T cell response to antigen stimulation is regulated by the 
interplay and complex interaction of positive (stimulatory) and negative (inhibitory) 
pathways (Zhu, Symonds et al. 2008). It is important that there is some mechanism 
to prevent auto reactivity of the T cells after they have emigrated from the thymus. 
This is achieved through the T cell tolerance process (Figure 1.12). Although most of 
the self-reactive T cells are eliminated in the thymus, negative selection has 
limitations and additional mechanisms of tolerance are required to limit 
autoimmunity  (Bandyopadhyay, Soto-Nieves et al. 2007).  
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Figure 1.12: Pathways to tolerance (Walker and Abbas 2002). 
T cells undergo both central tolerance and periphery tolerance.  A few self-reactive T cells 
escape the central tolerance and leave the thymus, in the periphery they go through 
further selection and auto-reactive T cells are removed.  
 
1.6.3 T cell activation 
T cell activation is initiated by the interaction of the TCR-CD3 complex with 
an antigenic peptide bound to either MHC class I or class II molecules on the 
surface of APC. However this interaction alone does not activate the T cells. A 
further two signal are required for the T cells to be activated once they come in 
contact with the APC, a co-stimulatory molecule, such as CD28 and cytokines that 
trigger the rapid growth and proliferation of effector T cells and are thought to 
increase the cytotoxic effects of the CD8+ T cells (Figure 1.13).  
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Figure 1.13: T cell Activation (Pietropaolo, Surhigh et al. 2008) 
Three signals are required to activate the T cell receptor; the TCR-CD3 complex interacts 
with either MHC class I or class II molecules, co-stimulatory molecules and cytokines, which 
trigger rapid growth and proliferation of the effector T cell. 
 
 
A strong signal in the T cell by APC surpass the threshold for T cell activation, 
which leads to a cascade signalling molecules, resulting in the generation or release 
of second messengers, such as Ca2+. This signalling cascade eventually results in the 
induction of transcription factors, such as nuclear factor of activated T cells (NFAT) 
(Dolmetsch, Lewis et al. 1997) and Early Growth Response (Egr) (Safford, Collins et 
al. 2005; Anderson, Manzo et al. 2006). The transcription factors initiate the 
process of proliferation and also induce the expression of cytokines, such as IL-2 or 
Il-17, leading to the differentiation of the effector T cells. 
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On antigen recognition, naïve T cells differentiation from naive T cells into  effector 
T cells with enhanced functional  (Wan and Flavell 2009). Based on the cytokines 
produced these effector cells can be classified into different groups with specialised 
functions (Table 1.5). 
 
Cytokine Produced T cell Type Function 
IFN-γ and IL-2 TH1 Macrophages activating effector 
cell. Cell-mediated immunity 
IL-4 and IL-5 TH2 Activation of B cells. 
IL-17 and IL-6 TH17 Promote acute inflammation by 
neutrophil recruitment 
TGF-β and IL-10 Treg Produce inhibitory cytokines. 
Involved in tolerance. 
 
Table 1.5: T cell effector subsets and function adapted from (Zhu and Paul 2008) 
 
 
After the effector cells have cleared the infection the majority of the 
responding effector T cells die, but a small cohort of cells remains for long-term 
protection. These cells, are termed memory cells, and can respond more rapidly 
than naïve T cells upon re-exposure to the same antigen in vivo (Sallusto, Lenig et 
al. 1999; Veiga-Fernandes, Walter et al. 2000). 
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1.6.4 T Cell Homeostasis 
T cell production and survival are tightly constrained by competition for 
cytokines and self-peptide MHC ligands. Such competition allows the size of T cell 
population to increase gradually during young life and then declines progressively 
with age (Sprent, Cho et al. 2008). Throughout this period the cellularity of the 
spleen and lymph nodes remains relatively constant (Surh and Sprent 2008), T cell 
homeostasis is the mechanism that exists to serve the maintenance of T cell 
number and cell survival. Homeostatic processes are vitally involved in T cell 
development, survival, and maintenance, as well as following antigen-driven 
responses (Boyman, Letourneau et al. 2009). The homeostasis of naïve and memory 
T cells is maintained differently. In the case of naïve T cells, prolonged survival of 
these cells in interphase is dependent on a combination of transform TCR signalling 
from interaction with self-peptide MHC ligands plus interaction with IL-7 and to a 
lesser degree with IL-15. In contrast, most of the memory T cells are MHC 
independent but rely heavily on contact with a mixture of IL-7 for cell survival and 
IL-15 for cell proliferation (Surh and Sprent 2008). 
 
As mentioned post-thymic naïve T cells depend on contact with IL-7 and 
self-peptide MHC molecules for their homeostatic survival. Homeostatic 
proliferation caused by the combination of IL-7 and Self-peptide MHC molecule 
continues at a slow rate and is readily detected for naïve CD4+ and CD8+ T cells 
upon adoptive transfer into syngeneic normal hosted that have been made acutely 
lymphopenic by irradiation, known as lymphopenia-induced proliferation (LIP) (Tan, 
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Dudl et al. 2001).  In addition to LIP, naïve T cells can also proliferate in non-
lymphopenic animals by increasing the intensity of IL-7 signals, using IL-7/anti-IL7 
mAb complexes. These complexes induce slow proliferation of the naïve T cells, 
particularly CD8+ cells (Boyman, Ramsey et al. 2008). Interestingly when naïve T 
cells are stimulated with other members from γc cytokines, such as IL-2 and IL-15, 
they undergo rapid proliferation. A Group performed adaptive transfer of naïve 
CD8+ T cells to IL-2Rβ-deficient hosts (they contain elevated levels of IL-2 and 
possibly IL-15). This led to rapid proliferation and differentiation of the donor T cells 
into effector T cells followed by the production of memory cells (Cho, Boyman et al. 
2007). The cytokines and the self-peptide MHC molecules are not the only factors 
involved in the homeostasis of naïve T cells, as evidence has shown TCR signals are 
also necessary. The initial prospect used to be that naïve T cells did not recognise 
self-peptide-MHC ligands in the periphery. However, recently several groups have 
shown that MHC molecules are important in maintaining peripheral pool of T cells. 
Individual experiments have demonstrated the importance of MHC class I and class 
II for the maintenance of naïve CD8+ and CD4+ T cells, respectively.  In two 
individual experiments, TCR transgenic CD8+ T cells were transferred into 
MHC class I-deficient hosts. In both experiments it was shown that the naïve CD8+ T 
cells were significantly reduced in the periphery (Tanchot, Lemonnier et al. 1997; 
Murali-Krishna, Lau et al. 1999).  
Memory T cells often divide in the periphery long after antigen stimulation. 
The homeostasis of memory T cells is controlled differently. Memory cells are 
generally recognised by their CD44 marker, which is expressed much lower in naïve 
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T cells. Studies using antigen specific memory cells establish that cells still continue 
to proliferate in the absence of MHC molecules (Murali-Krishna, Lau et al. 1999). 
Hence indicating that peptide-MHC ligands are not required for the survival of 
CD44high cells instead they require the presence of IL-7 and IL-15 cytokines 
(Boyman, Purton et al. 2007; Surh and Sprent 2008). 
 
1.6.5 Peripheral T cell Tolerance 
Throughout T cell development T cells maintain self-tolerance, which is 
divided into central and peripheral tolerance. As discussed previously central 
tolerance plays a key role in the early life of T cells, it is fostered by apoptosis 
through elimination of auto reactive lymphocytes in the thymus. Potentially self-
reactive T cells do escape central tolerance due to relatively low-avidity for the self-
peptide MHC complex molecule (Liu, Fairchild et al. 1995). These self-reactive T 
cells migrate to the periphery where they can lead on to cause autoimmune 
disease. Therefore the self-reactive T cells that escape the negative selection must 
be kept under control in the periphery. To simplify the tolerance process the 
peripheral tolerance can be divided into those that act directly on the responding T 
cell (T-cell intrinsic) and those that evoke additional subsets of cells, including 
dendritic cells (DCs) and regulatory cells (T cell extrinsic) (Walker and Abbas 2002). 
Here, the cell intrinsic, T cell clonal anergy is discussed further. 
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1.6.5.1 T cell Anergy 
The term anergy was first coined by Von Pirquet in 1908 to describe the loss 
of delayed-type hypersensitivity to tuberculin in individuals infected with measles 
virus (Schwartz 2003). Following a series of experiments describing antigen-specific 
B cell tolerance in vivo, Nossal and Pike employed the terminology clonal anergy to 
describe the antigen-specific nature of the unresponsiveness they observed (Nossal 
1993). However with respect to T cell tolerance, it is a tolerance mechanism in 
which the lymphocyte is intrinsically functionally inactivated following an antigen 
encounter, but remains alive for an extended period of time in the hypo-responsive 
state (Schwartz 2003). In earlier experiments, it was found that T cell clones that 
were initially stimulated with formaldehyde fixed APCs failed to proliferate or 
produce IL-2 upon re-challenge with live APC+peptide (Jenkins and Schwartz 1987). 
The idea of T cell anergy occurred when T cells were stimulated through the T cell 
receptor in the absence of co stimulation came when it was found that fixation of 
APCs inhibited the B7-CD28 interaction (Jenkins and Johnson 1993). 
Calcium signalling is critical for the first step of anergy induction (Macian, 
Garcia-Cozar et al. 2002). Calcium- induced anergy is mediated primarily by NFAT, a 
transcription factor regulated by the protein phosphatase calcineurin, and both 
NFAT activation and anergy induction are blocked by the calcineurin inhibitors 
cyclosporine A (CSA) and FK506 (Jenkins, Chen et al. 1990; Macian, Im et al. 2004; 
Podojil and Miller 2009). This model was formally proven by Rao’s group using cells 
from NFAT knockout mice and over expressing mutants of NFAT that could not 
cooperate with AP-1 (Macian, Garcia-Cozar et al. 2002). 
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Activated NFAT travels to the nucleus and up regulates the transcription of 
several genes, including the genes encoding the transcription factors early growth 
response 2 (EGR2) and early growth response 3 (EGR3) (Figure 1.14) (Fathman and 
Lineberry 2007).  
 
 
Figure 1.14: Induction of EGR2 or EGR3 by activated NFAT (Fathman and Lineberry 
2007). 
The initial steps of anergy require calcium signalling, which is mediated primarily by NFAT. 
Egr2 and Egr3 transcription factor genes are activated by NFAT. 
 
 
When self-reactive lymphocytes escape from tolerance and become 
activated, then the immune system will react to itself, leading to autoimmune 
diseases. It is still not clear how autoimmune diseases occur, however, 
autoimmunity is thought to result from a combination of genetic variants, acquired 
environmental triggers such as infections, and stochastic events (Rioux and Abbas 
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2005). By focusing on how our understanding of cellular and molecular mechanisms 
of self-tolerance and immunity, it will guide rational solutions to autoimmune 
disease (Goodnow, Sprent et al. 2005). 
A number of studies have been carried out to identify the exact process of 
how self-tolerance is initiated, managed and balanced along with immune 
response. Each of the mechanisms are essential for maintaining self-tolerance, as 
loss of one pathway can result in a limited set of autoimmune reactions (Abbas, 
Lohr et al. 2004). 
The complexity of the immune system has led to a lot of research in 
understanding the genetic model for the T cells differentiation into memory cells or 
the route of achieving self-tolerance. One study by Zhu et al has shown that Egr2 
controls the self-tolerance of T cells and prevent the development of autoimmune 
diseases, such as lupus like syndrome (Zhu, Symonds et al. 2008). 
 
1.7  Autoimmune Diseases  
Autoimmune diseases are still one of the top five diseases that are major 
causes of morbidity and mortality throughout the world. They are difficult to treat 
due to the focus on the immune response and self-antigens cannot be eliminated 
from the immune system. Self-reactive B and T cells are a normal component of the 
immune system for which many self-tolerance mechanisms are in place. 
Autoimmune diseases develop when self-reactive lymphocytes escape from 
tolerance and become activated (Rioux and Abbas 2005). Traditionally autoimmune 
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diseases were classified as T cell mediated or autoantibody mediated. However 
with the improved understanding of the immune system , the role of B cells in 
autoimmune diseases is more understood (Hampe 2012). 
The major autoimmune diseases include rheumatoid arthritis, multiple 
sclerosis, type 1 diabetes mellitus, inflammatory bowel disease and systemic lupus 
erythematosus (Cho and Gregersen 2011).  
Systemic lupus erythematosus (SLE) is an autoimmune disease characterised 
by the production of antibodies to components of the cell nucleus in association 
with a diverse clinical manifestations. The key features of SLE patients are 
inflammation, vacuities, immune complex depositions, and vasculopathy.  Most 
cases of SLE are sporadic but the observation of concordance of SLE in identical 
twins, and the increase frequency of SLE in first degree relatives, reflect a polygenic 
inheritance of the disease (Mok and Lau 2003).  
The common and basic pathology feature of SLE patients is that of 
inflammation and blood vessel abnormalities, which includes immune complex 
depositions. A key diagnoses performed by clinicians in diagnosing SLE is organ 
pathology, of which the main organ being the kidney (Weening, D'Agati et al. 2004). 
By  light and  immunofluorescence microscopy, renal biopsy in patients with SLE 
display mesangial cell proliferation, inflammation, basement membrane  
abnormalities, and immune complex depositions.(Mok and Lau 2003).  
Autoantibody production is the central immunological disturbance in SLE 
patients. These autoantibodies are directed at several self-molecules found in the 
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nucleus, cytoplasm, and cell surface, in addition to soluble molecules such as IgG 
(Arbuckle, McClain et al. 2003; Mok and Lau 2003).  
In both human patients and mouse models genetic predisposition plays a 
critical role in the susceptibility of SLE; in human SLE, a number of genes have been 
identified. Our group identified Egr2 to be a key gene involved in controlling self-
tolerance. We produced Egr2 conditional knockout mice, where Egr2 was 
specifically deleted in cells expressing CD2 promoter, i.e. lymphocytes. These mice 
exhibited features of SLE disease. The mice displayed hair loss, skin lesions and 
accumulations of inflammatory monoclear cells in various tissues, of which majority 
of them were T cells, with a small population of B cells. Kidney histology also 
revealed deposition of immune complexes in the glomeruli, as SLE patients also 
manifest glomerulonephritis (Zhu, Symonds et al. 2008). 
 
1.8  Early Growth Response Transcription Factors 
The Egr family consist of four members; Egr1 (also known NGFI-A, Zif268 or 
Krox-24), Egr2 (also known as Krox-20), Egr3 (also known as PILOT) and Egr4 (also 
known as NGFI-C). Three of the Egr genes (Egr1, Egr2 and Egr3) are growth factor 
inducible, whereas Egr4 is not. (Sukhatme 1990). All four Egr proteins share 
extensive 90% homology throughout the zinc finger DNA-binding domains and 
recognise the same consensus DNA-binding motifs (Beckmann and Wilce 1997). All 
the Egr proteins contain closely related Cys2-His2-type of the zinc finger proteins 
(Sukhatme 1990). However they do have unique functions as revealed by specific 
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phenotypes in the knockout mice. Egr1-/- mice are characterised by female 
infertility, Egr2-/- mice have a defective peripheral nerve myelination and hindbrain 
abnormalities, Egr3-/- mice have motor neuron disorders, such as ataxia, and Egr4-/- 
mice have male infertility (O'Donovan, Tourtellotte et al. 1999). Recent studies have 
also revealed that the Egr family performing opposing functions. Collins and 
colleagues demonstrated that Egr family play a critical role in directing the 
consequences of antigen recognition. Egr1 and NAB2 promote a TCR-induced 
activation program while Egr2 and Egr3 are responsible negatively regulating T cell 
function by suppressing Egr1 and NAB2 expression (Collins, Lutz et al. 2008) 
As well as their DNA binding domains, Egr protein also contain both 
transactivation and repressor domains, thus they function both as transcriptional 
activators and repressors (Thiel and Cibelli 2002).   
 
1.8.1 Egr protein DNA binding 
The Egr2 gene transcribes early growth response 2 transcription factors and 
is located at 10q21.3 near the MBS3 critical region (Van Der Zwaag, Verzijl et al. 
2002; Bult, Eppig et al. 2008).  The Egr family members are characterised by a DNA-
binding domain consisting of three zinc finger motifs which bind to 9-bp GC-rich 
DNA sequences (Dillon, Brown et al. 2007). Figure 1.15 provides a schematic 
representation of the four members of the Egr family.  
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Figure 1.15: The four members of the Egr family (Poirier, Cheval et al. 2008).  
This schematic representation shows the conserved regions of the different members of 
the Egr family. The most closely related members are Egr2 and Egr3, followed by Egr1. 
 
The first DNA sequence identified as the Egr1 binding site was GCGGGGGCG, 
which was discovered within its own promoter in 1989 (Christy and Nathans 1989). 
Later experiments demonstrated that all four members of the Egr could activate 
transcription from this sequence; hence this sequence was referred to the 
consensus binding site for Egr family of transcription factors, even though later 
GCGTGGGCG was identified as the optimal binding site for Egr2 (Swirnoff and 
Milbrandt 1995). 
 
1.8.2 Egr family function outside the immune system 
The Egr family has found to play a critical role in the formation and 
maintenance of myelin (Topilko, Schneider-Maunoury et al. 1994). Egr2 has been 
extensively studied in the nervous system. Mutations in Egr2 were identified to 
correlate with severity of human myelinopathies (Warner, Svaren et al. 1999) and 
Charcot-Marie-Tooth disease (Chung, Sunwoo et al. 2005). Studies have shown that 
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Egr2 transcription factor is tightly regulated during embryogenesis, mainly in the 
segmented hindbrain and immature myelinating Schwann cells. Egr2 knockout 
models display disrupted hindbrain segmentation and development, due to 
rhombomeres r3 and 5 missing in the developing hindbrain (Voiculescu, Charnay et 
al. 2000). 
Egr1 deficient animals have provided insight of fertilisation problems in 
these animals, leading to the discovery that they are deficient in luteinizing 
hormone β (LHβ), which contains an Egr response element in its promoter. These 
findings suggested that Egr1 mediates the phasic rise in luteinizing hormone (LH) 
indicted by luteinizing-hormone releasing hormone (O'Donovan, Tourtellotte et al. 
1999). Egr1 has also recently indicated that it plays a crucial role in angiogenesis, 
the formation of new blood vessels from the pre-exiting vasculature (Fahmy and 
Khachigian 2004; Khachigian 2004). 
Egr3 is highly expressed in developing muscle spindles, specialised muscles 
cells that are used to monitor muscle length and tension (Tourtellotte and 
Milbrandt 1998). Tourtellotte and Milbrandt, generated Egr3 deficient mice by 
targeting mutagenesis in embryonic stem cells and found that they displayed severe 
motor abnormalities, due to the absence of muscle spindles (Tourtellotte and 
Milbrandt 1998). Recently Egr3 has also been shown to be involved in the 
sympathetic nervous system, by regulating sympathetic neuron dendrite 
morphology and terminal axon branching (Eldredge, Gao et al. 2008; Quach, 
Oliveira-Fernandes et al. 2013). 
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Studies have shown that the Egr family have important roles in multiple 
pathways including development of prostate cancer, hematopoietic cell fate 
determination and thymic T cell development (Collins, Lutz et al. 2008).  
Two individual groups in Japan have demonstrated that Egr2 is associated 
with the apoptosis pathway. One group revealed that Egr2 plays a key role in the 
PTEN-induced apoptotic pathway. They suggested Egr2 may serve as a tumour 
suppressor mediator in the PTEN signalling pathway. They found that the 
exogenous expression of Egr2, with AdCAEGR2 induced apoptosis significantly in 
various cancer cell lines, such as colorectal cancer and prostate cancer (Unoki and 
Nakamura 2003). They proposed that Egr2 induces apoptosis in various cancer cell 
lines by direct transactivation of BNIP3L and BAK (Figure 1.16). However they did 
not investigate Egr2 in lymphoma or leukaemia cell lines.  
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Figure 1.16: Egr2 mediated cell death pathway (Unoki and Nakamura 2003).  
This schematic model shows PTEN that activates Egr2 gene. This then initiates the 
apoptotic pathway.  
 
The other group supporting the findings that overexpression of Egr2 induces 
apoptosis, Tokini and colleagues, reported that Egr2 expression was up-regulated 
by DNA damage-induced p53 activity. They also identified a responsive element of 
p53, Tap63 and Tap73 within Egr2 gene (Yokota, Sasaki et al. 2010). 
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1.8.3 Egr family proteins in B cells 
In 1989, it was reported by Seyfert and colleagues, that Egr1 is rapidly 
induced in mature B cells, upon stimulation by B cell antigen receptor (BCR) 
crosslinking (Seyfert, Sukhatme et al. 1989). Later it was reported that Egr1 
expression can be detected already in pre-B cells isolated from bone marrow and in 
fetal liver-derived pre-B cell cultures (Dinkel, Warnatz et al. 1998).  
Recently our group demonstrated that together with Egr1, Egr2 is also 
expressed in selected stages of B cell development and is repressed at pro-B cells 
(see Figure 1.17). The studies were carried out on Egr2 conditional knockout models 
(cKO), where Egr2 was specifically knocked out of CD2 positive cells, lymphocytes, 
and in Egr2 transgenic mice. Very little is known by the mechanism of how Egr2 
regulates B cell development but our group was able to demonstrate that the 
involvement of Her-2 in B cells was supported by the impaired expression of Pax5 in 
pro-B cells, demonstrated by Egr2 Transgenic mice. Pax5 is exclusively expressed in 
the B cells from the committed pro-B cells to mature B cell stage and control the 
commitment of lymphoid progenitors to the B cell pathway (Li, Symonds et al. 
2011). 
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Figure 1.17: Kinetic Expression of Egr in wild type bone marrow B lymphoid 
lineage (Li, Symonds et al. 2011). 
Egr2 is shown to be highly expressed at the early stages of B cell development (CLP and 
Pre-pro stages).  
 
 
1.8.4 Egr Family proteins in T cells 
Earlier studies demonstrated that during the engagement of the T cell 
receptor (TCR), Egr1, Egr2 and Egr3 are induced. Egr1, Egr2 and Egr3 are all 
expressed in DN thymocytes after the β-selection checkpoint correlating with pre-
TCR signals (Carleton, Haks et al. 2002). Egr4 is thought to remain constantly 
expressed in T cells (Skerka, Decker et al. 1997). Li and colleagues performed kinetic 
expression of Egr1, Egr2 and Egr3 mRNA in the T cell lineage stages (Figure 1.18) 
and found Egr2 and Egr3 were expressed at significant levels while Egr1 was 
induced at lower levels. 
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Figure 1.18: Kinetic Expression of Egr genes in wild type T lymphoid lineage (Li, 
Symonds et al. 2011). 
Egr2 and Egr3 genes are expressed throughout the development of T cells, especially during 
DN3 and DN4 stage. 
 
Recent studies have revealed opposing functions among the Egr in 
regulating T cell activation. Egr1 through the up-regulation of IL-2, TNF, CD154 and 
IL-2r, is associated with enhancing function. Whereas, Egr2 and Egr3 are emerging 
as negative regulators of T cell activation (Collins, Lutz et al. 2008). The role of Egr2 
in the immune compartment is not extensively described, although it has been 
shown that Egr2 transactivation is dependent on members of the NFAT family in T 
cells (Harris, Bishop et al. 2004).  
 
1.8.4.1  Egr proteins in thymocytes and mature T cell Function 
Studies have shown that the activity of the Egr proteins is essential for 
development of immature DN thymocytes to the DP stage (Carleton, Haks et al. 
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2002). Carleton and his group were able to produce the first report, which 
demonstrated that the Egr family members are required to enable the pre-TCR 
complex to promote the differentiation of immature DN thymocytes beyond the 
β-selection checkpoint (Carleton, Haks et al. 2002). Two individual groups also 
demonstrated that both transgenic over-expression of Egr1 and Egr3 proteins in 
Rag2-/- and Rag1-/- thymocytes, respectively, enable the T cells to pass through the 
β-selection checkpoint to the DN4 and  in SP stages, due to the lack of pre-TCR 
signalling (Miyazaki 1997; Xi and Kersh 2004). Hence, demonstrating the 
involvement of Egr proteins in thymocytes β-selection. 
As well as in the thymocytes, Egr proteins are also shown to be expressed in 
mature T cells. Egr1 has been demonstrated to be involved in the expression of IL-2 
(Decker, Skerka et al. 1998). 
Mouse natural killer T (NKT) cells function in the first line of defence against 
infectious agents. Recently Lazarevic V., et al (2009) demonstrated that a 
calcineurin-NFAT-Egr2 pathway is essential for the productive selection, survival 
and maturation of NKT cells (Lazarevic, Zullo et al. 2009) (Seiler, Mathew et al. 
2012). 
 
1.8.4.2  Egr family, T cell tolerance and anergy 
Egr2 and Egr3 are important mediators of the negative regulatory program 
downstream of isolated NFAT signalling (Figure 1.19). Collins and colleagues have 
also shown that Egr2 is up-regulated by Egr3. Both Egr2 and Egr3 inhibit T cell 
function by promoting the up-regulation of negative regulators such as Cbl-b and by 
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inhibiting the expression of the T cell activators Egr1 and NAB2 (Safford, Collins et 
al. 2005; Collins, Lutz et al. 2008). Cbl-b has shown to have a major tolerogenic 
factor.  
 
 
Figure 1.19: Model for the regulation of T cell function by Egr1, Egr2, Egr3 and 
NAB2 (Collins, Lutz et al. 2008).  
This schematic representation shows possible routes of TCR activation leading to 
upregulation of either Cbl-b or IL-2. 
 
 
Including our group, three individual groups have published their initial 
findings on the role of Egr2 in tolerance and anergy. Initially in 2004 Dr. Michael P. 
Czech from University of Massachusetts, USA, silenced the Egr2 expression, by RNAi 
technology, in an established A.E7 T cell line. They reported that depletion of Egr2 
through siRNA-mediated gene silencing disrupts anergy, suggesting that Egr2 
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expression is required for the full induction of anergy in T cells (Harris, Bishop et al. 
2004). 
Around the same time similar studies were also carried out by another 
group at John Hopkins School of Medicine, USA. Jonathan, D. Powell’s group, 
carried out microarray analysis to identify Egr2 and Egr3 as negative regulators of T 
cell activation (Safford, Collins et al. 2005). They took an alternative approach to 
the Czech’s group by using lentiviral system to over-express Egr2 , resulting in the 
reduced expression of IL-2 after T cell activation (Safford, Collins et al. 2005).  
Both groups performed their studies in vitro and had not tested it in vivo 
since Egr2 knockout mice die perinatally due to the defects in the hindbrain 
development (Schneider-Maunoury, Topilko et al. 1993). To assess the function of 
Egr2 in lymphocytes in vivo, our group established Egr2 conditional knockout (CD2-
specific Egr2-/-) model, in which the Egr2 gene was deleted specifically in CD2+ 
lymphocytes using the Cre/LoxP system.  Our group reported that T cells from CD2-
specific Egr2-/- mice were hyper proliferative in response to prolonged stimulation 
and IFN-γ and IL-17 was highly induced, resulting in infiltration of T cells in multiple 
organs. Hence, the results demonstrated that Egr2 is important for controlling self-
tolerance of T cells and preventing autoimmunity (Zhu, Symonds et al. 2008). 
 
1.8.5 Egr family and apoptosis 
Fas ligand (FasL) is a crucial ligand for the apoptotic pathway. Fas ligand 
(FasL) is the membrane associated cytokines of the TNF family and is also induced 
after TCR stimulation and can bind to the Fas receptor.  The FasL-triggered 
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apoptotic death pathway is crucial for T cell homeostasis. A group demonstrated 
that Egr2, along with previously identified Egr3, is a direct regulator of fasL 
transcription in activated T cells. Ectopically expressed Egr2, like Egr3, was sufficient 
to induce fasL specific transcription (Mittelstadt and Ashwell 1999). 
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1.9  Aims of the study 
Intensive research has been associated with the Egr family in the hindbrain 
development and myelination but their association with the immune system is still 
in the early stages. The involvement of Egr2 and Egr3 in T cell tolerance was first 
suggested less than a decade ago. Our group was the first group to produce Egr2 
conditional knockout mice, which had deleted Egr2 expression in CD2+ cells, 
lymphocytes. Previously, it was found that a defect in Egr2 in T cells results in 
accumulation of IFN-γ and IL-17 in CD44highCD4 T cells leading to lupus-like 
autoimmune disease.  Here we have bred CD2-specific Egr2-/- (CD2-Egr2-/-) mice 
with Egr3-/- mice to produce Egr2 and 3 double knockout (Egr2-/-Egr3-/-) mice to 
study the role of Egr2 as previously we proposed that Egr3 compensated the role of 
Egr2. Therefore, the aim of the project was as follow: 
 
1. To distinguish the phenotype of the CD2-Egr2-/-Egr3-/-mice model, as in the 
CD2-Egr2-/- mice. 
2. To characterise the lymphoma developed in CD2-Egr2-/- and Egr2-/-Egr3-/-
mice by histology and immunophenotype. 
3. To identify the mechanism by which Egr2 and/or Egr3 control the 
development of lymphoma development. 
 
The hypothesis of my research is that Egr2 and Egr3 act as tumour suppressor 
genes and are important for the control of tumourgenesis.
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2.1 Experimental Tools and Conditions 
All mice used in this study were maintained in the Biological Services Unit, 
Brunel University, and used according to established institutional guidelines under 
the authority of the UK Home Office project licence (guidance on the Operation of 
Animals, Scientific Procedures Act 1986). 
 
2.1.1  Egr2 Conditional Knockout mice 
Egr2 conditional knockout (CD2-Egr2-/-) mice have a deletion of Egr2 in CD2+ 
lymphocytes.  CD2-Egr2-/- were generated by crossing Egr2LoxP/LoxP mice (obtained 
from P.Charnay, Institute National de la Santé et de la Recherche Médicale, Paris, 
France)  and hCD2-Cre transgenic mice (obtained from Dr D. Kioussis, National 
institute for Medical Research, London) (Taillebourg, Buart et al. 2002; de Boer, 
Williams et al. 2003). The hCD2-Cre transgenic mice induce Cre recombination only 
in T and B cells (de Boer, Williams et al. 2003). Henceforth Egr2 deficient mice will 
be referred as CD2-Egr2-/- mice. 
 
2.1.2  Egr3 Knockout Mice 
Egr3 knockout mice were obtained from Tourtellotte group (Washington 
University School of Medicine, St Louis, USA), which were generated by targeting 
mutagenesis in embryonic stem cells by homologous recombination.  Tourtellotte, 
W.G and Milbrandt, J. cloned the entire Egr3 gene into pBluescript vector. They 
disrupted the Egr3, using a 1.5kb fragment containing a neomycin resistance 
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selection cassette pMC1NeopA , which deleted a 0.9kb fragment of the gene that 
encoded the entire zinc finger DNA binding domain and the remaining carboxyl 
terminus of the protein (Tourtellotte and Milbrandt 1998). From this point forward, 
these will be referred as Egr3-/- mice. 
 
2.1.3  CD2-specific Egr2-/- and Egr3-/- Mice 
Egr2 and Egr3 double knockout mice were generated by interbreeding 
CD2-Egr2-/- and Egr3-/- mice on the C57BL/6 background. From this point forward 
these will be referred as Egr2-/-Egr3-/- mice. 
 
2.1.4  Genotyping 
All the mice were genotyped prior to any studies carried out. The mice tails 
were collected and the genomic DNA was extracted using the REDExtract-N-Amp 
Tissue PCR Kit (Sigma) according to the manufacturer’s instructions. Briefly, the 
DNA was extracted by adding extraction buffer and tissue preparation solution to 
the tails. For the protease enzyme to react with tissue sample, the samples were 
heated at 55˚C for 30mins. Both solutions contain protease enzyme, which break 
down the proteins. The protease enzyme was broken down by heating the samples 
at 95˚C for 3mins. The samples were neutralised by adding neutralisation buffer 
and then used for genotyping. 
The CD2-Egr2-/-, Egr3-/- and Egr2-/-Egr3-/- mice were identified by polymerase 
chain reaction (PCR). PCR is a technique that was developed by Kary Mullis in the 
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1980s. It allows the amplification of nucleic acid sequences, with the aid of an in 
vitro enzyme (Mullis, Faloona et al. 1986; Mullis and Faloona 1987). The 
thermostable DNA polymerase from Thermus aquaticus (also referred to as taq), is 
not denatured at the same temperature as the DNA and can withstand the high 
temperatures required during PCR.  PCR amplifies a specific region of the DNA with 
the aid of primers, which are designed specifically to a particular gene sequence. 
The Taq enzyme extends the primers with the aid of dNTPs complementary to the 
pre-existing strand, therefore producing a copy of the DNA. The primers used for 
genotyping are shown in Table 2.1 with the PCR product size. The wild type PCR 
product is referred to as WT. 
 
Primer Sequence (5’-3’) 
Annealing 
Temperature 
Product Size 
Egr2 
LoxP 
Sense GTG TCG CGC GTC AGC ATG CGT 
65°C 
LoxP allele: 
210bp 
WT allele: 
150bp 
Antisense GGG AGC GAA GCT ACT CGG ATA CGG 
hCD2-
iCre 
Sense CCA ACA ACT ACC TGT TCT GCC G 
56°C 150bp 
Antisense TCA TCC TTG GCA CCA TAG ATC AGG 
Egr3-/- 
Sense CTA TTC CCC CCA GGA TTA CC 
57°C 
Neo Allele: 
800bp 
WT Allele: 
400bp 
Antisense TCT GAG CGC TGA AAC G 
Neo GAT TGT CTG TTG TGC CCA GTC 
 
Table 2.1: Primer Sequences for genotyping 
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2.2 Cell Culture and Stimulation 
2.2.1 Mouse CD4+ and CD19+ Cells 
CD4+ T cells and CD19+ B cells were cultured in Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with 300mg/L L-glutamine, 10% foetal 
bovine serum (FBS), 50µM β-mercaptoethanol (2-ME), and 50µg/ml gentamicin (all 
from Invitrogen). They were maintained in a humidified incubator at 37°C in 5% 
CO2. CD4
+ T cells were stimulated with 200ng/ml PMA/INO or with plate-bound 
anti-CD3 at 5µg/ml or anti-CD28 (2µg/ml) antibodies. CD19+ B cells were activated 
with 5µg/ml of soluble anti-F(ab’)2 fragments of goat anti-mouse IgM (anti-TgM 
F(ab’)2, (Jackson ImmunoResearch Laboratories, Inc.) or Lipopolysaccharide (LPS) 
(Sigma-Aldrich) at 5µg/ml. 
 
2.3  Isolation of primary cells from mouse lymphoid organs 
The secondary lymphoid organs were extracted and single cell suspensions 
were prepared by homogenising the organs. The cells were pelleted by 
centrifugation at 1300rpm for 5 minutes at room temperature. The erythrocytes 
were lysed from the cell pellet using 0.8% ammonium chloride lysis buffer at 37°C 
for 5 minutes. The lysis buffer uses a hypotonic solution to lyse the erythrocytes 
while maintaining the viability of the lymphocytes. The lysis was stopped by diluting 
the lysis buffer with phosphate buffered saline (PBS) and centrifugation at 1300rpm 
for 5 minutes at room temperature.  
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The naïve CD4+ cells were then isolated by Magnetic Activated Cell Sorting 
(MACS) using positive selection kit (Miltenyi Biotec) according to the 
manufacturer’s instructions. Briefly, the cells were incubated with anti-CD4 
antibodies (L3T4) attached to magnetic beads (Miltenyi Biotec) at 4°C for 20 
minutes in beads buffer, composed of PBS containing 0.5% FBS. This labels any CD4+ 
cells with magnetic beads. The unlabelled anti-CD4 antibody was washed with 
beads buffer and centrifuged at 1300ropm for 5 minutes at room temperature. The 
cell pellet was resuspended in beads buffer and run through a magnetic column. 
CD4+ cells are retained on the column due to the magnetic beads while the 
unlabelled cells pass through the column into a collecting tube. The column was 
washed three times with beads buffer to remove any non-specifically bound cells 
and then the CD4+ cells were eluted by removing the column from the magnetic 
field and washing with RPMI 1640 medium containing 10% FBS. The naïve CD19+ 
cells were also isolated by MACS using positive selection kit following the same 
procedure using the remaining unlabelled cells from the previous step. These were 
then labelled with anti-CD19 antibodies attached to magnetic beads (Miltenyi 
Biotec) followed by the same as CD4+ Cells. 
 
2.3.1 Cell Viability  
The cell viability assays measures the percentage of a cell suspension that is 
viable. The cell viability was examined by trypan blue exclusion assay using the 
CountessTM Automated Cell Counter (Invitrogen). The trypan blue dye is traversed 
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into cells without an intact membrane (dead cells), whereas cells with an intact cell 
membrane (live cells) are not coloured by the dye. 
The CD4+ and CD19+ cells were isolated from Egr2-/-Egr3-/- and wild type 
secondary lymphoid organs as described in section 2.3. 2 x 106 cells were cultured 
in RPMI 1640 medium. The initial basal cell viability was examined at day 0 by 
preparing a 1:1 dilution of the cell suspension using a 0.4% trypan blue solution 
(Invitrogen, T10282). This was then loaded into the chamber port on the 
CountessTM cell counting chamber slide (Invitrogen, C10228). The cell viability was 
analysed on the CountessTM Automated Cell Counter. The cells were cultured for 12 
days at 37°C, and cell viability was measured on days 3, 5, 7, 10 and 12.  
 
2.4 Proliferation assay 
To analyse proliferation of T and B cells, tritiated thymidine (3[H]-TdR) 
incorporation was measured. This technique uses the nucleotide thymidine (TdR) 
that is radioactively labelled with radioactive isotope of hydrogen called tritium 
(3H). As the cell proliferates and replicates its DNA, the tritium is incorporated in 
proportional to DNA synthesis, alternatively the proliferation. 
  The proliferation assay was performed by isolating purified CD4+ T and 
CD19+ B cells (as described in section 2.3) and 2 x 106/ml cells were seeded into 96-
well plates. The cells were first incubated for 72 hours in RPMI-1640 medium. The 
cells were then stimulated with 200ng PMA/INO for 48 hours. 1µCi of 3[H]-TdR was 
added to each well  and cultured for 8 hours at 37˚C, then the DNA was harvested 
onto glass fibre filters and unincorporated 3[H]-TdR was washed away. Tritium 
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incorporation was measured by scintillation counting, as tritium emits β radiation 
which excites scintillation fluid causing it to emit light which can be detected.  
Proliferation was measured at days 3, 5 and 10. The scintillation counting 
was carried out at Barts and London School of Medicine and Dentistry, Queen Mary 
University of London, by Professor Ping Wang. 
 
2.5 Adoptive Transfer 
The adoptive transfer was carried out by Dr Su-Ling Li and Professor Ping 
Wang at Brunel University. Briefly a total of 106 resting B or Naïve CD4+ T cells were 
isolated from a 4 week old wild type or Egr2-/-Egr3-/- mice and suspended in 100µl of 
physiological saline and injected into the dorsal tail vein of a 12 week old Rag2-/- 
female. The phenotype was assessed at two and six weeks after transfer through 
isolation of the B and T cells from the spleen. The wild type mice were positive for 
CD45.1+ marker and the Egr2-/-Egr3-/- were positive for CD45.2+ marker. 
 
2.6 RNA Extraction of Cells 
Total RNA was extracted using Trizol reagent (Invitrogen). The Trizol reagent 
is a monophasic solution of phenol, guanidine isothiocyanate, which allows the 
sequential precipitation of RNA, DNA, and proteins from a single sample 
(Chomczynski and Sacchi 1987; Chomczynski 1993). RNA extraction was carried out 
according to the manufactures instructions. Briefly, cells were pelleted and then 
lysed in 1ml Trizol per 107 cells and then incubated at room temperature for 10 
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minutes. 200µl of chloroform was added to the sample for homogenization and the 
sample was mixed vigorously, incubated at room temperature for 15 minutes and 
then centrifuged at 12000rpm for 15minutes at 4°C. The chloroform increases the 
efficiency of nucleic acid extractions by reducing loss of RNA due to its ability to 
denature proteins and aid in the removal of lipids, therefore improving separation 
of nucleic acid into the aqueous phase (Chomczynski and Sacchi 2006).  
After centrifugation, the sample was separated into a lower red organic 
phase, interphase and a colourless aqueous upper phase. The RNA is separated into 
the aqueous phase while the protein and DNA is located in the organic and 
interphase. The aqueous phase was transferred into a new eppendorf tube and the 
RNA was precipitated with 500µl isopropanol, incubated at room temperature for 
10 minutes. The sample was then centrifuged at 12000rpm for 10minutes at 4°C. 
The supernatant was removed and the pellet was washed with 75% RNA free 
ethanol at 7500rpm for 5 minutes at 4°C. The waste was discarded and the RNA was 
air dried and then resuspended in RNase-free DEPC water.  
 
2.7 RNA Extraction for Tumour Samples 
Total RNA was extracted from the tumour tissue samples using the RNeasy 
mini kit (Qiagen, UK). Prior to RNA extraction, fresh 1ml RLT buffer (guanidine 
thiocyanate buffer) was prepared by adding 10µl of 2-ME.  Briefly the tumour 
samples (no more than 30mg) were sectioned into small pieces no less than 0.5cm 
and homogenised in 600μl of prepared RLT buffer.  
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The cell and the tissue sample were homogenised using a syringe and a 
needle. The lysate was passed through a 20-gauge (0.9mm) needle attached to the 
sterile plastic syringe until a homogeneous lysate was achieved. 600μl of 70% 
ethanol was added to homogenised lysate; the sample was mixed well by pipetting. 
700μl of the sample was transferred into an RNeasy spin column placed in a 2ml 
collection tube and centrifuged at 10000rpm for 15 seconds. The waste was 
discarded and the step was repeated for the remaining 500μl sample. 700μl of RW1 
wash buffer was added to the column and centrifuged at 10000rpm for 15 seconds. 
Flow through waste was discarded and the column was washed with 500μl of RPE 
buffer (to which ethanol was added) by centrifugation at 10000rpm for 15 seconds. 
The column was washed again with RPE buffer by centrifugation at 10000rpm for 2 
minutes. The RNA was eluted in 50ul of RNase-free water into a new eppendorf 
tube by centrifugation at 10000rpm for 1 minute.  
The RNA quantity was measured using the spectrophotometer NanoDrop 
2000C (Thermo Fisher Scientific) and the RNA quality was assessed by both the 
NanoDrop 2000C and confirmed by electrophoresis. 
 
2.8 First-Strand cDNA Synthesis  
RNA was converted to first strand cDNA using SuperScriptTM III (Invitrogen). 
The SuperScriptTMIII Reverse Transcriptase is a version of Murine Moloney 
Leukaemia Virus (MML V-RT). The enzyme catalyses the formation of the 
complementary cDNA strand using the RNA template. cDNA synthesis was 
performed in the first step using total RNA with random primers, they act as 
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primers for reverse transcriptase. Volumes of solutions were chosen to give 1µg 
RNA per reaction, 50ng of random primers and 500µM each of dATP, dTTP, dCTP 
and dGTP were added to each tube. These were then heated to 65°C for 5 minutes 
to denature any secondary structures present in the RNA, facilitating the binding of 
the oligo (dT) or random primers. The samples were then placed on ice. Reagents 
were added to give a final concentration of 0.01M DDT (Dithiothreitol), 2 Unit/µl of 
RNase Inhibitor and 10 Units/µl of SuperScriptTM Reverse Transcriptase in 1x First 
Strand Buffer (all Invitrogen). The reaction was mixed and heated to 25°C for 5 
minutes and then to 50°C for 1 hour. The reaction was then inactivated by heating 
to 70°C for 15 minutes. The samples were stored at -20°C. 
 
2.9 Primer Design 
PerlPrimer was used to design the primers for the Real Time PCR, using the 
following criteria (Marshall 2004). Primers were designed to have approximately 20 
to 23 nucleotides with around 50% G/C content. The sense and antisense primers 
were designed so that they anneal to different exons of the sequence of interest. 
Hence allowing the identification of genomic DNA contaminants as these will 
contain the intervening introns in addition to the exons so will be larger and 
therefore detectable via electrophoresis. The melting temperature (Tm) of each 
primer was estimated using the Wallace rule (Tm = 4 x [G + C] +2 x [A + T]) and the 
annealing temperature was initially set at Tm - 2°C and altered as necessary. All 
primers were then checked using NCBI primer blast software. For the endogenous 
gene, mouse β-actin was used (Table 2.2). 
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Gene Primer Strand Primer Sequence (5'-3') 
β-actin 
Sense AATCGTGCGTGACATCAAAG 
Antisense ATGCCACAGGATTCCATACC 
Brca1 
Sense CTGGACAGAAGACAGCAACTGC 
Antisense ACCAGGTAGGCAACCAGATC 
Casp3 
Sense CAGAAGATACCGGTGGAGGC 
Antisense AGCTTGTGCGCGTACAGCTTC 
Ccna2 
Sense CCTTCACCAGACCTACCTCAA 
Antisense ATGGACTCCGAGCGACTCCT 
Ccnb1 
Sense CGTAGAGCATCTAAAGTCGG 
Antisense ACTGTAGGATAGGTAGTGCTG 
Ccnb2 
Sense GAACACCAAAGTACCAGCTC 
Antisense CCTGTCCTCGTTATCTATGTC 
Ccne1 
Sense CCACACCAACAGCTTGGATT 
Antisense TGCTCTGCTTCTTACTGCTGG 
Ccnf 
Sense GATGCACCCAAAGACTACAG 
Antisense CACAAGTCAGCATAGCTCAG 
Cdc25b 
Sense ACAAGGAGTTCTTCCCACAG 
Antisense GAGTCTTAAGGCGAAAGTTCC 
Chek1 
Sense GATACTGGTTGACTTCCGAC 
Antisense CAGAGCTGACAGCTTCCTCA 
Gadd45a 
Sense GAAAGGATGGACACGGTGG 
Antisense GATCTGCAGAGCCACATCC 
E2f1 
Sense TTGGATCCCAGTCAATCCCT 
Antisense AAGTGATAGTCAAGGGCCTC 
E2f2 
Sense GGATCGCAGAGACCATAGAG 
Antisense CAGCATGTTGTCAGTGGCTT 
Cks1b 
Sense ATCTGAATGGAGGAACCTCG 
Antisense AGAAAGCAACATGGTCACGC 
 
Table 2.2: Real Time PCR primer sequences 
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Gene Primer Strand Primer Sequence (5'-3') 
Mad2l1 
Sense ATTCGCTCAGTGATTAGACA 
Antisense AATTGCGGTCCCGATTCTTC 
Mcm2 
Sense GCTGAGCAGGTGACATATCA 
Antisense TGAAGAGGTCGCTGTCGTAG 
Mcm3 
Sense CCGATGATTCTCAGGAGACC 
Antisense TGGATTCTGTGAGGTGGAGC 
Mki67 
Sense CAGCAAGAGGCATGTATCACC 
Antisense CTTTATCCCGACATTCTCTGC 
Mybl2 
Sense GAGAAGCAGAAGAGAAAGCC 
Antisense ATGTTACCCTCTTTGCTACC 
Nek2 
Sense CCTGCTGAAGGAGCACAGGC 
Antisense AGAATTCTCACTCCTTGCGG 
Rad51 
Sense GTCGCAGTGGTAATCACCAA 
Antisense TTCTCAGGTACAGCCTGGTG 
Rad51ap1 
Sense TGAGGCATCAGTGACTTCAG 
Antisense CCAATGCATTGCTGCTAGAG 
Wee1 
Sense AAGAGCGCAGAGCAGTTACG 
Antisense AGTGGCCATCCGATCTGTGA 
Abl1 
Sense CTATGGCATGTCACCTTACC 
Antisense GTGGATTTCAGCAAAGGAGG 
Atm 
Sense AGCAGAGACCAGAAGATGAG 
Antisense TAAGCAAGTTCACCTGTCCAC 
Macf1 
Sense CATCCCTCAGAACATAGACAG 
Antisense CAAGGACTTTCTGCTACCAC 
Pkd1 
Sense CGCTTTACTAGAGTCCAGAG 
Antisense GCCAAATAGACAGGGTAGAC 
Rad9b 
Sense TCTGCAGCTGAAACCAAGAG 
Antisense CTGTTCACAAGATACAGCTCC 
Dstyk 
Sense GCCCTCAAATCAGTTGTTCC 
Antisense GCTCCATGATAAGCAGTACAG 
Table 2.2: Continued 
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Gene Primer Strand Primer Sequence (5'-3') 
Rad9b 
Sense TCTGCAGCTGAAACCAAGAG 
Antisense CTGTTCACAAGATACAGCTCC 
Sfn 
Sense TTTCAGTCTTCCACTACGAG 
Antisense TCCTTGTAGGAGTCCTCAC 
sp100 
Sense CCAAACCAAAGCAAAGGAAAGAG 
Antisense CTGTGGTTGTGAAAGATGAGG 
Siglech 
Sense TTCTTCCTCAGCAAGAGATCC 
Antisense ACCATCATCCATGACTTTCTTGAC 
Rbm38 
Sense CTTACAGACGGGCTTTGCTG 
Antisense CTGGCTGGTGTATACTCAAGG 
Prkcq 
Sense TTGTCTACAGGGACCTGAAGC 
Antisense GGAATGGTTGTACTTCTGACCC 
Prdm9 
Sense CACAGCAGGAAGAGAACTAAGG 
Antisense GATTTCAGTGCGATGATTCCA 
Prdm1 
Sense AACCTGAAGGTCCACCTGAG 
Antisense TGCTAAATCTCTTGTGGCAGAC 
Irgm1 
Sense CCCTTTACTATATGACTTCCCGA 
Antisense GTTGGCTATTCTCTGCTTCC 
Irf4 
Sense CAGCTCATGTGGAACCTCTG 
Antisense GTATTTCTTCTCACTCTTGGATGG 
Ipcef1 
Sense GCATTTAAGATCAATCACCCAC 
Antisense CTCTCACTGTAACATTCTTCATCC 
Il9r 
Sense CATCCTTGTAGTTGTGCCCA 
Antisense CCTGTCCAACTCTGGAAGTC 
Ikzf1 
Sense AATTTCTTGGAGACAAGTGCCT 
Antisense CTGGTACATGGAGCTGATGAC 
Ikzf3 
Sense CAGATTAGCAAGCAATGTGG 
Antisense CATCATCTCGTTCTCCTTCTC 
Ifng2 
Sense AATCGAAGAGTATCTAAAGGACCC 
Antisense CTGGAGAAGAAATAATTGACACGG 
Table 2.2: Continued 
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Gene Primer Strand Primer Sequence (5'-3') 
Ikzf3 
Sense CAGATTAGCAAGCAATGTGG 
Antisense CATCATCTCGTTCTCCTTCTC 
Ifng2 
Sense AATCGAAGAGTATCTAAAGGACCC 
Antisense CTGGAGAAGAAATAATTGACACGG 
Hjurp 
Sense GGAATACACTCAGGTGATTGAC 
Antisense CAAGATGGCCAGTTCTCCTC 
Hivep3 
Sense CGAAGAAGGAACCAGTGATGAC 
Antisense CCTCCTCATCTTCATCCAGGT 
Hdac7 
Sense GGGTGCACAGGAAATACTGG 
Antisense GAGGTTCATGGGTTCTTCCTC 
Gtf3c5 
Sense CAAGAAGACATCCAACCAGCC 
Antisense CAACTCCTCCACATTCAAATCAC 
Gfi1 
Sense CAAATGCAGCAAGGTGTTCTC 
Antisense TCTTGCCACAGATCTTACAGTC 
Foxo3 
Sense CAAAGCAGACCCTCAAACTG 
Antisense ATGTTATAGAGTTCTGTTCCACGG 
Dgkz 
Sense TGGATCATGCACCTCCAGAG 
Antisense CTGTGTCTTGAGCCTTCTCAG 
Dcun1d4 
Sense CTTCCCTACAATGTGATACAACAG 
Antisense ACTTGGCAGTGTTTATGTCTAGG 
Dcaf6 
Sense CCGTTTGACCCAATTCTAGCC 
Antisense GGTGTTCCGAGTCTCTTCCA 
Chd3 
Sense TAAGCCTGCTACTCCAGCTC 
Antisense CACTTTGCTGTTCTTCTCTGG 
Chd2 
Sense AGTAAATCAAAGCGATCTCAGG 
Antisense CATCCTCTCCTTACAAATGCTG 
Cdk12 
Sense CAGCGGCACTTGATCTATTGG 
Antisense CAGTGAGGTAGGTCTGGAGG 
Btaf1 
Sense AGACTATTACTGTACTCTCAGCCC 
Antisense ATTGTAACGCCTGGAATACATGAC 
Table 2.2: Continued 
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Gene Primer Strand Primer Sequence (5'-3') 
Bcl9 
Sense CAGACCACATCAAGTCCCAG 
Antisense CTTCTGCAGCCTTATTTGCC 
Zmynd8 
Sense CTCCAATCAAAGCTCTGTTAGCA 
Antisense GGGAATGGTACTTCTGGGCT 
Zfp36l2 
Sense CACAAGCACAACTTTCCGTC 
Antisense GGGATTTCTCCGTCTTGCAC 
Unc5a 
Sense CTTTAACATCACTAAGGACACGAG 
Antisense GGTGAAGTTTCTGGGCTAGAG 
Ubr3 
Sense AGTTAAGGGCACTGAAGAGG 
Antisense CAATAGGACTGACCATCGCAC 
Ssh2 
Sense GACCAGTCGAAGGCAATCAC 
Antisense CATGAATGGTGCTCTTCTTTGGT 
Spic 
Sense AATGTCACCCACAGAGAACC 
Antisense TTTCTCCTGCCTCTTCCTCC 
Bptf 
Sense CTGTGATCGGTGTCAGAATTGG 
Antisense TCTTGTGGGCCTGTAAGGAG 
mTERT 
Sense TCAAGAATCCAGGAATGACAC 
Antisense AGCTTTAAGGATGGTCATTGTC 
Table 2.2: Continued 
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2.10 Real Time RT-PCR 
Real Time PCR is a highly sensitive technique based on the same principle as 
normal PCR with the adaptation of allowing the quantitative comparison of gene 
expression from different samples (Pfaffl 2001). Real Time RT-PCR performs a 
relative quantification based on the relative expression of a target gene against a 
reference gene (often referred as ‘housekeeping’ or ‘endogenous’ gene). The 
quantification is simply performed by the detection technique for newly 
synthesised PCR products in real-time PCR using SYBR Green I fluorescence dye 
which directly binds to double stranded DNA. After each round of the product 
synthesis, the amount of product is calculated by the measurement of the 
fluorescence (Morrison, Weis et al. 1998). The Real Time RT-PCR was performed 
with QuantiTect SYBR Green PCR kit (Qiagen) as per the manufacturer’s 
instructions; briefly using 1µl of  cDNA and a final concentration of 0.2µM of 
relevant sense and antisense primers in 1 x SYBR Green Master Mix. The Real Time 
RT-PCR was performed on a Rotor-Gene System (Corbett Robotics) using the 
following program.  
 
95°C for 10 minutes 
95°C for 20 seconds 
Annealing temperature (50-65°C) for 30 seconds 
72°C for 20 seconds 
 
 
40 cycles 
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Like all techniques, there is a limitation that occurs with RT-PCR; the SYBR 
Green also binds non-specifically to double strand DNA and can form primer dimer 
complexes. Therefore, after the Real Time RT-PCR cycles had completed, a melting 
curve analysis was performed, during which the fluorescence intensity was 
monitored as the temperature was increased from 50°C to 90°C. The melting curve 
identifies any non-specific products such as the primer dimers. The Tm is the 
temperature at which 50% of a particular DNA duplex dissociates and becomes a 
single stand DNA. The shape and the position of the DNA melting curve are 
dependent on the GC/AT ratio, with the melting temperature of nucleic acid duplex 
increases with both its length and width increasing GC content (Ririe, Rasmussen et 
al. 1997). To validate, once the PCR reaction had completed, the products were run 
on an agarose gel to confirm that there was only one band with the correct product 
size. 
 
2.10.1 Real Time RT-PCR Data Analysis 
The data analysis for the Real Time RT-PCR was carried out using the Rotor-
Gene Software. The analysis was performed by choosing a threshold value which 
was at the exponential phase of the reaction (when the number of copies of DNA 
molecule doubles, during each cycle). Eventually the reaction comes to a plateau 
phase, due to a number of factors such as utilisation of primers or nucleotides or 
thermal inactivation of DNA polymerase.  Hence the threshold value is chosen at 
the exponential phase and the number of cycles (Ct) for the florescence to reach 
the threshold for each sample is identified. The Ct values of the samples are then 
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compared to the Ct value of the reference gene (mouse β-actin was used), this is to 
normalise the results, correcting any variances in the mRNA amount that permits 
the comparison of different samples. The relative expression was calculated by the 
ΔΔCt method using the following equation: 2^(Ct(β-actin)-Ct(target gene))x10000 (Livak and 
Schmittgen 2001; Pfaffl 2001) 
 
2.11 Western Blot 
Some of the western blots were performed by Dr Tizong Miao at Barts and London 
School of Medicine and Dentistry, Queen Mary University of London. 
 
2.11.1 Protein Extraction 
The cells were harvested and washed once with PBS. The cells were then 
resuspended in 100µl of CelLytic M lysis buffer containing 1mM PMSF 
(Phenylmethylsulfonyl fluoride) and protease and phosphatase inhibitors (Roche). 
The cells were then swelled on ice for 15 minutes. The samples were centrifuged at 
13000rpm for 5 minutes at 4°C and the supernatant containing the protein was 
transferred into a new tube. The protein extraction was aliquoted and stored at 
80°C.  
 
2.11.2 Protein Quantification 
The protein extraction was quantified using the Bradford Assay. Briefly a 
standard curve was prepared using a serial dilution series (0mg/ml to 10mg/ml) of 
  Chapter 2 – Materials and Methods 
 
87 
 
purified BSA 100X (10mg/ml). The standard curve was constructed by plotting the 
absorbance value against the known BSA concentration. The protein concentrations 
of the samples were measured against the BSA standard curve. 
 
2.11.3 SDS PAGE Electrophoresis and Western Blotting 
The protein samples were mixed with 1x LDS buffer (Invitrogen) and 2-ME 
and heated to 70°C for 10 minutes to denature and reduce the proteins. The 
protein samples and 5µl of Novex® Sharp Pre-stained protein standard (Invitrogen) 
were loaded into the wells of 12% NuPAGE® Bis-Tris Gel (Invitrogen). The SDS-PAGE 
(Sodium Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis) gels were cast and 
run using the Bio-Rad Western apparatus and electrophoresed in 1X SDS-PAGE 
running buffer at 200V for 35 minutes at 4°C.  SDS-PAGE is a technique that 
separates proteins according to their electrophoretic mobility (size and charge of 
protein). The SDS detergent is used to coat the proteins with a negatively charged 
sulphate group, as there is no relationship between the charge and size of a 
protein. The SDS treated proteins will then migrate, in an electric field, according to 
their size and can be separated by electrophoresis using a Polyacrylamide gel.  
After separation by electrophoresis, the proteins were transferred onto a 
nitrocellulose membrane (Amersham). Before the transfer, the membrane was 
activated by incubating it in methanol for less than one minute, followed by 5 
minute incubation in dH2O and finally soaking it in wet-transfer buffer.  The gel was 
placed on top of the nitrocellulose membrane, which was then sandwiched 
between two pieces of Whatman filter paper. The sandwiched gel and 
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nitrocellulose paper were place in a cassette in the wet transfer system. The 
transfer of the protein to the membrane for 1.5 hours at 30V was performed at 4°C. 
This allowed the negatively charged proteins to move across towards the anode; 
however it does not allow the proteins to pass through the nitrocellulose 
membrane and hence are retained on the surface in the same alignment as in the 
gel. 
After the proteins were transferred on to the membrane, the membrane 
was blocked in 5% w/v milk in TBST (Tris Buffered Saline with 0.1% Tween 20) for 
1-2 hours at room temperature, before being incubated with the corresponding 
primary antibodies (see Table 2.3). The primary antibodies were diluted according 
to manufacturer’s instructions in blocking buffer and incubated at 4°C with 
agitation. The following day, unbound primary antibody was removed by washing 
the membrane 3 times in TBST, 15 minutes each at room temperature. The 
membrane was then incubated in either goat anti-rabbit IgG HRP (Horseradish 
peroxidase) conjugated or goat anti-mouse IgG HRP conjugated secondary antibody 
for 1 hour at room temperature (Table 2.3). The secondary antibody was prepared 
in 5% milk in TBST, at a 1:2000 dilution. The membrane was washed 3 times in TBST 
for 15 minutes each at room temperature to remove any unbound secondary 
antibody.  
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     Primary Antibodies        Secondary Antibodies 
Antibody Species(Details) 
 
Dilution Antibody Dilution 
pSTAT3 Rabbit (Cell Signalling 
Technology, 9145) 
1:2000 Goat anti rabbit IgG 
HRP (Biorad, 
172-1019) 
1:2000 
STAT3 Rabbit (Cell Signalling 
Technology, 9132) 
1:1000 Goat anti rabbit IgG 
HRP (Biorad, 
172-1019) 
1:2000 
IKZF3 Rabbit (Abcam, ab26083) 1:500 Goat anti rabbit IgG 
HRP (Biorad, 
172-1019) 
1:2000 
FOXO3 Rabbit (Abcam, ab47409) 1:1000 Goat anti rabbit IgG 
HRP (Biorad, 
172-1019) 
1:2000 
Egr2 Rabbit (Santa Cruz, 
sc-20690) 
1:1000 Goat anti rabbit IgG 
HRP (Biorad, 
172-1019) 
1:5000 
Egr3 Rabbit (Santa Cruz, 
sc-191) 
1:200 Goat anti rabbit IgG 
HRP (Biorad, 
172-1019) 
1:5000 
β-actin Mouse (Cell Signalling 
Technology, 3700) 
1:1000 Goat anti mouse IgG 
HRP (Sigma, A4416) 
1:10000 
 
Table 2.3: List of primary and secondary antibodies used for western blot with 
relevant dilutions. 
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2.11.4 Protein Detection with Chemiluminescence 
The membrane was transferred onto a cling film where the antibody 
complexes were detected by ECL (Enhanced Chemiluminescence) plus kit 
(Amersham) according to the manufacturer’s instructions. Briefly Solution A 
containing 100mM Tris and 30% H2O2 was mixed with solution B containing 
100mM Tris, 90mM coumaric acid and 250mM luminol was applied to the 
membrane blot for 5 minutes at room temperature. This reagent contains 
substances that are oxidised, catalysed by HRP, producing a luminescence signal.  
All excess solutions were drained and the luminescence was detected by exposing a 
photographic film (Kodak, Biomax x-ray film) to the membrane and then developing 
the film.  
 
2.12 Flow Cytometry 
Flow cytometry is a technique used to investigate the multiple phenotype 
and functional parameters simultaneously within a single cell or a mixed population 
of cells. The protein of interest is identified by the use of antibodies that have a 
high affinity to it. The antibodies are usually directly conjugated to a fluorescent 
marker that is detectable by the fluorescence emitted from stained cell. Flow 
cytometry can also detect the cell complexity and size by the forward and side 
scattered light.  
Single cell suspensions were obtained from the homogenised spleens or 
lymph nodes, which were then incubated with indicated fluorescently labelled 
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antibodies on ice for 30 minutes in PBS containing 3% FBS. Fluorescein 
isothiocyanate (FITC)-conjugated antibodies to B220, CD4, and CD8 were used. 
Other antibodies that were used were phycoerythrin (PE)-conjugated antibodies to 
CD3, CD4, CD8, CD19, CD25, CD62L, CD69; PerCP labelled antibodies to CD3, CD19, 
B220; allophycocyanin (APC)-conjugated antibodies to CD44, CD3, and CD19. All 
these antibodies were obtained from BD Biosciences. PE-conjugated antibody to 
Aiolos was obtained from eBioscience (12-5789-80). Anti-Mouse Egr2 PE-
conjugated and Anti-Mouse Egr2 APC-conjugated antibodies were obtained from 
eBioscience. After incubation the cells were washed and resuspended in PBS and 
run through the flow cytometer, LSRII (BD Immunocytometry Systems) and the data 
was analysed using FlowJo (Tree Star) at Queen Mary University of London BY 
Professor Ping Wang.  
 
2.13 Apoptosis Assay 
The process of apoptosis brings about a number of changes to the cells 
specific morphologic features, such as loss of plasma membrane asymmetry, 
condensation of cytoplasm and nucleus. The loss of the plasma membrane 
asymmetry occurs at the early stages of apoptosis and causes the membrane 
phospholipid phosphatidylserine (PS) to translocate from the inner to the outer 
leaflet of the plasma membrane, hence exposing it to the external cellular 
environment. To determine the number of apoptotic cells, they were stained with 
Annexin V (BD Bioscience); a protein that binds to the PS. The cells were also 
stained in conjunction with Propidium Iodide (PI). This was to exclude the cells that 
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were already dead, as PI binds to nucleic acids and hence these are only obtainable 
by the permeable membranes of dead cells. Therefore cells that are negative for 
both Annexin V and PI are considered viable, while cells that are positive for 
Annexin V and negative for PI are in their early stages of apoptosis. Cells that are 
identified positive for both Annexin V and PI are cells in their late apoptosis or 
already dead.  
The staining was carried out as per the manufacturer’s instructions. Briefly 
the cells were resuspended in Annexin V binding buffer containing 100mM HEPES, 
140mM NaCl, 25mM CaCl2, pH 7.4 and APC-conjugated Annexin V and PI. The cells 
were incubated for 15 minutes in the dark at room temperature. After 15 minutes, 
the sample was further diluted in the binding buffer containing 
7-amino-actinomycin (7AAD from BD Bioscience), which is used for the exclusion of 
nonviable cells. The cells were analysed on a LSRII (BD Immunocytometry Systems) 
at Queen Mary University of London.  
 
2.14 Identification and characterisation of tumours  
2.14.1 Tissue Preparations 
All tissue samples collected were recorded and assigned an ID number. All 
tumours were assigned the name “KO” followed by the next ascending letter, such 
as ‘A’, ‘B’, or ‘C’.  
The tissue samples were collected and fixed in 4% paraformaldehyde (PFA) 
overnight at 4°C. The 4% PFA was replaced with 70% ethanol prior to paraffin 
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processing to wash away the PFA. The organs were secured within the cassettes 
and placed within the Shandon Hypercenter XP tissue processor which takes the 
tissue sample through a series of graded alcohol concentration washes to 
dehydrate the tissues and then into xylene followed by the tissues permeating in 
hot paraffin (Table 2.4). 
Tissues processed into paraffin were melted at 65°C and the paraffinized 
specimens were placed into a mould and embedded with hot paraffin. The samples 
were left to cool and stored at room temperature. The tissue samples were 
sectioned into 7μm sections using a microtome. The cut sections were placed into a 
50°C water bath and then mounted onto polysine-coated microscope slides. The 
slides were incubated at 60°C for approximately 30 minutes and left at 37°C 
overnight. 
 
Program Temp Immersion Time 
1 x 70% Alcohol Room Temp 2 hours 
1 x 90% Alcohol Room Temp 2 hours 
1 x 95% Alcohol Room Temp 2 hours 
3 x 100% Alcohol Room Temp 2 hours 
2 x Xylene Room Temp 2 hours 
2 x Paraffin wax 60°C 2 hours 
Table 2.4: Tissue processing program. Tissues were dehydrated with alcohol, 
cleared with xylene and infiltrated with paraffin wax. 
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2.14.2 Haematoxylin and Eosin Staining 
Haematoxylin and eosin staining (H&E) is the most commonly used tissue 
staining for the histology of animal tissues and routine pathology. Haematoxylin 
gives a dark purplish blue, which stains the chromatin within the nucleus. Eosin is a 
pink to red dye that stains the cytoplasmic material, as well as the connective 
tissues and collagen.  
The staining was performed as follow; the tissue sections were 
deparaffinised and rehydrated by first incubating in 100% xylene and then in 
decreasing concentrations of ethanol (100%, 95%) for 3 minutes each. The tissue 
sections were dipped in ddH2O before incubating in Harris acidified haematoxylin 
(6 minutes), acid alcohol (~15 secs), 0.2% ammonium, solution (40secs), Eosin 
(45secs). Between each step, the slides were cleansed under running tap water. The 
tissue sections were then dehydrated in a series of ethanol solutions (95%, 100%) 
for 2 minutes each, followed by 3 times in 100% xylene. The slides were mounted 
with Histomount (National Diagnostics, HS-103 ), covered with coverslips and left 
overnight to dry. Histomount is a neutral solution of isomers and non-hazardous 
ingredients in xylene. By applying this solution the coverslips were permanently 
attached to the slides. The tissue sections were analysed using a conventional 
microscopy (Axioskop 2). The histology examination of the tissue sections was done 
in a blind manner. 
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2.14.3 Immunohistochemistry Staining  
All Immunohistochemistry staining were analysed using a Zeiss fluorescence 
microscope equipped with a CCD camera and the Smart Capture software (Digital 
Scientific Cambridge, UK). 
 
2.14.3.1 Immunohistochemistry Staining on cells 
The cells were harvested and smeared onto Superfrost plus microscope 
slides (Thermo Scientific). The cells were left to dry at room temperature for 30 
minutes and then fixed in acetone for 10 minutes at -20°C. The slides were left dry 
for approximately 10 minutes. The cells were washed twice in sterile cold 1 X PBS 
for 5 minutes each followed by blocking in 10% normal goat serum (Invitrogen) for 
one hour at room temperature, to minimise any non-specific binding of IgG. The 
cells were incubated with the appropriate primary antibody (Table 2.5) in a 
humidified chamber at 4°C overnight.  
The following day, the cells were washed three times in 1 X PBS for 10 
minutes each, at room temperature to remove any unbound primary antibody. The 
cells were incubated with their respective secondary antibody (Table 2.5) for 2 
hours in the dark at room temperature. The cells were washed again three times 
with 1 X PBS for 10 minutes each at room temperature to remove any unbound 
secondary antibody. The slides were dried before mounting them in Vectashield® 
Mounting Medium containing DAPI and covered with a coverslip, removing any 
excess mounting media and the cells were visualised with a fluorescent microscope. 
  Chapter 2 – Materials and Methods 
 
96 
 
Negative controls were prepared by omitting the primary antibody during the 
immunohisotchemsitry procedure. 
 
Primary Antibodies 
 
Secondary Antibodies 
Antibody Species(Details) Dilution Antibody Dilution 
Ikaros Rabbit (Abcam, 
ab26083) 
1:200 Goat anti rabbit Alex Flour 
594 (Invitrogen, A11012 ) 
1:2500 
FOXO3 Rabbit (Abcam, 
ab47409) 
1:300 Goat anti rabbit Alex Flour 
594 (Invitrogen, A11012 ) 
1:4000 
Table 2.5: List of primary and secondary antibodies used in IHC on cells. 
 
 
2.14.3.2 Immunohistochemistry staining on paraffin-
embedded tissues. 
For the identification of the tumour phenotype, the paraffin embedded 
tumour tissues were deparaffinised and rehydrated by incubating first in 100% 
xylene and then in decreasing concentrations of ethanol (100%, 90%, 70%). Antigen 
retrieval was performed by boiling the slides in 10mM Tris/1mM EDTA, pH 9.0 (or in 
EDTA) for 20 minutes at 95°C. The slides were cooled at room temperature for 30 
minutes and then blocked in 10% normal goat serum in PBS for 1 hour. The slides 
were then stained with the relevant primary antibody (Table 2.6) prepared in 10% 
normal goat serum in PBS and incubated overnight at 4°C in a humidified chamber.  
After washing with PBS, the sections were stained with the relevant 
secondary antibody (Table 2.6) for 2 hours at room temperature.  The sections were 
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washed thrice with PBS and counterstained with DAPI and visualised with a 
fluorescence microscope.  
 
Primary Antibodies Secondary Antibodies 
Antibody Species(Details) Dilution Antibody Dilution 
CD3 Rabbit (Dako, A0452) 1:100 Goat anti rabbit Alexa 
Flour 594 (Invitrogen, 
A11012) 
1:400 
B220 Rabbit (BD, 550286) 1:20 Goat anti rat FITC (Sigma, 
F-625) 
Or 
Rabbit anti rat Texas Red 
(Abcam, ab6732)  
1:200 
pSTAT3 Rabbit (Cell Signalling 
Technology, 9145) 
1:200 Goat anti rabbit Alexa 
Flour 594 (Invitrogen, 
A11012) 
Or 
Goat anti rabbit Alexa 
Fluor 488 (Invitrogen, 
A-11008) 
1:2000 
 
 
1:1000 
PCNA 
 
Mouse (Santa Cruz, SC-
56) 
1:100 Rabbit anti Mouse Alexa 
Flour 488 (Invitrogen, 
A11059) 
1:100 
Table 2.6: List of primary and secondary antibodies used in IHC on paraffin tissue 
sections. 
 
2.14.3.3 Detection of Immunoglobulin deposition in Kidney 
The detection of the immunoglobulin deposition in the glomeruli was 
performed by deparaffinising the kidney sections as mentioned above. The sections 
were stained with Texas Red conjugated donkey anti-mouse IgG (Jackson 
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ImmunoResearch Lab, INC) at room temperature for 2 hours. The sections were 
washed with PBS and counterstained with DAPI.  
 
2.15 Microarray 
CD4+ T cells were isolated from CD2-Egr2-/- and wild type mice by MACS, as 
described in section 2.2, and were stimulated with or without plate bound anti-CD3 
for 6 hours. Total RNA was extracted using the Trizol reagent as described in section 
2.5. The genome –wild transcriptional profiles were analysed using MouseRef-8 
v2.0 BeadChip expression array (Illumina). The BeadChip array consists of 50-mer 
oligonucleotide probes that targets ~ 25,600 well-annotated RefSeq transcripts.  
The probe labelling, array hybridization and data processing were carried 
out at the Microarray Facility, Barts and London School of Medicine and Dentistry, 
Queen Mary University of London, according to the manufacturer’s instructions. 
Briefly the fluorescently labelled RNA sequence is hybridised to the array, where 
the labelled RNA will hybridise to the complementary sequences present on the 
array. Any unbound RNA was washed away. The array was then scanned to detect 
the fluorescence intensity, providing the genome wide transcriptional profile for 
the sample compared to the control.  
The data analysis was also performed by Dr Alistair Symonds at Barts and 
London School of Medicine and Dentistry, Queen Mary University of London, which 
was returned to us to perform further data analysis. We focused on the gene that 
showed a difference of at least 2 fold between the wild type and CD2-Egr2-/- CD4+ T 
cells and excluded the gene that had a detection p value greater than 0.05. The 
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differently expressed genes were first grouped based on self-organisation maps 
(SOMs) by clustering algorithm method. The SOM clusters were further clustered by 
a hierarchical clustering program to confirm the different profile. The gene 
expression profile genes were validated by Real Time RT-PCR and any genes that 
has a detection p-value greater than 0.05 were excluded. 
 
2.16 Chromatin Immunoprecipitation. 
Chromatin Immunoprecipitation (ChIP) is a technique that enables the 
detection of Protein DNA interaction in vivo. The protein of interest is specifically 
precipitated by an antibody to its associated DNA. The ChIP assays were performed 
in accordance with the protocol supplied with the kit (cat 9003 from Cell Signalling 
Technology). This procedure was performed by Dr Tizong Miao. 
Briefly, 5 x 107 CD4+ T cells from Egr2 transgenic mice were stimulated with 
plate bound anti-CD3 and anti CD28 for 3 hours at 37˚C. The cells were cross-linked 
with 4ml of 10% formaldehyde for 10 minutes at room temperature (final 
concentration of 1%). This chemical binds the chromatin together preventing the 
dissociation that normally occurs upon cellular lysis. The formaldehyde was 
quenched with 125 mM glycine and the cells were washed twice with PBS, followed 
by the cell lysis with lysis buffer containing 1% SDS, 10mM EDTA, 50mM Tris pH8. 
The cells were transferred into a 15ml tube and the lysed cells were then sonicated 
to shear the DNA protein complexes into small length fragments. The sonication 
was verified by taking a small sample of the chromatin and heating it to 65 ˚C 
overnight, to reverse the crosslinks, and running it on 1% agarose gel. The sample 
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was centrifuged and the supernatant was dialysed in 200ml dilution buffer and 
protease inhibitors for 1 hour at room temperature. This was repeated two more 
times at 4°C for 1 hour each time.  
The dialysed chromatin was transferred into a 15ml tubes containing 500µl 
salmon sperm DNA (ssDNA)/BSA blocked protein A beads (Amersham) and 
incubated at 4°C for 1hour with rotation to preclear. This step was done to remove 
any proteins or DNA that binds non-specifically to Protein A beads. Chromatin 
(500µg) was centrifuged and the supernatant was transferred into a new tube 
(ensuring beads were present in supernatant). The chromatin was then used as a 
template for immunoprecipitation. An anti-Egr2 antibody (Covance) or 
anti-histone 3 antibody as positive control or anti-Ig as a negative control was 
added and incubated at 4˚C overnight. The anti-Egr2 antibody binds to the Egr2 
protein and associated DNA and this antibody-protein-DNA complex can then be 
precipitated by the addition of ssDNA/BSA-blocked Protein A beads. The antibody-
chromatin complex was collected and purified using  QIAquick PCR purification kit 
to purify the DNA, after the final wash the pellet was resuspended in elution buffer 
containing SDS, which denatures the antibody and Protein A, resulting in the 
release of the immunoprecipitated chromatin complexes. The crosslinks were then 
reversed by heating the complexes at 65˚C overnight. The DNA was purified in 
accordance with the kit and template was used for PCR with ChIP primer sequences 
shown in Table 2.7. 
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Gene Primer Strand Primer Sequence (5'-3') 
SOCS3-1 
Sense CAAGGATTTCACAAACGCCTG 
Antisense GAGAGGCCTGTAGTACACCA 
SOCS3-2 
Sense CCAACTTCTCATTCACACTTTCC 
Antisense TACATGAGGACCTCGGAGTG 
Nab2 
Sense ATAGCTCGGCCTCGGTCAC 
Antisense GGACTCAAGAATCGGGCTC 
IKAROS 
Sense CCCTCTAAGTCCTTCTTTATTCCT 
Antisense GAAATGAGACACATCAGCCC 
FOXO3 
Sense CTGTATTCCAAAGTTGGCCG 
Antisense CTAAGGAGGAAGGACCAAGAC 
Table 2.7: ChIP primer sequences. 
 
 
2.17 Chromatin Immunoprecipitation Microarray chip 
One of the recent techniques performed to identify genes that directly 
interact with Egr2 transcription factor was Chromatin Immunoprecipitation 
Microarray chip (ChIP-on-chip). 
The procedure follows on from the ChIP protocol. The purified 
immunoprecipitated sample from the ChIP experiment was amplified using the 
GenomePlex Whole Genome Amplification (WGA2) kit. The amplified sample was 
labelled and hybridised to the GeneChip® Mouse Promoter 1.0R Array (a 49 Format 
Array from Affymetrix). This array studies the protein/DNA interaction in over 
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26,000 mouse promoters. This was performed by Professor Ping Wang and Dr 
Tizong Miao. 
After hybridisation the chip was analysed using bioinformatics tools by Dr 
Alistair Symonds. The genes of interest were validated by both Real Time RT-PCR 
(section 2.10) and ChIP (section 2.16). 
 
2.18 Enzyme-Linked immune Sorbent Assay (ELISA) 
All cytokine analysis was performed by Dr T. Miao and Meera Raymond at 
Barts and London School of Medicine and Dentistry, Queen Mary University of 
London. The procedures have been briefly explained below. The concentrations of 
cytokines in the cell culture supernatants and sera were measured using ELISA kits. 
ELISA kits IFN-γ and IL-3 were obtained from R & D; whereas IL-6, IL-10, IL-17A, IL-
17F and GM-CSF were from BD Bioscience. The procedure was performed according 
to the manufacturer’s instructions. The ELISA plates were coated with the relevant 
1 X capture antibody at 4˚C overnight. The coating buffer was washed 5 times with 
wash buffer (1 X PBS and 0.05% tween-20) for 5 minutes each at room 
temperature. The plate was blocked with 1 X assay diluent (blocking buffer) for 3 
hours at room temperature. The plate was washed five times with wash buffer at 5 
minutes each followed by the addition of 1 X assay diluent to the control wells. A 2-
fold serial dilution was performed using the provided standard for each antibody 
analysis. To the remaining wells, the serum from Egr2-/-Egr3-/- and wild type samples 
were centrifuged at 8500rpm for 5 minutes and plated out into the relevant wells. 
The ELISA plate was wrapped in foil and incubated at 4˚C overnight. The following 
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day the plate was washed 5 times with wash buffer, as previously mentioned. 100µl 
of the appropriate detection buffer was added to each well and incubated for 3 
hours at room temperature.  The wells were washed 5 times with wash buffer. The 
enzyme Avidin-HRP was added to the plates and incubated for 1 hour at room 
temperature followed by 7 washes with the wash buffer. The substrate solution 
was added to the wells for 15 minutes at room temperature followed by the 
reading the plate at 450nm and the data was analysed. 
 
2.19 Telomere Length 
2.19.1 Metaphase Preparation  
CD4+ T cells and CD19+ B cell were isolated as described in section 2.3. The 
cells were cultures in medium with or without simulation as described in section 
2.2. The cells were treated with colcemid (10μg/ml) (Sigma-Aldrich) for 2 hours at 
37°C. Colcemid arrest the cells in metaphase by inhibiting the mitotic spindle 
formation. The treated cells were transferred into a 15ml tube and centrifuges at 
1200rpm for 5 minutes. The decant was discarded and the cells were treated with 
pre warmed hypotonic buffer (75mM KCl) at 37°C for 15 minutes. This step is 
critical and had to be performed with a Pasteur pipette with a drop at a time, 
followed by gentle agitation. A total of 3 ml was added and the incubation time was 
started from the first drop. The cells were centrifuged and then fixed in freshly 
prepared fixative containing methanol and glacial acidic acid (3:1) for 10 minutes at 
room temperature. The fixative process was repeated twice more, with incubation 
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times of 10 minutes and 30 minutes, respectively. When adding the fixative, care 
was taken by initially adding the first ml of the fixative slowly and drop wise and 
then gently followed by the remaining 2 ml.  The cell pellet was resuspended in 
fresh fixative and 20μl of the cells were dropped onto pre-cleaned slides. The cells 
in the fixative solution ensure that the mitotic cells were spread over the surface of 
slide effectively. The slides were left to dry and checked under a phase contrast 
microscope. 
 
2.19.2 Quantitative Fluorescent in situ hybridization (QFISH) 
The slides containing the metaphase cells were aged at 54˚C overnight. The 
slides were washed with PBS for 5 minutes. The slides were then fixed with 4% 
Formaldehyde for 2 minutes followed by three 5 minute washes with PBS.  The 
slides were further processed with pre-warmed 0.1% pepsin (Sigma) prepared in 
50ml acidified waster (49.5ml of ddH20 containing 0.5ml HCl) for 10 minutes at 
37˚C. The slides were washed twice with PBS and fixed in 70% Formaldehyde for 2 
minutes. The fixative was washed away with three PBS washes followed by 
dehydration of the slides in ethanol series of 70%, 90% and 100%. The slides were 
left to air dry at room temperature. 
The slides were then hybridised to the synthetic oligonucleotide PNA 
(peptide nuclei acid) labelled with FITC, which is specific for the telomeric DNA 
sequence (CCCTAA)3. The slides were heated at 72˚C for 2 minutes and then left at 
room temperature for 2 hours in a dark humidified chamber for hybridisation.  
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After hybridisation, the slides were washed twice in 70% formamide 
solution for 15 minutes at room temperature, followed by three PBS washes. 
Samples were then dehydrated in ethanol series as before and mounted with 
Vectashield® Mounting Medium containing DAPI. 
Images of both interphase and metaphase cells were acquired using the 
Smart Capture software (Digital Scientific, Cambridge) and the telomere 
fluorescence analysed using the IP Lab software. 
 
2.20 Statistical Analysis 
Data was expressed as mean± SEM. Statistical analysis was performed using 
Student’s unpaired t-test to analyse the statistical significance of differences 
between groups. A p-value of <0.05 was considered as significant.  
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 - Results Chapter 3
3.1 Genotyping of Egr2 and Egr3 Knockout Mice Model 
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The aim of the project was to understand the mechanism of Egr2 and 3 in 
the regulation of peripheral lymphocyte function. In order to establish Egr2 and 3 
deficient lymphocytes, we  cross-bred CD2-Egr2-/- mice, which were established in 
our group (Zhu, Symonds et al. 2008) with Egr3-/- mice (Tourtellotte and Milbrandt 
1998) to produce Egr2-/- Egr3-/- mice.  
 
3.1.1 The CD2-specific Egr-2 knockout mice. 
Before cross-breeding, the CD2-Egr2-/- mice were genotyped with specific 
primers that resulted in three PCR products, which were the Egr2 LoxP, Cre and wild 
type Egr2 bands. The PCR from CD2-Egr2-/- mice showed 210 base pair (bp) LoxP-
Egr2 and 150 bp Cre products (Figure 3.1).  Wild type mice produced a 190bp band. 
 
                 
Figure 3.1: Generation of CD2-Egr2-/- mice. 
Egr-2LoxP/LoxP mice were crossed with hCD2-Cre transgenic mice to produce CD2-Egr2-/- mice. 
The genomic DNA was extracted from the mouse tail and the CD2-Egr2-/- mice were 
identified by PCR. Lane 1 – positive control, lane 2 – WT (CD-Egr2+/+), lane 3 - CD2-Egr2-/+ 
and lane 4- CD2-Egr2-/- homozygous mice. 
 
 
 
 
LoxP Allele
WT Allele
Cre
1 2 3 4
  Chapter 3 – Results 
 
108 
 
3.1.2 Egr2 and Egr3 knockout mice. 
We took F1 littermates from parental breeding to breed F2. From F2, we 
selected mice with homozygous deletion of Egr3 or Egr2-LoxP and Cre for further 
breeding. The sequential breeding reached final generation with homozygous 
deletion of Egr3 and with homozygous positive for Egr2 LoxP and Cre. These mice 
were then used as breeding pairs to produce experimental mice. The genotyping of 
mice showed an 800bp PCR product of Neo allele, 400bp of Egr3 wild type allele, 
150bp of Cre and 210bp of LoxP (Figure 3.2). Thus, we developed Egr2-/-Egr3-/- mice.  
 
               
Figure 3.2:  Generation of Egr2-/-Egr3-/- mice. 
CD2-Egr2-/- mice were crossed with Egr3-/- mice. Egr2-/-Egr3-/- mice were identified by PCR, 
testing for LoxP, Cre and Egr-3 Neo. Lanes 1 – Positive Control, lane 2 - CD2-Egr2-/+Egr3-/+ 
mice. Lanes 3 - Egr2-/-Egr3-/- positive mice. 
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1 2 3
  Chapter 3 – Results 
 
109 
 
3.1.3 Protein Expression of Egr2 and Egr3 in Egr2-/- Egr3-/- mice 
The complete deletion of Egr2 and Egr3 at protein levels (by Tizong Miao) 
was confirmed by western blot and flow cytometry. As expected the level of Egr2 
and Egr3 was significantly reduced or undetected in the Egr2-/-Egr3-/- mice 
compared to wild type (Figure 3.3).  
 
Figure 3.3: Defective Egr2 and Egr3 protein expression in lymphocytes from Egr2-/-
Egr3-/- mice. 
(A) Western blot analysis of Egr2 and Egr3 in unstimulated (-) and stimulated (+) CD4+ T 
cells and CD19+ B cells(B) Egr2 protein expression validated by flow cytometry. Egr2-/-Egr3-/- 
mice for unstimulated and stimulated CD4+ T cells and CD19+ B cells. 
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All Egr2-/-Egr3-/- mice were born healthy with no visible symptoms and 
displayed normal cell surface phenotypes in the spleen for the first month of their 
lives. The noticeable features of Egr2-/-Egr3-/- mice were the splenomegaly and 
super-enlarged lymph nodes compared to aged match WT, CD2-Egr2-/- and Egr3-/- 
mice (Figure 3.4). 
 
                 
Figure 3.4: Enlarged spleen and lymph nodes in mice lacking Egr2 and Egr3 genes. 
The spleen from Egr2-/-Egr3-/- mice is visibly enlarged compared to WT, Egr2-/- and 
Egr3-/- mice. 
 
 
Egr2-/-Egr3-/- and wild type mice were monitored over a period of 16 months. It 
was observed that all Egr2-/-Egr3-/- mice became moribund at approximately 8 
months of age. However 68% of these mice did not survive beyond the age of 5 
months. No deaths were observed in the aged match wild type mice (Figure 3.5). 
 
  Chapter 3 – Results 
 
111 
 
 
Figure 3.5: Survival Rate of Egr2-/-Egr3-/- and wild type mice. 
Egr2-/-Egr3-/- mice became moribund at approximately 8 months of age compared 
to WT. 
 
Along with the prominent features of splenomegaly and lymphadenopathy, 
the mice also developed tumours (please refer to section 3.2) and chronic 
inflammation (please refer to section 3.4). 
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3.2 Spontaneous Lymphoma Development in Egr2 and Egr3 
Double Knockout Mice 
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3.2.1 Characterisation of lymphomas from Egr2 and Egr3 defective 
mice. 
 Surprisingly we observed the development of spontaneous lymphoma in 
Egr2-/-Egr3-/- mice (Figure 3.6). The initial step was to classify the tumour from the 
Egr2-/-Egr3-/- mice. All the tumour samples and the organs, such as the spleen, lung, 
liver, kidney, and various lymph nodes were processed for sectioning. To observe 
the morphology of the cells, the tissue section slides were prepared and stained 
with haematoxylin and eosin (H&E). Tissue sections were examined blindly, and 
classified according to the Bethesda proposal (Morse, Anver et al. 2002) (Figure 
3.7).  
The tumours were characterised by immunostaining using antibodies 
against T cell, B cell and monocytes specific markers, CD3, B220 and CD11b, 
respectively. As expected we found the tumours to be of either T cell or B cell origin 
and negative for monocytes (data not shown). Figure 3.7 shows both B cell positive 
and T cell positive tumours in the Egr2-/-Egr3-/- mice.  
The great majority of the tumours found in our cohort were classified as 
small B cell lymphoma (SBCL) or small T cell lymphoma (STCL), due to their 
histological characteristics of small, uniform cell size and round shape and scant, 
basophilic cytoplasm. The majority of the tumours were of diffuse pattern as 
suggested in the Bethesda proposal (Morse, Anver et al. 2002). It should be 
mentioned, however, that the mouse SBCL and STCL cannot be considered the 
counterpart of human small cell lymphoma because of notable differences in 
histology features (Morse, Anver et al. 2002). According to the same classification, 
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cases of T cell lymphoblastic lymphoma, large cell anaplastic T cell lymphoma and 
diffuse large B cell lymphoma occurred at very low frequencies. 
 
 
Figure 3.6: Tumour formation in Egr2 and Egr3 defective mice. 
(A) Tumour (2 x 1.5 x 1.5cm2) formed outside of the chest of Egr2-/-Egr3-/- mice. (B) Tumour 
found in the spleen (1cm2) of Egr2-/-Egr3-/- mice. (C) Tumour in spleen (6 X 2 x 2cm2), kidney 
and liver of CD2-Egr2-/- mice. (D) Tumour (1cm2) formed outside of the chest in Egr2-/-Egr3-/- 
mice. 
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Figure 3.7: B and T Lymphoma Development in Egr2-/-Egr3-/- mice models. 
H&E (at x10) and Immunohistochemistry staining of tumour sections with T cell marker 
(CD3) and B cell marker (B220) (at x20). (A, B and C) B cell lymphoma identified in Egr2-/-
Egr3-/- mice. (D) T cell Lymphoma identified in Egr2-/-Egr3-/- mice.  
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3.2.2 Lymphoma in Egr2-/-Egr3-/- mice show malignant features 
The lymphoma samples were analysed and a few mitotic cells were identified ( 
Figure 3.8). This is in line with the Bethesda proposal which characterises 
SBCL and STCL as having few mitotic cells.  
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
Figure 3.8: Histology of B and T cell Lymphoma Developed in Egr2-/-Egr3-/- mice 
models. Black arrows indicate mitotic cells (x40). 
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One of the characteristics of malignant tumours is metastasis; hence both 
lymphoid and non-lymphoid organs were checked for any metastasis. As expected, 
all the Egr2-/-Egr3-/- mice developed malignant tumours, which also extensively 
invaded into the non-lymphoid organs.  Histology of the organs from Egr2-/-Egr3-/- 
mice revealed complete effacement of their normal tissue architecture by 
accumulating lymphocytes (Figure 3.9).  
Furthermore, immunostaining of the organs from the tumour bearing mice 
also demonstrated the same immunophenotype as the tumour tissues. As seen in 
Figure 3.9, the lymphoma was found outside of the chest and was confirmed as 
SBCL (Figure 3.7B). The cell morphology and immunophenotype of the spleen, liver, 
kidney and lung from this mouse were analysed. As seen in Figure 3.9, the normal 
splenic architecture was obliterated with extensive invasion of the red pulp area by 
lymphomatous infiltrations. Similar invasion of the lung, liver and kidney by 
lymphoma cells was also observed. The immunophenotype of the lymphocytes was 
confirmed to be B cell positive (Figure 3.9).  
These results clearly demonstrate that the lymphomas in Egr2-/-Egr3-/- mice 
are highly malignant.  
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Figure 3.9: Lymphoma in Egr2-/-Egr3-/- deficient mice is highly malignant.  
Lymphoid and non-lymphoid organs from B cell lymphoma mice stained with H&E (X10) 
(left panels) and B cell marker B220 (X20) (right panels). All of the organs shown are 
infiltrated with and positive for B cells. 
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3.2.3 Genetic dose effect of Egr2 and Egr3 in lymphomagenesis 
Interestingly, the lymphoma development is associated with the doses of 
deficiency of Egr2 and 3. No lymphomagenesis was observed in aged match wild 
type and Egr3-/- mice (Figure 3.10A). The majority of CD2-Egr2-/- mice had 
lymphoma formation at later stages of their life. Surprisingly, we found that the 
Egr2-/-Egr3-/+ and Egr2-/-Egr3-/- mice developed lymphoma much earlier, before  the 
age of 5 to 6 months compared to CD2-Egr2-/- mice which were up to 10 months of 
age. Figure 3.10B and Figure 3.10C clearly demonstrate the genetic dose effect of 
Egr2 in tumour formation.  
All the tumours from the Egr2-/-Egr3-/- mice had metastasised into other 
organs, specifically in the kidney, liver and lung, whereas only around 70% of the 
CD2-Egr2-/- showed metastatic tumours.  The number of tumour formation in the 
Egr2-/-Egr3-/- mice was less compared to CD2-Egr2-/-, which could be owing to the 
fact the Egr2-/-Egr3-/- became moribund at a much earlier age, due to the onset of 
inflammatory autoimmune disease. 
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Figure 3.10: Genetic Dose effect of Egr2 and Egr3 in lymphomagenesis. 
(A) Tumour induction of all mice from birth and beyond 12 months. (B) and (C) are adapted from (A). (B) Tumour induction in all mice models ages 5 
months or younger. (C) Tumour induction in all mice ages 10 months or older. NB: Egr2-/-Egr3-/- mice do not survive beyond 8 months.
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3.3 Hyper-Homeostatic Proliferation in Egr2 and Egr3 
Defective  Mice  
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3.3.1 Increased lymphocytes in Egr2-/-Egr3-/- in lymphoid organs 
The noticeable features of Egr2-/-Egr3-/- mice, along with lymphoma 
development were the extremely enlarged spleen and super-enlarged lymph nodes 
compared to aged match WT, CD2-Egr2-/- and Egr3-/- mice (Figure 3.4). The early 
onset of spontaneous lymphomas led us to investigate the cell survival of the 
lymphocytes. Firstly, we quantified the lymphocytes in peripheral lymphoid organs. 
Consistent with the enlarged lymphoid organs, the total cells in spleen and lymph 
nodes were significantly increased compared to wild type counter parts. The 
absolute number of T cells was 7 times that of wild type age matched mice. This 
was also seen in the B cells, which showed 6 times that of wild type age matched 
mice. This suggests hyper-homeostatic proliferation in the Egr2-/-Egr3-/- mice (Figure 
3.11B).  
To observe the effect of the enlarged spleen and lymph nodes, we observed 
the number of lymphocytes from wild type and Egr2-/-Egr3-/- mice, in different aged 
mice. We found that up until 5 weeks the number of CD19+, CD4+ and CD8+ cells in 
Egr2-/-Egr3-/-  mice were similar to aged matched wild type mice. Conversely, from 7 
weeks onwards we noticed an increase in the number of lymphocytes in our 
Egr2-/-Egr3-/- mice, with a significant difference at 11 week old mice (Figure 3.11A).  
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Figure 3.11: Absolute number of B and T cells in Egr2-/-Egr3-/- and wild type mice 
(A) Absolute numbers of T and B lymphocytes in the spleen of wild type and Egr2 and Egr3 deficient mice at the indicated ages. N = 4 in each group.  (B) 
Absolute number of Splenic B and T cells in 8 week old Egr2-/-Egr3-/- and wild type mice adapted from Figure (A). * p<0.05
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3.3.2 Survival of Egr2 and Egr3 deficient T and B cells 
Lymphoma development was observed in our model, as supported by the 
increased number of lymphocytes in Egr2-/-Egr3-/- compared to wild type; hence we 
looked at the cell survival. This was performed by studying the cell viability of the 
lymphocytes from Egr2-/-Egr3-/- mice compared to wild type. Briefly the CD4+ and 
CD19+ cells were collected and their cell viability was examined by Trypan blue 
exclusion assay from day 0 to day 13. As expected, we found both the CD4+ and 
CD19+ cells from the Egr2-/-Egr3-/- mice to be more viable compared to the wild type 
mice. Both CD4+ and CD19+ cells started with similar cell viability but by day 5, 
Egr2-/-Egr3-/-  CD4+ and CD19+ cells were around 2 times more viable than wild type 
mice. This was also seen at Day 10, where CD4 cells in the Egr2-/-Egr3-/-   show to be 
2 times more viable and CD19+ cells show to be 3 times more viable than wild type 
(Figure 3.12).  
These results clearly show that the lymphocytes from Egr2-/-Egr3-/- mice are 
more viable compared to wild type. 
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Figure 3.12: Cell Viability of CD4+ and CD19+ cells in Egr2-/-Egr3-/- and wild type 
mice. 
(A) Cell viability of CD4+ T cells from Egr2-/-Egr3-/- and wild type mice for 13 days. (B) Cell 
viability of CD19+ B cells from Egr2-/-Egr3-/- and wild type mice. Results represent 3 
experiments;    ** p<0.01; * p<0.05. 
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Cell survival was further confirmed in lymphocytes from 5 month old Egr2 
and Egr3 defective mice compared to aged matched wild type. Two 
Egr2-/-Egr3-/- mice with different levels of severity symptoms (labelled K-1 and K-2) 
were taken and compared with wild type.  Enlarged spleen and lymph nodes were 
observed in the K2-Egr2-/-Egr3-/- mouse but not in the K1-Egr2-/-Egr3-/-mouse. A 
survival recall experiment was performed, where the CD4+ T cells and CD19+ B cells 
were isolated and cultured for 3, 5 and 10 days, without the change of medium. On 
these incubation days, the cells were stimulated with 200ng/ml PMA/INO for 48 
hours followed by the incorporation of 3[H]-TdR for 8 hours.  
Interestingly, both of the Egr2-/-Egr3-/- mice showed significant levels of 
proliferating cells compared to wild type at day 3 and 5, whereas at day 10 the level 
of proliferation was almost at a halt. An unexpected observation was seen  in the 
K2-Egr2-/-Egr3-/- mouse which demonstrated proliferation at a much higher rate 
than that of K1-Egr2-/-Egr3-/- mouse, suggesting that this mouse  was possibly at the 
early stages of developing lymphoma (Figure 3.13). 
This experiment clearly demonstrated that the lymphocytes from 
Egr2-/-Egr3-/- mice have the ability to survive longer compared to wild type, under 
homeostatic conditions. 
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Figure 3.13: Cell Survival of CD4+ and CD19+ cells in Egr2-/-Egr3-/- and wild type 
mice. 
(A) Cell viability of CD4+ cells from Egr2-/-Egr3-/- and wild type mice for 13 days. (B) Cell 
viability of CD19+ cells from Egr2-/-Egr3-/- and wild type mice. Egr2-/-Egr3-/- cells are more 
viable than wild type lymphocytes. Results represent 3 experiments; * p<0.05, ** p<0.01; 
*** p<0.001, NS – Not Significant 
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3.3.3 Survival of Egr2 and Egr3 deficient B and T cells in vivo. 
The initial experiments demonstrated that the primary lymphocytes from 
Egr2-/-Egr3-/- have the ability to survive longer in vitro. Hence we investigated the 
proliferation ability of the lymphocytes in Egr2-/-Egr3-/- mice in vivo.  To determine 
whether the function of Egr2 and Egr3 in lymphoma development is intrinsic or 
extrinsic, we looked at the population of Egr2-/-Egr3-/- lymphocytes in Rag2-/- mice. 
Rag2-/- mice carry a germ line mutation, resulting in a large portion of Rag2 coding 
region being deleted. This results in these mice lacking mature B and T cells, with a 
severe combined immune disorder (SCID) phenotype (Shinkai, Rathbun et al. 1992).  
We transferred either resting B or naïve CD4+ T cells from a 4 week old wild type 
and Egr2-/-Egr3-/- mice into the Rag2-/- mice, before the onset of lymphadenopathy 
and splenomegaly. Six weeks after the transfer, CD19+ B cells and CD4+ T cells were 
isolated from the spleen and the phenotype of the cells were analysed. As 
expected, the wild type B and T cells displayed a resting phenotype in the Rag2-/- 
recipient mice. However the Egr2-/-Egr3-/- B and T cells were seen to be highly 
activated in their recipient  Rag2-/- mice (Figure 3.14) allied with high levels of Ig and 
cytokines respectively (see section 3.4 for further details on cytokines in 
Egr2-/-Egr3-/- mice).  
We also transfected 50:50 B and CD4+ T cells from a 4 week mice old CD45.1 
wild-type and CD45.2 Egr2-/-Egr3-/- mice into a Rag2-/- mice. After 2 and 6 weeks we 
sacrificed the mice and isolated the CD19+ B cells and CD4+ T cells from the spleen. 
As expected we identified a similar activated phenotype in the 
Egr2-/-Egr3-/- deficient but not the wild type CD4+ T and B cells from the Rag2-/- mice. 
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Additionally, when we looked at the absolute number of B and CD4+ T cells, we 
found that the percentage of Egr2-/-Egr3-/- deficient mice were increased after 6 
weeks of transfer. We identified 71% of B cells from Egr2-/-Egr3-/- compared to 21% 
from wild type. Similarly we found 68% of CD4+ T cells derived from Egr2-/-Egr3-/- 
compared to 38% from wild type (Figure 3.14). Consequently, Egr2 and Egr3 
regulate the homeostasis of both B and T cells in a cell intrinsic manner. 
 
 
Figure 3.14: Egr2 and Egr3 regulate the homeostasis of lymphocytes. 
(A) Naïve B or CD4+ T cells from spleen of 4 week old WT and Egr2-/-Egr3-/- mice were 
adoptively transferred into Rag2-/- mice. After six weeks the cells harvested from spleen 
and lymph nodes and surface marker expression analysed. (B) Cell number was analysed. 
(C) 50:50 mixture of wild type (CD45.1+) and Egr2-/-Egr3-/- (CD45.2+) lymphocytes, from 4 
week old mice were transferred into Rag2-/- mice. 2 and 6 weeks after transfer activation 
marker expression were analysed. The data are representative of two independent 
experiments and N=3 in each. 
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To support the hyper homeostatic proliferation observed in the 
Egr2-/-Egr3-/- mice, we stained the spleen and tumour bearing tissue sections from 
Egr2-/-Egr3-/- mice with a proliferating marker, proliferating cell nuclear antigen 
(PCNA).  The spleen from the wild type mice was also stained as control (Figure 
3.15). PCNA is associated with the cell cycle and immunocytochemical detection of 
PCNA represents a useful tool for the study of tumour proliferation activity, 
whereby a correlation can be detected between PCNA index and the lymphoma 
grading (Czader, Porwit et al. 1995; Rabenhorst, Burini et al. 1996). We found that 
the lymphocytes from both lymphoid organs and invaded non-lymphoid organs 
from the tumour bearing mice were highly proliferative.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Enhanced proliferation of lymphocytes in Egr2-/-Egr3-/- mice. 
H&E staining of spleen tissue and PCNA staining on the same tissue section. Shown at 
magnitude X5 and X20. The PCNA staining shows that the lymphocytes are proliferating. 
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As seen in Figure 3.15, there is increased proliferation in both 4 week old 
and 5 month old Egr2-/-Egr3-/- mice compared to wild type. Supporting the in vivo 
cell survival mentioned in section 3.2.5, the level of proliferation is significantly 
increased in the older mice compared to the 4 week old mice, resulting in the 
normal splenic architecture being eradicated with extensive invasion of the red 
pulp area by lymphocyte infiltrations. The extensive proliferation in the 
Egr2-/-Egr3-/- mice affects the splenic architecture and results in fragmentation of 
the follicular structure, whereas in young Egr2-/-Egr3-/- mice we still see a certain 
level of follicular structure. 
The level of proliferation was also checked in the lymphoma tissues and in 
organs metastatically invaded by tumour cells. As expected the lymphoma cells also 
carried a proliferating phenotype. Both the tumour tissues and the organ with 
metastasis from B and T cell positive lymphomas were positive for the PCNA marker 
(Figure 3.16). 
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Figure 3.16: Enhanced proliferation in both T and B cell lymphomas in 
Egr2-/-Egr3-/- mice. 
(A) B cell lymphoma metastatically spread into the kidney. Sample stained for B cells, B220 
(red) and for proliferation marker, PCNA (green). Staining shows the B cells to be highly 
proliferative. (B) T cell lymphoma metastatically spread into the liver. Sample stained for T 
cells, CD3 (red) and for proliferation marker, PCNA (green). Staining shows the T cells to be 
highly proliferative. 
 
It is evident that the Egr2-/-Egr3-/- mice are hyper proliferating, leading to 
lymphoma development. Both Egr2 and Egr3 are transcription factors and have the 
potential to regulate a number of other genes. The question arises as to which 
regulation process causes the development of lymphoma in the absence of Egr2 
and Egr3.  
Cancer is a multi-step, genetic disease (Hanahan and Weinberg 2000). As 
the normal cells progress to a neoplastic state, they acquire a succession of the 
hallmarks of cancer. Initially six hallmarks of cancer were suggested by Hanahan 
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and Weinberg in 2000; however since then they have identified a number of 
emerging hallmarks that also contribute to the development of cancer, these 
include tumour-promoting inflammation, genomic instability and mutation 
(Hanahan and Weinberg 2011). 
Uncontrolled proliferation is the main hallmark of all cancers and we were 
able to demonstrate that the lymphocytes in our model were hyper-proliferative in 
physiological conditions.  
The second hallmark of cancer is the evasion of apoptosis; hence we looked 
at the apoptosis in our model. 
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3.3.4 Apoptosis not affected in lymphocytes from Egr2-/-Egr3-/- mice 
A number of functional studies over the years have shown that programmed 
cell death by apoptosis serves as a natural barrier to cancer development (Lowe, 
Cepero et al. 2004). The evasion of the apoptosis pathway is also one of the 
hallmarks of cancer. In 2003, Unoki and Nakamura demonstrated that Egr2 induced 
apoptosis significantly in a number of cancer cell lines by directly inducing the 
expression of two proapoptotic proteins of the Bcl-2 family. They carried out their 
study mainly on different Human Carcinoma and Glioblastoma cell lines (Unoki and 
Nakamura 2003). Yokota and colleagues have identified Egr2 as a direct target of 
the p53 family in human cancer cell lines. They also confirmed the Egr2 expression 
is induced in mouse and rat fibroblast cells by DNA-damage-induced p53 activity 
(Yokota, Sasaki et al. 2010).  
Here we studied the effects of apoptosis in our Egr2-/-Egr3-/- lymphocytes to 
understand if suppression of apoptosis could play a role in the lymphoma 
development. Naïve CD4+ T cells were isolated from 3 month old wild type, 
Egr2-/-Egr3-/-, CD2-Egr2-/- and Egr3-/-. The CD4+ T cells were stimulated with plate-
bound anti-CD3 and anti-CD28 for 16 hours and stained for Annexin V and 7AAD. 
The cells were measured by flow cytometry. As seen in Figure 3.17, there was a 
slight but not significant difference in the percentage of apoptotic cells from the 
Egr2-/-Egr3-/- CD4+ T cells compared to wild type.   
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Figure 3.17: Apoptosis of activated T cells. 
(A) Resting CD4 T cells from indicated mice were stimulated with anti-CD3 and anti-CD28 
for 16 hours and Annexin V positive cell were measured. The data are representatives of 
three experiments. 
 
 
There was half the amount of early stage apoptotic steps (Annexin V 
positive and 7-AAD negative cells) in the Egr2-/-Egr3-/- CD4+ T cells compared to wild 
type, Egr3-/- and CD2-Egr2-/-. The same fold change was seen for cells at the late 
stage of apoptosis (Annexin V and 7-AAD positive).  
Clearly it is shown that apoptosis is not affected in the Egr2-/-Egr3-/- mice 
model and possibly not the direct pathway causing the lymphoma development in 
our model. 
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3.3.5 Shorter Telomere Length in Egr2-/-Egr3-/- mice 
One of the hallmarks of cancer cells is that they acquire an infinite 
replication potential (Negrini, Gorgoulis et al. 2010). Telomeres, a repetitive DNA 
sequence are based at the ends of the chromosomes which functions as the 
molecular counter of the cell’s replicative potential. The telomeres are composed of 
several thousand repeats of the sequence TTAGGG bound by a set of specific 
protein. As the cell divides the telomeres shorten, eventually causes the cell to 
undergo senescence, once it has reached its limit (Allsopp, Vaziri et al. 1992). It has 
been proven that in cancer cells, telomeres are extremely short due to the intense 
proliferation properties of the cells (Artandi and DePinho 2000).  
We examined the telomere lengths of lymphocytes in Egr2-/-Egr3-/- and wild 
type mice. The lymphocytes were collected from secondary lymphoid organs. Half 
of the lymphocytes were stimulated with PMA/INO for 48 hours (hrs). The other 
half was cultured without stimulation for 48hrs. Metaphase spread were prepared 
and fixed onto slides. The telomere length was examined by Q-FISH, which 
measures the fluorescence intensity of the telomere repeats (Wong and Slijepcevic 
2004) (Figure 3.18). 
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Figure 3.18: Q-FISH image of interphase and metaphase CD4+ T cells from wild 
type and CD2-Egr2-/- mice 
 
 
The telomere length of interphase CD4+ T cells and CD19+ B cells were 
measured with the aid of IPLab software. The telomere length shortening was 
compared between CD2-Egr2-/- and wild type. The telomere length of CD2-Egr2-/- T 
and B cells were significantly shorter than wild type under homeostatic conditions 
(unstimulated) (Figure 3.19). 
We also tested the telomere length in fibroblast cells from both wild type 
and CD2-Egr2-/- mice as a negative control because Egr2 was specifically removed 
from the lymphocytes. As expected there was no significant difference in the 
telomere length from both wild type and CD2-Egr2-/- fibroblast cells. 
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Figure 3.19: Telomere Length of Lymphocytes. 
(A) Telomere length in CD4+ T cells of CD2-Egr2-/- and wild type. (B) Telomere length in 
CD19+ B cells of CD2-Egr2-/- and wild type. The telomere length is shorter in both T and B 
cells compared to wild type. (C) Telomere length in fibroblast cells from  wild type and CD2-
Egr2-/- . Standard error bars indicate SEM, ** P<0.01, NS-Not Significant. 
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In line with telomere length, it is also known that the telomere length 
shortening is maintained by telomerase enzyme (Meyerson 2000). We then looked 
at the telomerase enzyme activity within the lymphocytes. RNA was extracted from 
the isolated CD4+ T cells and CD19+ B cells before and after stimulation with 
PMA/INO. RNA expression was determined by real-time PCR for mTERT gene. 
Consistent with our findings for the telomere length, the expression of mTERT was 
increased in the CD2-Egr2-/- model compared to wild type. 
There was no difference in the expression of telomerase enzyme in the 
unstimulated CD4+ T cells or CD19+ B cells, as no or very little telomerase activity is 
detected in mature resting CD4+ and CD8+ T lymphocyte (Weng, Levine et al. 1996; 
Weng, Granger et al. 1997). There was a 2 fold difference in the stimulated CD4+ T 
cells and a 4 fold difference in CD19+ B cells.   
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Figure 3.20: Telomerase Enzyme Expression. 
(A) mTERT expression in CD4+ T cells from both wild type and CD2-Egr2-/- . (B) mTERT 
expression in CD19+ B cells from both wild type and CD2-Egr2-/-. Standard error bars 
indicate SEM ** p<0.01, NS – Not significant difference. 
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3.4 Molecular Mechanism of Egr2 and Egr3 in Preventing 
Tumour Development 
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To understand the mechanism of Egr2 and Egr3 in tumourgenesis two 
approaches were taken.  
1. The possible effect of the inflammatory microenvironment in the 
support of tumour development was investigated in the 
Egr2-/-Egr3-/- mice. 
2. Using functional genomic tools to identify the transcriptional 
program regulated by Egr2 in the control of tumourgenesis. 
 
 
3.4.1 Possible effect of inflammatory microenvironment supports 
the tumour development in Egr2-/-Egr3-/- mice. 
Inflammation has long been associated with the development of cancer 
(Rakoff-Nahoum 2006). The effect of microenvironment for the tumour 
developments was investigated in the Egr2-/-Egr3-/- Mice. 
Previously, our group found that Egr2 deficient T cells are highly active in 
vivo under homeostatic conditions, leading to the development of autoimmune 
diseases in the CD2-Egr2-/- mice in later age (Zhu, Symonds et al. 2008). However no 
autoimmune symptoms were found in the Egr3-/- mice.  An early onset of the 
pathological phenotypes was seen in the Egr2-/-Egr3-/-  mice. At 2 months of age, 
both male and female Egr2-/-Egr3-/- mice developed chronic inflammation. Zhu, et al 
(2008) demonstrated the inflammatory autoimmune disease in adult CD2-Egr2-/- 
mice, with lymphocyte infiltration and severe glomerulonephritis (Zhu, Symonds et 
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al. 2008). Here we report similar symptoms in the Egr2-/-Egr3-/- mice but onset 
much earlier in age. In 3 month old Egr2-/-Egr3-/- mice the kidney histology revealed 
deposition of immune complexes in the glomeruli and infiltration of lymphocytes in 
non-lymphoid organs, but these symptoms were not seen in wild type mice (Figure 
3.21). 
 
Figure 3.21: Mice lacking Egr2 and Egr3 develop chronic inflammation disease.  
(A) H&E analysis of the lung and kidney, from a  3 month old wild type and Egr2-/-Egr3-/- 
mice. lymphocyte infiltration seen in the Egr2-/-Egr3-/- mice (marked by an arrow) compared 
to wild type   (B) Glomerular Ig deposits in 3 month Egr2-/-Egr3-/- mice (Texas red labelled 
anti-mouse Ig). 
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The CD4+ and CD8 T+ cells expressed high levels of activation markers such 
as CD44, CD69 and CD25, while CD62L positive T cells were significantly reduced  
compared with wild type (Figure 3.22A) suggesting that the Egr2 and 3 deficient T 
cells are hyper-active. The activation markers, CD86 and CD69, were also analysed 
for the splenic B cells. Both CD86 and CD69 were expressed significantly at high 
levels (especially CD69) compared to wild type, suggesting that the B cells were 
highly activated in the spleen (Figure 3.22A). The same active phenotype was seen 
the LN too (Figure 3.22). 
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Figure 3.22: Functional analysis of peripheral lymphocytes. 
(A) Surface marker expression on splenic lymphocytes from 8-week-old wild type and Egr2-/-Egr3-/- mice. (B) Surface marker expression on lymph nodes 
lymphocytes from 8-week-old wild type and Egr2-/-Egr3-/- mice. Results represent 3 experiments.
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Chronic inflammation observed in the Egr2-/-Egr3-/- mice provides the 
inflammatory microenvironment for the tumour to progress. Tissue inflammation is 
also brought upon due to a deregulated production of cytokines, such as IL-6, IL10 
and IL-17 (Ohl and Tenbrock 2011). It was observed that the Egr2-/-Egr3-/- mice 
became moribund at around 8 months of age, due to the multi-organ inflammation, 
which is known to be associated with high levels of serum inflammatory cytokines. 
We, therefore, checked the presence of cytokines in the Egr2-/-Egr3-/- mice 
compared to wild type and as expected, we found that there was high levels of 
inflammatory cytokine expressions of IL-17, IL-17F, IL-10, IL-6 and IL-3, granulocyte 
macrophage colony stimulating factor (GM-CSF) and IFN-γ in the serum of 
Egr2-/-Egr3-/- mice (Figure 3.23). 
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Figure 3.23: Egr2 and Egr3 control the homeostasis of inflammatory cytokines.  
Serum cytokine levels in 3 month old wild type (WT) and Egr2-/-Egr3-/- mice. High levels of inflammatory cytokines observed in Egr2-/-Egr3-/- mice 
compared to WT. * p<0.05
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3.4.2 Constitutive activation of STAT3 oncogene expression 
detected in Egr2-/-Egr3-/- mice. 
Cytokines play an essential role in the development and differentiation of 
lymphoid cells, which include interleukins and interferon. In section 3.4.1, cytokines 
were described to be significantly increased in the Egr2-/-Egr3-/- serum compared to 
those in wild type mice. Cytokines bind to their specific receptor chain, the 
hematopoietin receptor, to initiate the formation of a functional cytokine receptor 
complex and the intracellular signalling pathway (Kishimoto, Taga et al. 1994). The 
cytokine signalling pathway induces proteins, such as Signal transducers and 
activators of transcription (STATs). STATs function as transcription factors to 
regulate gene expression of target genes, such as c-Myc. Importantly the cytokine 
signalling pathways are negatively regulated by suppressors of cytokine signalling 
(SOCS) proteins, which have also be profound to play additional roles in many 
immunological processes (Kubo, Hanada et al. 2003). 
Our group have earlier shown that SOCS1 and SOC3, suppressors of STAT1 
and STAT3 activation, are induced in T cells by TCR stimulation (Anderson, 
Sundstedt et al. 2003). Hence we reviewed the cytokine signalling pathways in B 
and T cells. We focused our investigation on STAT3 as it is a known oncogene and 
shown to be constitutively active in nearly 70% of solid and haematological tumours 
(Avalle, Pensa et al. 2012). STAT3 protein expression was analysed in both T and B 
cells from Egr2-/-Egr3-/- and wild type mice. As expected, STAT3 was highly activated 
in the lymph nodes from 3 month old Egr2-/-Egr3-/-mice. This was further confirmed 
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by western blot, where CD4+ T cells and CD19+ B cells were isolated from both 
Egr2-/-Egr3-/- and wild type mice. The endogenous STAT3 was used as the 
endogenous control. The pSTAT3 was significantly increased in both unstimulated 
and stimulated CD4+ T cells and CD19+ B cells from the Egr2-/-Egr3-/- mice compared 
to aged match wild type mice 
          
 
Figure 3.24: Hyper activated STAT3 in Egr2 and Egr3 deficient B and T 
lymphocytes. 
(A) Phosphorylation of STAT3 in lymphocytes in both wild type and Egr2-/-Egr3-/- lymph 
nodes at 3 months of age. (B) Western Blot analysis of phosphorylation of STAT3. Results 
demonstrate high expression of pSTAT3 in Egr2-/-Egr3-/- compared to WT. 
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Further, the expression of STAT3 mRNA was confirmed to be upregulated in 
both B and T cell lymphomas, as represented in Figure 3.25. The level of relative 
mRNA expression was significantly increased in all representing B and T cell 
lymphomas compared to normal T and B cell isolated from wild type lymphocytes. 
Constitutive activity of STAT3 is essential for proliferation and survival in many 
established primary tumour cells and its inhibition impairs tumour growth (Avalle, 
Pensa et al. 2012).  
To further investigate whether Egr2 and/or Egr3 can regulate the expression 
of SOCS3, we analysed the expression of SOC3 in naïve B and CD4+ T cells from a 4 
week old mice before and after antigen receptor stimulation. Supporting the 
findings of hyper activated STAT3, the SOCS3 were highly deficient in the 
Egr2-/-Egr3-/- mice in comparison to wild type mice (Figure 3.26A).   
To investigate whether Egr2 regulates the expression of SOC3 we looked at 
proximal promoters of SOCS3 for potential Egr2 binding sites with the aid multiTF 
utility (http://multitd.dcode.org) (Figure 3.26B). By ChIP we demonstrated that Egr2 
directly interacts with SOCS3 promoters and a conserved intergenic element in the 
SOCS3 locus (Figure 3.26C). Hence the impaired function of SOCS3 leads to the 
hyper-activation of STAT3 in the Egr2-/-Egr3-/- B and CD4+ T cells. 
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Figure 3.25: Hyper activated STAT3 in B and T lymphoma from Egr2-/-Egr3-/- mice. 
(A) STAT3 mRNA expression in B cell lymphomas (labelled KOJ and KOB) from Egr2-/-Egr3-/- 
mice. (B) STAT3 mRNA expression T cell lymphomas (labelled KOB and KOG) from Egr2-/-
Egr3-/- mice. The expression was compared to normal STAT3 expression in wild type B and T 
cells. Standard error bars indicate SEM.  *p<0.05, **p<0.01 and ***p<0.001. 
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Figure 3.26: Egr2 regulated the mRNA expression of SOCS3 
(A) mRNA expression of SOCS3 in naïve B and CD4+ T cells from a 4 week old wild type and Egr2-/-Egr3-/- mice before and after antigen receptor 
stimulation. (B) Identification of potential Egr2 binding sites in the proximal regions of SOCS3. (C) Binding of Egr2 to the proximal regions of the SOCS3 
promoters. CD4+ T cells from Egr2 Transgenic mice (Egr2cTg) were stimulated with anti-CD3 and anti-CD28 for 3 hours and used in the ChIP with primers 
flanking Egr2 binding sites in the promoters of SOCS3, and Nab. Total input DNA and anti-H3 precipitates served as positive control and anti-IgG 
precipitates as negative control. Standard error bars indicate SEM.  * p<0.05. 
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3.4.3 Transcriptional profile of Egr2 in the control of 
tumourgenesis. 
Since Egr2 and Egr3 are transcription factors, they could have the potential 
to regulate many other genes, any of which might be involved in preventing tumour 
development. Therefore to observe the effects of Egr2 and Egr3 in lymphocytes, we 
assessed the genome-wide transcriptional profiles of unstimulated and anti-CD3 
stimulated cells for both wild type and CD2-Egr2-/- CD4+ T cells using MouseRef-8 
v2.0 BeadChip expression arrays (Illumina). These arrays consistent of oligo-
nucleotide probes directed against ~24,000 well annotated RefSeq transcripts.  
CD4+ T cells from CD2-Egr2-/- and wild type mice, were isolated and 
stimulated with anti-CD3 or left unstimulated and the RNA was extracted and 
purified as described in the chapter 2. RNA labelling, array scanning and data 
normalisation was performed by the Microarray facility, Barts and London School of 
Medicine and Dentistry, according to the manufacturer’s instructions. Upon receipt 
of the normalised data, we first examined the expression of Egr2. Consistent with 
the previous findings, Egr2 had very weak expression in unstimulated CD2-Egr2-/- 
CD4+ T cells and further reduced expression in stimulated CD2-Egr2-/- CD4+ T cells 
compared to wild type (data not shown).  
To distinguish the gene expression profiles in CD2-Egr2-/- CD4+ T cells from 
wild type CD4+ T cells the microarray data was carefully evaluated, focusing on 
genes that showed difference of at least 2-fold between wild-type and CD2-Egr2-/- 
CD4+ T cells and excluded genes that had a detection p-value >0.01, anything with a 
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p-value greater than 0.01 was considered background. The genes that were 
deferentially expressed were first grouped based on self-organizing maps (SOMs) by 
clustering algorithm method. To confirm the differential profile of the expressed 
genes, the SOM clusters were further clustered by hierarchical clustering program 
(Figure 3.27). 
The full set of microarray data is available from the ArrayExpress database 
(http://www.ebi.ac.uk/arrayexpress) under the accession number E-MEXP-1698.  
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Figure 3.27: Gene expression profile. 
Altered expression of transcription factors, inflammation and cell cycle genes in CD2-Egr2-/- (represented as KO) CD4+ T cells as assessed by genome-wide 
transcriptional analysis. The SOM cluster of transcription factors, inflammation and cell cycle genes were further clustered by hierarchical clustering 
program to show the genes with differential expression profile. Note: Tg represents Egr2 Transgenic mice, which were not included as part of this 
study.
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3.4.3.1 Egr2 regulates the gene expression of cell cycle genes 
Cancers results from multiple molecular events that essentially amend the normal 
properties of the cell. In the cancer cells, the cell cycle control, a process of regulating 
normal cell division is disrupted. Cancer cells differ from normal cells, such as they have loss 
of differentiation and increased invasiveness. However other characteristic of cancer cells 
includes a category of genes that, when mutated, increases the genetic instability and 
accelerates the cancer growth. These are the genes that regulate the cell cycle control 
(Hartwell and Kastan 1994). 
From our microarray analysis we looked at possible cell cycle genes that were 
differently expressed in CD4+ T cells from Egr2-/-Egr3-/- model compared to the wild type. We 
identified 23 genes that were 2 fold or more upregulated in the CD4+ T cells from Egr2-/-Egr3-
/- compared to wild type. We also identified 7 genes that were 2 fold downregulated in the 
CD4+ T cells from Egr2-/-Egr3-/- compared to wild type (Table 3.1). 
32 genes, categorised from cell cycle control function were validated by Real-Time 
RT-PCR; of which only 7 did not correlate with the microarray data (Table 3.1).   
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Gene Expression Microarray 
Fold Change 
RT-PCR  
Fold Change 
p-value 
from 
RT-PCR  
Brca1 Upregulated 2.44 2.55 < 0.01 
Casp3 Upregulated 3.06 6.43 < 0.01 
Ccna2 Upregulated 3.89 3.81 > 0.05 
Ccnb1 Upregulated 3.67 0.77 > 0.05 
Ccnb2 Upregulated 3.08 0.34 < 0.01 
Ccne1 Upregulated 2.78 2.92 < 0.05 
Ccnf Upregulated 3.13 1.89 < 0.01 
CDC25B Upregulated 2.05 1.41 > 0.05 
Chek1 Upregulated 3.25 4.08 < 0.05 
Cks1b Upregulated 4.41 3.01 > 0.05 
E2f1 Upregulated 2.18 0.75 > 0.05 
E2f2 Upregulated 2.36 2.66 < 0.05 
Itgb1 Upregulated 2.8 6.85 < 0.05 
Mad2l1 Upregulated 2.74 4.76 < 0.05 
MCM2 Upregulated 2.01 2.06 < 0.05 
Mcm3 Upregulated 2.55 3.78 < 0.05 
Mki67 Upregulated 2.57 4.48 < 0.01 
Mybl2 Upregulated 2.05 0.41 > 0.05 
Nek2 Upregulated 4.21 4.01 < 0.05 
Pmp22 Upregulated 2.06 3.03 < 0.05 
Rad51 Upregulated 4.34 5.76 < 0.01 
Rad51ap1 Upregulated 2.31 5.27 < 0.01 
Wee1 Upregulated 2.34 1.81 > 0.05 
Abl1 Downregulated 2.17 4.51 < 0.05 
Atm Downregulated 2.74 2.77 < 0.01 
Dstyk Downregulated 2.33 3.41 < 0.01 
Macf1 Downregulated 3.06 5.98 < 0.01 
Pkd1 Downregulated 2.62 2.83 < 0.05 
Rad9b Downregulated 2.62 4.09 < 0.05 
Sfn Downregulated 4.66 2.81 < 0.01 
 
Table 3.1: Validation of Microarray Expression Profile with Real-Time PCR. 
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While the pattern of expression usually related fairly well with those from the 
microarray, the relative levels of expression sometimes differed. For example, Figure 3.28, 
compares the expression of three differently expressed genes, Brca1, Ccna2 and SFN, in 
unstimulated CD2-Egr2-/- and wild type CD4+ T cells, as detected by the two different 
methods. The validated Real-Time expression shows a similar pattern to the normalised 
microarray expression.  Brca1 and Ccna2 both showed exactly the same fold change ratio of 
2.5 and 3.8 respectively. SFN showed a slight decrease in the microarray expression 
compared to Real-Time PCR. This quantitative difference may be due to the different 
sensitivity of the two techniques. 
 
 
               
Figure 3.28: Brca1, Ccna2 and SFN mRNA expression in CD2-Egr2-/- CD4+ T cells.  
Splenic CD4+ T cells were isolated from the CD2-Egr2-/- and wild type mice. (A) Normalised expression 
from the microarray. (B) Relative Expression from the Real-Time RT-PCR validation. Data represents 3 
experiments. Standard error bars indicate SEM. *p< 0.05 and ** p< 0.01. 
 
*
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The validation of the microarray results revealed number of genes that were 
significantly (p<0.01) up-regulated in the CD2-Egr2-/- CD4+ T cells than in wild type CD4+ T 
cells, which play an important role in the cell cycle control. Some of the interesting genes 
were RAD51, RAD51AP1, and MKI67 (Figure 3.29). 
Both RAD51 and RAD51AP1 participate in the DNA response pathway associated with 
the activation homologous recombination and double-strand break repair.  The microarray 
data of normalised expression showed a 4.97 and 1.1 fold increases in Rad51 and Rad51ap1 
respectively. The Real Time RT-PCR showed a 5 fold increase for both Rad51 and Rad51ap1 
confirming the increased expression of these two DNA repair genes. A number of studies 
have found that overexpression of RAD51 in cells leads to increased resistance to 
chemotherapeutic drugs (Klein 2008). Overexpression of RAD51 genes results in the 
overstimulation of homologous recombination and chromatid exchange mechanisms, this is 
predicted to lead to genomic instability and eventually contributing to carcinogenesis 
(Raderschall, Stout et al. 2002). 
Mki67 (also known as Ki67) is a known marker for proliferation, with evidence of high 
expression of this gene in diffuse large B-cell lymphoma and mantle cell lymphoma (Ek, 
Bjorck et al. 2004; Li, Huang et al. 2012). The microarray indicated that CD2-Egr2-/- CD4+ T 
cells expressed around 3 fold more Mki67 than WT CD4+ T cells. A similar correlation was 
also seen with the Real Time RT-PCR data with around 4 fold increase in CD2-Egr2-/- CD4+ T 
cells.  This data also supports the enhanced expression of PCNA marker in Egr2-/-Egr3-/-  
spleen and tumour samples (section 3.3). 
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Figure 3.29: Cell cycle genes mRNA expression upregulated in CD2-Egr2-/- CD4+ T cells. 
Relative expression of cell cycle genes analysed by Real Time RT-PCR for wild type (white) and CD2-Egr2-/- CD4+ T cells. Standard error bars represent 
SEM. * P<0.05, ** p<0.01 and NS – Not Significant. 
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7 genes were identified to have a 2 fold decrease gene expression from the 
microarray data. All 7 genes were validated by Real Time RT-PCR and the results 
correlated with the microarray data. Some of the interesting genes were Stratifin 
(SFN) and Ataxia Telangiectasia Mutated (ATM) (Figure 3.30). 
SFN, commonly known as 14-3-3, regulates a number of cellular processes 
that are crucial for tumour biology, such as cell cycle regulation and apoptosis 
(Dong, Kang et al. 2007). Here we have shown, from our microarray data, that SFN 
is significantly reduced (by 4 fold) in the CD2-Egr2-/- CD4+ T cells. This correlation 
was also demonstrated by Real Time RT-PCR, with a 3 fold reduction in the 
CD2-Egr2-/- CD4+ T cells compared to the wild type. 
There are seven isomers of 14-3-3, of which 14-3-3σ (sigma) is the most 
researched and has shown to be directly linked to cancer (Hermeking 2003). 
14-3-3σ acts in support of their relevance to tumour biology by negatively 
regulating cell cycle control. 14-3-3σ has been shown to inactivate CDC25 proteins 
by cytoplasmic sequestration, which prevents CDC25C and CDC25B from 
dephosphorylating and activating cyclin-dependent kinase CDC2, hence the cells 
become arrest at G2 (Graves, Lovly et al. 2001; Bulavin, Higashimoto et al. 2003). 
Interestingly our microarray data reported a 3 fold increase of CDC25C gene in our 
CD2-Egr2-/- CD4+ T cells compared to wild type (data not shown), showing a 
correlation between the reduction of SFN gene expression and the increase of 
CDC25C gene expression.  
Both the microarray and Real-Time RT-PCR reported a 2.7 fold reduced 
expression in the ATM gene in CD2-Egr2-/- CD4+ T cells compared to wild type 
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(Figure 3.30). ATM is a pleiotropic protein kinase that is activated in response to a 
double-stranded DNA breaks (Rotman and Shiloh 1997). This leads on to ATM 
rapidly activating many factors that aid DNA repair and regulate cell cycle control 
(Yan, Kuang et al. 2002). Deficiencies in ATM has been linked to a number of 
deficiencies, including thymic lymphoma (Taylor, Metcalfe et al. 1996). Zha and 
colleagues have provided compelling evidence of ATM deficiency and tumour 
development. They showed that ATM-deficient mice developed a striking 
predisposition to lymphoid malignancies, particularly thymic lymphoma, due to 
V(D)J recombination errors at Tcrd, as opposed to Tcra locus (Zha, Bassing et al. 
2010).  
 
 
 
 
 
                                                                                                                                                                                                                      Chapter 3 – Results 
163 
 
 
Figure 3.30: Cell cycle genes mRNA expression downregulated in CD2-Egr2-/- CD4+ T cells.  
Relative expression of cell cycle genes analysed by Real Time RT-PCR for wild type and CD2-Egr2-/- CD4+ T cells. Standard error bars represent SEM.  
* P<0.05, ** p<0.01 and NS – Not Significant
0
200
400
SFN
0
10
20
RAD9B
0
1000
2000
PKD1
0
100
200
ABL1
0
1000
2000
ATM
0
100
200
DSTYK
0
1000
2000
MACF1
R
e
la
ti
v
e
 E
x
p
re
s
s
io
n
0
1000
2000
3000
WT Egr2-/-Egr3-/-
CDC25B
WT Egr2-/-Egr3-/-
*
*
*
** **
** **
                                                                                                                    Chapter 3 – Results 
 
164 
 
The microarray gene expression profile was conducted on CD4+ T cells, 
which were also validated by Real Time RT-PCRs. However our group has shown 
that Egr2 regulated both T and B cell development (Li, Symonds et al. 2011), 
supported by the B cell lymphomas identified in the Egr2 deficient mice model. This 
lead us to look at the genes, which demonstrated a significant difference in CD4+ T 
cells, and further investigated in CD19+ B cells, by Real-Time RT-PCR. 
From the 23 up-regulated genes, 18 showed a significant mRNA expression 
increase in CD2-Egr2-/- CD4+ T cells. Interestingly, when the gene expression of the 
23 genes was examined in CD19+ B cells, 57% of them also showed a significant 
up-regulation in CD2-Egr2-/- cells compared to wild type (Figure 3.31).  
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Figure 3.31: Cell cycle genes mRNA expression upregulated in CD2-Egr2-/- CD19+ B cells.  
Relative expression of cell cycle genes analysed by Real Time RT-PCR for wild type and CD2-Egr2-/- CD19+ B cells. Standard error bars represent SEM. 
 * P<0.05, ** p<0.01 and NS – Not Significant
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Unlike CD4+ T cells, where all 7 down regulated genes showed a significant reduction 
in the CD2-Egr2-/-Egr3-/- mice compared to wild type, all, except ABL1, showed an up-
regulation in CD2-Egr2-/-Egr3-/- compared to wild type. However, only three of the genes 
showed a significant difference (SFN, PKD1 and MACF1) (Figure 3.32).  
 
 
Figure 3.32: Cell cycle genes mRNA expression downregulated in CD2-Egr2-/- CD19+ B cells. 
Relative expression of cell cycle genes analysed by Real Time RT-PCR for wild type and CD2-Egr2-/- 
CD19+ B cells. Standard error bars represent SEM. * P<0.05, ** p<0.01 and NS – Not Significant
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3.4.4 Identification of target genes for Egr2 by ChIP-on-chip 
With microarray gene expression alone we were unable to identify key genes that 
demonstrate the effect of Egr2 and Egr3 leading to tumour development, as Egr2 
and Egr3 are transcription factors and play a role in transcribing other genes. To 
understand the mechanism between the loss of Egr2 and tumour development we 
need to identify the genes that are regulated by Egr2 directly. The microarray gene 
expression provided us with an insight of which genes might be involved under the 
influence of Egr2, however it does not provide direct evidence that Egr2 directly 
regulates the expression of these genes.   
Hence, we carried out ChIP-on-chip. In ChIP-on-chip the Eg2 protein was 
covalently cross-lined to the DNA by formaldehyde, cells were lysed, the chromatin 
was immunoprecipitated with an Egr2 antibody and then fragmented DNA was 
fluorescently labelled and hybridised to the GeneChip® Mouse Promoter 1.0R 
Array.  
The data generated, consisting of the intensity, which measures the relative 
quantity of DNA at the probe’s genomic position in the immunoprecipitated 
material, was analysed.  We looked at both ChIP-on-chip data and microarray 
expression data, to identify possible genes which are controlled or interact with 
Egr2. The criteria used to identify these genes was set to include the genes that 
were enriched with a p-value more than 0.01 in the ChIP-on-chip compared with 
the genes that were 2 fold down regulated in the CD2-Egr2-/- CD4+ T cells from the 
microarray analysis. The ChIP-on-chip suggests promoter regions of genes to which 
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Egr2 binds to. The microarray 2 fold downregulated genes in CD-Egr2-/- CD4+ T cells 
identified possible genes which are expressed in the presence of Egr2. From this 
data mining we identified 137 genes, of which a number of these genes were found 
to be involved in cell regulation, chromatin remodelling, etc. (Figure 3.33). 
 
 
Figure 3.33: ChIP-chip Vs. Expression comparison. 
137 genes enriched with a p-value greater than 0.01 in ChIP-on-chip and with a 2 fold 
change in the microarray gene expression. 
 
 
From the 137 genes identified, 33 of the genes were validated, which had a 
known function in cell regulation, chromatin remodelling or tumour development. 
These genes were validated by Real Time RT-PCR. From the 33 genes, three of the 
genes; Ikaros, Aiolos and FOXO3, demonstrated a 2 fold downregulation in the 
microarray expression as well as a DNA binding site for Egr2. These genes are also 
known to function as tumour suppressor genes.  
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3.4.4.1 Egr2 regulates the expression of Ikaros and Aiolos in    
lymphocytes 
 
Ikaros family, consisting of Ikaros (IKZF1), Aiolos (IKZF3), Helios (IKZF2), Eos 
(IKZF4) and Pegasus (IKZF5) - are zinc finger nuclear proteins that play critical role in 
T and B cell development and differentiation. These proteins are essential for the 
normal development of lymphocytes and also function as tumour suppressor genes 
(Clevers, Oosterwegel et al. 1993; Georgopoulos, Bigby et al. 1994; Molnar and 
Georgopoulos 1994).  
The comparison of the ChIP - on- chip and microarray gene expression 
identified IKZF1 and IKZF3 as two possible target genes for Egr2 and their role in 
preventing lymphoid tumour development. Inspection of the microarray data 
revealed that the mRNA expression of IKZF1 and IKZF3 was reduced in CD2-Egr2-/- 
CD4+ T cells compared to wild type. Under unstimulated (homeostatic conditions) 
there was a 1.5 fold and 3 fold decreases in IKZF1 and IKZF3, respectively. After 
stimulation a 2 fold and a significant 11 fold reduction was seen in IKZF1 and IKZF3, 
respectively (Figure 3.34). 
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Figure 3.34: mRNA expression of IKZF1 and IKZF3 in CD2-Egr2-/- CD4+ T cells. 
(A) Microarray normalised expression of Ikzf1 and Ikzf3 in splenic CD4+ T cells isolated from the CD2- Egr2-/- and wild type mice. (B) Relative expression 
measured by Real-Time PCR in splenic CD4+ T cells isolated from the Egr2-/-Egr3-/- and wild type mice. Standard error bars indicate SEM.  ** p< 0.01, 
NS - Not Significant. 
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A lot of evidence has reported that a defect in IKZF1 and IKZF3 expression in 
lymphocytes leads to lymphomas. Winandy and Colleagues found that the loss of Ikaros 
activity at the late stages of thymocyte maturation leads to uncontrolled 
lymphoproliferation and rapid development of malignant T cell leukaemia and lymphoma 
(Winandy, Wu et al. 1995). More surprisingly the phenotype of the Ikaros heterozygous mice 
was similar to that found in the Egr2-/-Egr3-/- mice, with a lymphadenopathy and 
splenomegaly (Winandy, Wu et al. 1995). The same group also studied the Aiolos gene and 
found that in a similar fashion to Ikaros in T cells, lack of Aiolos in B cells leads to 
uncontrolled proliferation, causes the breakdown of B cell tolerance and facilitates the 
development of B cell malignancies (Wang, Avitahl et al. 1998).  
Here at mRNA gene expression level we have also shown a reduced level of IKZF1 and 
IKZF3 in the Egr2-/-Egr3-/- mice model and that there is protein-DNA interaction, which we 
further validated by ChIP assay. Below is a graph of the enriched regions for the IKZF1 locus 
and possible binding sites for Egr2 (analysed by Dr Alistair Symonds). This was further 
validated by ChIP, which demonstrated that Egr2 directly interacts with the IKZF1 promoters 
(Figure 3.35). 
At protein level we found that the Ikaros protein was significantly defective in our 
Egr2-/-Egr3-/- CD4+ T cells. From the western blot there is a significant reduction of Ikaros 
after stimulation but not in the unstimulated cells (Figure 3.36 B and C). However, when the 
Ikaros was studied by immunohistochemistry we found that the Ikaros was also reduced 
significantly in the CD4+ unstimulated T cells (Figure 3.36A). 
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Figure 3.35: Graph of MAT scores and enriched regions for the IKZF1 locus. 
(A) Data were exported into bedGraph format using the rtracklayer package (Lawrence et al., 2009) 
and imported into the UCSC Genome Browser. “Egr2 - Input” is the difference in MAT score between 
the Egr2 and Input samples and was used to calculate enriched regions (p<0.01). (B) Binding of Egr2 
to the IKZF1 promoters. Total input DNA and anti-H3 precipitates served as positive controls and 
anti-Ig precipitates as negative control. Standard error bars indicate SEM.  ***p<0.001 as compared 
to IgG. 
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Figure 3.36: Lack of Egr2 Reduced the Protein Expression of Ikaros. 
(A) Reduced Ikaros expression in Egr2-/-Egr3-/- unstimulated CD4+ T cells. (B) Western Blot analysis of 
Ikaros protein expression in WT and Egr2-/-Egr3-/- CD4+ T cells.  Ikaros is significantly reduced in Egr2-/-
Egr3-/- after stimulation. (C) Protein Density measured from the western blot. 
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Aiolos protein expression was also studied in both B and T cells and as expected 
there was no major difference in the protein expression in Egr2-/-Egr3-/- CD4+ T cells but a 
significant reduction in CD19+ B cells. Interestingly when the expression of Aiolos was 
measured in Egr2 Transgenic mice (TG), which has an over expression of Egr2 protein, there 
was a significant increase in the AIolos expression (Figure 3.37). These results are in line with 
the Georgopoulos group, who also reported that a defect in Ikaros results in T cell 
malignancies and defects in Aiolos results in the B cell malignancies  (Maxwell, Li et al. 2009; 
Zha, Bassing et al. 2010). 
 
                   
Figure 3.37: Aiolos Protein Expression. 
Aiolos protein expression was measure in WT, Egr2-/-Egr3-/- and Egr2 TG B and T cells by flow 
cytometry. A significant reduction in Aiolos protein observed in Egr2-/-Egr3-/- B cells but not in T cells.  
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3.4.4.2 Egr2 regulates the expression of FOXO3 in lymphocytes 
The Forkhead box, class O (FOXO) family are transcription factors that function as 
tumour suppressors that control cell fate, induce quiescence or cell cycle arrest (Fu and 
Tindall 2008). Four subfamily members have been identified in mammals, FOXO1, FOXO3 
(previously known as FKHRL1; (Anderson, Viars et al. 1998)), FOXO4 and FOXO6. 
FOXO3 is the prime member of the FOXO family in lymphoid peripheral tissues. The 
inactivation of FOXO3 is required for the lymphocytes to proliferation, this has been shown 
in both B and T cells (Stahl, Dijkers et al. 2002; Yusuf, Zhu et al. 2004). It has also been shown 
that the constitutively inactive form of FOXO3 also leads to leukaemia and lymphomas 
(Obrador-Hevia, Serra-Sitjar et al. 2012). 
FOXO3 was identified as one of the targets for Egr2 from the ChIP-on-chip and 
microarray gene expression profile. The normalised expression was validated by Real-Time 
RT-PCR and confirmed a significant reduced expression of FOXO3 in Egr2-/-Egr3-/- CD4+ T cells 
compared to wild type. For unstimulated CD4+ T cells both the microarray and Real Time RT-
PCR showed a 3 fold reduced expression in CD2-Egr2-/-. The microarray normalised 
expression for stimulated cells demonstrated a 4 fold reduction in FOXO3 gene expression 
however when validated by Real Time RT-PCR there was only a 2 fold reduction in gene 
expression, which statistically was not significantly different due to a p value of 0.06 (Figure 
3.38). 
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Figure 3.38: mRNA expression of FOXO3 in CD2-Egr2-/- CD4+ T cells. 
(A) Microarray normalised expression of Ikzf1 and Ikzf3 in splenic CD4+ T cells isolated from the CD2- 
Egr2-/- and wild type mice. (B) Relative expression measured by Real-Time PCR in splenic CD4+ T cells 
isolated from the Egr2-/-Egr3-/- and wild type mice. Standard error bars indicate SEM. ** p< 0.01, 
NS - Not Significant. 
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To assess whether Egr2 proteins associates with the proximal regions of the 
mouse FOXO3 promoter (analysed by Dr Alistair Symonds) , a ChIP assay was 
performed. The results demonstrated that Egr2 binds to the promoter region of 
FOXO3 and as expected, no signal above background was seen with irrelevant IgG 
(Figure 3.39).  At protein level no difference in FOXO3 expression was seen in 
unstimulated CD4+ T cells from both wild type and Egr2-/-Egr3-/-. However a 
significant 4 fold difference was seen in both the immunohistochemistry staining 
and western blot for stimulated Egr2-/-Egr3-/- CD4+ T cells (Figure 3.40). 
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Figure 3.39: Graph of MAT scores and enriched regions for the FOXO3 locus. 
(A) Data were exported into bedGraph format using the rtracklayer package (Lawrence et 
al., 2009) and imported into the UCSC Genome Browser. “Egr2 - Input” is the difference in 
MAT score between the Egr2 and Input samples and was used to calculate enriched regions 
(p<0.01). (B) Binding of Egr2 to the FOXO3 promoters. Total input DNA and anti-H3 
precipitates served as positive controls and anti-Ig precipitates as negative control. 
Standard error bars indicate SEM. **p<0.01 as compared to IgG. 
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Figure 3.40: Lack of Egr2 Reduced the Protein Expression of FOXO3. 
(A) Reduced FOXO3 protein expression in Egr2-/-Egr3-/- after stimulation. (B) Western Blot 
analysis of FOXO3 protein expression in WT and Egr2-/-Egr3-/- CD4+ T cells.  FOXO3 is 
significantly reduced in Egr2-/-Egr3-/- after stimulation. (C) Protein Density measured from 
the western blot. 
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The study of Egr family in the immune system is still in its young ages. Egr2 
and Egr3 transcription factors are members of the Egr family and have been 
demonstrated to be involved in a number of different processes. To investigate the 
role of Egr2 and Egr3 in lymphocytes we developed Egr2 and Egr3 double knockout 
mice, where Egr2 was specifically deleted in lymphocytes with the aid of CD2 
promoter.   
In this study, we have discovered that Egr2 and Egr3 have major regulatory 
functions in lymphocytes and the deficiency of these genes in B and T cells results in 
the development of spontaneous lymphomas. The novel findings of this thesis have 
been categorised into two sections. 
 Firstly, deficiency in Egr2 and Egr3 in B and T cells results in lymphoma 
development. We demonstrated that the lymphocytes from the Egr2-/-Egr3-/- mice 
were hyper-proliferative in all lymphoid tissues and also invade all major organs. 
Egr2 transcription factor was found to interact with the promoters of Ikaros and 
FOXO3 tumour suppressor genes, all of which are crucial for lymphocyte 
development, as well as controlling lymphocyte proliferation and homeostasis. We 
also demonstrated that the absence of Egr2 and Egr3 genes impaired the 
expression of Ikaros, FOXO3 and Aiolos. Taken together, these observations clearly 
demonstrate that Egr2 and Egr3 are essential regulators of Ikaros, Aiolos and 
FOXO3 tumour suppressor genes. 
Secondly, deficiency in Egr2 and Egr3 genes in the lymphocytes resulted in 
inflammatory autoimmune disease. There was an overproduction of inflammatory 
cytokines by the lymphocytes in Egr2-/-Egr3-/- mice, which we found was associated 
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with hyper-activation of STAT3. We found that Egr2 and Egr3 play an important role 
in the control of inflammatory cytokine signalling under homeostatic conditions by 
directly regulating the expression of SOCS3, which is an essential regulator of 
STAT3. 
 
4.1 Defective Egr2 and Egr3 lymphocytes lead to rapid 
development of lymphoma. 
Egr2 and Egr3 deficiency in lymphocytes lead to spontaneous lymphoma, 
bearing the immunophenotype of either T or B cells. The hyper-homeostatic lymph-
proliferation in Egr2-/-Egr3-/- mice and the accumulation of active lymphocytes led 
to the development of spontaneous lymphoma in mice as young as 5 months old. 
Interestingly, spontaneous lymphoma development was also seen in the CD2-Egr2-/- 
mice models, but at a much later age. Importantly, no tumours were observed in 
aged match wild type mice or Egr3-/- mice. These observations demonstrate that 
Egr3 compensates for the functions of Egr2 in its absence, hence the late onset of 
lymphoma development. This is a novel finding, as to date no reports have been 
published on linking Egr2 and Egr3 knockout mice with the development of 
lymphoma.  
The hyper-homeostatic proliferation of lymphocytes in Egr2-/-Egr3-/- mice 
initiates spontaneous lymphoproliferation, which manifests as splenomegaly and 
lymphadenopathy at an early age. This may be due to an accumulation of active 
lymphocytes in the periphery caused by the increased production of cytokines.  
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Notably, several models that have perturbed lymphocyte cell homeostasis 
also develop an onset of chronic inflammation and lymphoma (Ohashi 2002; 
Suarez, Lortholary et al. 2006; Zhang, Wang et al. 2007) as observed in 
Egr2-/-Egr3-/- mice model.  
Similar to our model, Hagenbeek and Spits (2008) developed T cell specific 
PTEN deficient mice, using either proximal Lck promoter (Lck-Cre mice) or CD4 
promoter (CD4-Cre mice). They found that both PTEN Lck-Cre deficient and PTEN 
CD4-Cre deficient mice developed T cell lymphomageneis in the thymus, as early as 
1 month of age, much earlier than what we observe in the Egr2-/-Egr3-/- mice. 
However these mice had a much shorter lifespan of 3 months in comparison to 
Egr2-/-Egr3-/- mice which survived to 4-8 months in age. Similar to the Egr2-/-Egr3-/- 
mice, the T cells from PTEN T cell deficient mice reflected a constitutive state of 
activation and infiltration of lymphocytes into non lymphoid organs (Hagenbeek 
and Spits 2008). Interaction between PTEN and Egr2 was first described in the 
hindbrain study.  Suzuki, et al., 1998 used Egr2 as a hindbrain marker in PTEN 
deficient mice embryos, where they found cephalic region was severely overgrown 
and abnormal Egr2 expression occurred on one side of the prospective forebrain. 
This indicated that Egr2 expression was regulated by PTEN (Suzuki, de la Pompa et 
al. 1998). Similarly Unoki, and Nakamura, (2003) identified Egr2 as an important 
mediator of the PTEN growth suppressor signalling pathway. They found exogenous 
expression of Egr2, with AdCAEGR2 significantly induced apoptosis in various cancer 
cell lines (Unoki and Nakamura 2003). In contrast we did not see any effect in the 
level of apoptosis in theEgr2-/-Egr3-/- mice in our model. However Unoki, M., et al., 
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2003 carried out the analysis of apoptosis only in carcinomas cell lines and not in 
lymphoma/leukaemia cell lines. PTEN expression was evaluated in our microarray 
data and we found that the normalised expression was reduced, but not 
significantly in CD2-Egr2-/- CD4+ T cells compared to wild type. 
Although a number of spontaneous lymphoma models have been proposed, 
here we have found a novel model which demonstrates aggressive spontaneous B 
or T cell lymphoma development in the absence of Egr2 and Egr3. 
As it is well known that tumourgenesis results from a multiple molecular 
events that amend the normal properties of a cell. We looked at the possible 
hallmarks of cancer formation and to our surprise we identified Egr2 and/or Egr3 
are essential for the regulation  of tumour suppressor genes; Ikaros, Aiolos and 
FOXO3, which are important for lymphoid lineage development and homeostasis.  
 
4.1.1 Ikaros family in haematological malignancies 
 We found Egr2 regulates the expression of Ikaros protein, which is a zinc 
finger transcription factor encoded by the IKZF1 gene. The Ikaros gene was 
discovered 20 years ago and is part of the Ikaros family, which also consists of 
Helios, Aiolos, Eos and Pegasus. Ikaros and Aiolos are highly conserved and are 
expressed in the lymphoid tissues (Molnar and Georgopoulos 1994; John, Yoong et 
al. 2009). Aiolos was identified as a homologue to the largest Ikaros isoform with 
similarities in the DNA binding activation and dimerisation domains. Aiolos forms 
homo and heterodimers with Ikaros proteins in T and B cells (Rebollo and Schmitt 
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2003). Ikaros was first identified in 1990s by Georgopoulos’ team, they proposed it 
as a master regulator of haematopoiesis and found it to be essential for lymphocyte 
development (Georgopoulos, Moore et al. 1992). The importance of Ikaros as a 
tumour suppressor in murine T cell leukaemia has been known for about 20 years 
and more recently the Ikaros inactivation in human T-ALL is becoming clearer.  
 The role of Ikaros in lymphoid development was illustrated by the complete 
lack of lymphoid cells following gene inactivation by targeted deletion of exons 3-5, 
which generate dominant negative Ikaros isoform in mice. Mice homozygous to the 
mutation fail to prosper after birth and completely lack T and B cells and their 
earlier progenitors (Georgopoulos, Bigby et al. 1994; Nichogiannopoulou, Trevisan 
et al. 1999). In contrast, mice heterozygous for this mutation have a normal 
lymphoid cell distribution after birth but after a few months the activity at the late 
stage of thymocyte maturation leads to uncontrolled lymphoproliferation and rapid 
development of malignant T cell leukaemia and lymphoma, with the lymphocytes 
being highly activated (Winandy, Wu et al. 1995), as seen in the Egr2-/-Egr3-/- mice. 
Interestingly, the phenotype of the heterozygous mutant of Ikaros mice was very 
similar to our model. They also demonstrated splenomegaly and lymphadenopathy 
in their Ikaros heterozygous mice, with 10-fold increase in the number of 
splenocytes and circulating lymphocytes in the peripheral blood, supporting the 
increase in absolute T and B cells in secondary lymphoid organs found in 
Egr2-/-Egr3-/- mice. Increase in the white pulp and decrease in the red pulp areas of 
the spleen was consistently observed in their Ikaros heterozygous mice, in align 
with the structure of our spleen and destruction of the follicular structure of the 
                                                                                                              Chapter 4 –Discussion 
 
186 
 
lymph nodes due to the hyper-proliferation of the lymphocytes (Winandy, Wu et al. 
1995). They observed a general lymphoproliferative lead to T cell leukaemia and 
lymphoma.  
In contrast, in human disease, Ikaros mutations are rare in T cell leukaemia. 
One group studied the Ikaros mRNA and protein expression in 25 human T-ALL 
samples and found only one sample harboured non-functional Ikaros (Davis 2011). 
In contrast to the findings in mice, deregulation of Ikaros function in humans is far 
more common in primary B progenitor ALL (B-ALL). Notably, dominant negative 
isoforms of Ikaros proteins are present in about a quarter of high-risk paediatric B-
ALL cases (Mullighan, Su et al. 2009). Ikaros mutations are also associated with a 
poor prognosis in terms of overall survival and frequency of relapse, most of which 
was studied in paediatric B-ALL but has also shown true for adult B-ALL (Kuiper, 
Waanders et al. 2010; Dupuis, Gaub et al. 2013). 
Ikaros has been shown to regulate expression of multiple genes that are 
essential for T cell differentiation. One of the pathways that are essential for T cell 
development is the Notch pathway. Activation of the Notch-1 gene has been found 
in over 50% of T-cell ALL (Weng, Ferrando et al. 2004; Chiaramonte, Basile et al. 
2005). Synergism between the loss of Ikaros and the Notch activation in T cell 
leukemogenesis has been demonstrated by Beverly and Capobianco (Kleinmann, 
Geimer Le Lay et al. 2008). Ikaros directly bind to the upstream regulatory element 
of a Notch target gene Hes-1 and down regulates its expression. High expression of 
HES-1 is found in T-cell ALL cells (Chiaramonte, Basile et al. 2005; Kleinmann, 
Geimer Le Lay et al. 2008).  
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Ma et al, have demonstrated that Aiolos and Ikaros suppress c-Myc 
expression in pre-B cells, by directly binding to its promoter in vivo. c-Myc as well as 
cyclin D3 is crucial for the expansion of pre-B cells, which are driven by signals from 
the IL-7 receptor. The downregulation of c-Myc by Ikaros and Aiolos precedes p27 
induction and cyclin D3 suppression (Ma, Pathak et al. 2010). However in our 
model, we did not find any difference in the normalised expression of p27 and 
c-Myc. 
Along with Ikaros, Aiolos has also been shown to act as a tumour suppressor 
gene. The inactivation of the Aiolos gene in knockout mice produced an increase in 
B cell precursors and spontaneous production of autoantibodies, hence causing the 
breakdown of B cell tolerance and facilitating the development of B cell lymphoma 
(Wang, Avitahl et al. 1998). In the Aiolos null mice the marginal zone B cells were 
severely deleted, hence the enhanced maturation of the follicular B cells. In 
addition, those mice that were heterozygous for null mutation in Ikaros and 
homozygous for a null mutation in Aiolos developed T cell lymphomas more rapidly 
than mice with a homozygous knockout of Ikaros (Rebollo and Schmitt 2003). This 
also supports the interaction of Aiolos and Ikaros, together function to inhibit pre-
B-BCR signalling, as the loss of these two genes results in continued or even 
increased signalling (Thompson, Cobb et al. 2007). 
Elevated expression of Bcl-xL (part of the Bcl-2 family) has also been 
associated with the loss of Ikaros function. It is suggested that Ikaros downregulates 
Bcl-xL expression (Yagi, Hibi et al. 2002; Kano, Morimoto et al. 2008), hypothesising 
that Ikaros regulated apoptosis. However this hypothesis still remains speculative 
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due to lack of evidence to define the mechanism of this action. Bcl-xL normalised 
gene expression was not effected in our Egr2 deficient mice. 
The observations of all the studies and analysis in both mouse and human 
lymphomas have always concluded Ikaros and Aiolos as tumour suppressor genes. 
The findings in this study have identified Egr2 and Egr3 to regulate the mRNA and 
protein expression of Ikaros and Aiolos in lymphocytes, supporting the hypothesis 
of Egr2 and/or Egr3 functioning as a tumour suppressor genes. 
 
4.1.2 FOXO3 in haematological malignancies 
FOXO3 is a transcription factor that is crucial for the haematopoietic cell 
fate and controls proliferation and apoptosis, amongst other processes. FOXO3 is 
the predominant member of the FOXO family in lymphoid peripheral tissues (Lin, 
Hron et al. 2004). The deactivation of FOXO3 is associated with proliferation of B 
cells (Yusuf, Zhu et al. 2004) and T cells (Stahl, Dijkers et al. 2002).  
A study looked at the key FOXO genes, in particular FOXO3 in a panel of MCL 
cell lines and primary MCL cultures. The analysis of the MCL cell lines and patient 
derived cells found the phosphorylated form of FOXO3 in the cytoplasm, 
representing that the FOXO3 was in the inactive state. (Obrador-Hevia, Serra-Sitjar 
et al. 2012). A similar expression of phosphorylated and cytoplasmic FOXO3 was 
also reported in acute myeloid leukaemia (Kornblau, Singh et al. 2010). The 
phosphorylation of FOXO3 causes the recruitment of 14-3-3 proteins; microarray 
expression of CD4+ T cells in Egr2-/-Egr3-/- mice and the validation of mRNA 
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expression by Real-Time PCR confirmed the significant reduction of 14-3-3. 
However, it is unknown if the 14-3-3 protein is reduced due to the downregulation 
of FOXO3 protein or vice versa. 
Interestingly, one group studied the role of FOXO3 in lymphoid homeostasis. 
They derived mice deficient in FOXO3a by generating animals bearing a disabled 
FOXO3 allele. They observed that the FOXO3a deficiency leads to spontaneous 
lymphoproliferation, which was also associated with inflammation of several key 
organs. Immunohistochemical examination revealed a mixed infiltration of CD4+ 
and B220+ cells, suggesting a lymphoid infiltration (Lin, Hron et al. 2004). Similarly 
we also found chronic inflammation in the Egr2-/-Egr3-/- mice and hyper activated T 
and B cells. Surprisingly, same as the lymphocyte phenotype in our model, they also 
observed that the T cells were highly activated, but they did not observe any 
autoantibody production.  
Tsai group have demonstrated that FOXO3a DNA-damage pathway is 
mediated by protein complexes such as ATM and its downstream mediators to 
sense DNA damage and control damage induced cell cycle checkpoints and DNA 
repair (Tsai, Chung et al. 2008). This is in align with our results which show a 
reduction in FOXO3 expression and  significant downregulation of ATM mRNA in 
CD4+ T cells.  
Collectively, the observations on FOXO3 function as a tumour suppressor 
gene, by inducing apoptosis and inhibiting proliferation in lymphocytes, supports 
the findings of Egr2 regulating the expression of FOXO3. However the exact 
mechanism of action is still unknown. 
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4.1.3 Egr2 and Egr3 essential for the control of homeostatic 
proliferation 
Notably, several models that have disturbed T cell homeostasis also develop 
late onset of inflammation disease (Salvador, Hollander et al. 2002; Doyle, Gee et 
al. 2003; Arias, Ballesteros-Tato et al. 2007). Deficiency in both Egr2 and Egr3 in 
lymphocytes resulted in chronic inflammatory disease. The Egr2-/-Egr3-/- mice 
developed symptoms similar to those seen in systemic lupus erythematosus, with 
lymphocyte infiltration in multiple organs, severe glomerulonephritis, and deposits 
of immune complexes in the glomeruli. Egr2 and Egr3 deficient B and T cells 
induced excessive production of inflammatory cytokines, despite the impaired 
production of IL-2 (data not shown). The transfer of either naïve B or CD4+ T cells 
from Egr2-/-Egr3-/- mice into Rag2-/- mice resulted in the development of 
inflammation in recipient mice and importantly an increase in hyper-homeostatic 
proliferation was observed. These observations validate that Egr2 and Egr3 function 
via cell-intrinsic mechanisms to regulate inflammatory autoimmune response and 
homeostasis of lymphocytes.  
In our Egr2-/-Egr3-/- mice model the lymphocytes resulted in hyper-
homeostatic proliferation, coinciding with the splenomegaly and super-enlarged 
lymph nodes. Previously in our CD2-Egr2-/- mice no effect was seen on the 
development of the major thymocyte subsets, regulatory T cells, and major sub-
groups of peripheral T and B cells. This was due to the incomplete excision of the 
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floxed Egr2 gene in the B cells from specific Egr2-/- mice affected by the 
heterozygous phenotype of Cre-transgene (Zhu, Symonds et al. 2008).  
Egr2 and Egr3 are induced in both naïve and tolerant T cells (Harris, Bishop 
et al. 2004; Anderson, Manzo et al. 2006). The B and T cells from Egr2-/-Egr3-/- mice 
were hyper-proliferative, with hyper-activated phenotypes and produced excessive 
levels of proinflammatory cytokines.  
 
4.1.4 Egr2 and Egr3 essential for the control of inflammation 
and cytokine microenvironment 
The over-production of inflammatory cytokines by B and T cells in 
Egr2-/-Egr3-/- mice is allied with the hyper activation of STAT3, the major 
inflammatory cytokine pathway controlling the development of Th17 cells and 
expression of inflammatory cytokines. This indicates that Egr2 and 3 play vital roles 
in the control of inflammatory cytokine signalling under homeostatic conditions. 
Several key effector cytokines were altered in the serum of Egr2-/-Egr3-/- 
mice, compared to wild type mice, such as IL-6 and IL-3. We also found increased 
expression of the anti-inflammatory cytokine IL-10 in our mice model. Although IL-
10 is an anti-inflammatory cytokine, IL-10 has been implicated as having a 
pathogenic role in lupus (Moore, de Waal Malefyt et al. 2001). 
Interestingly, we detected high levels of IL-17 producing CD4+ T cells in 
diseased Egr2 and Egr3 mice, in which half of them also produced IFNγ. Hence we 
put forward that Th17 play major roles in inflammatory pathology of diseased 
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Egr2-/-Egr3-/- mice. Li, et al, 2012 have demonstrated that Egr2 and 3 directly 
regulate SOCS3 expression and deficiency in Egr2 and 3 results in reduced 
expression of SOCS3 (Li, Miao et al. 2012). SOCS3 is a critical regulator for the 
control of STAT3 mediated cytokine expression and differentiation of Th17 cells 
(Yang, Panopoulos et al. 2007; Tamiya, Kashiwagi et al. 2011). 
In unstimulated cells, STATs are inactive and typically the SOCS genes are 
not expressed. Upon binding of cytokines, receptor aggregation occurs and the 
STATs are activated by phosphorylation, which allows their dimerisation and 
translocation to the nucleus, where they stimulate the transcription of cytokines 
responsive genes, as well as those that encode for SOCS proteins. The SOCS 
proteins bind to Janus Kinase (JAK) or cytokine receptors, thereby suppressing 
further signalling events (Alexander 2002).  
SOCS3 is a major negative feedback regulator of STAT3 activating cytokines. 
SOCS3 is crucial for the control of Th17 differentiation by desensitising STAT3 to 
activating cytokines, such as IL-23, thus governing the expression of Th17 cytokines 
(Chen, Laurence et al. 2006; Tanaka, Ichiyama et al. 2008). Therefore the absence of 
SOCS3 has a dramatic proinflammatory effects by promoting TH17 development. 
However, T cell specific SOCS3 defect showed a reduced immune response, and 
produced significant levels of transforming growth factor (TGF)-β1 and IL-10, but 
less of IL-4, hence inhibiting Th1 and Th2 development (Kinjyo, Inoue et al. 2006; 
Taleb, Romain et al. 2009; Yoshimura, Suzuki et al. 2012). Deficiency of SOCS3 
specifically in lymphoid and myeloid cells results in the development of 
inflammatory diseases (Chong, Metcalf et al. 2005; O'Sullivan, Liongue et al. 2007). 
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These findings put forward that inflammatory pathology, which normally 
results from pathological functions of Th17 cytokines, is controlled by SOCS3. We 
have now established that SOCS3 are expressed in B and T cells in response to 
antigen receptor stimulation. The excessive production of Th17 cytokines and 
activation of STAT3 in Egr2 and 3 deficient B and T cells propose that regulation of 
SOCS3 expression by Egr2 and 3 is vital, not only for averting the development of 
autoimmune diseases, but similarly for preventing immunopathology during 
productive adaptive immune responses.  
STAT3 has been implicated in tumourgenesis in both mice and humans. 
STAT3 is considered as a powerful oncogene, as it plays an important role in cell 
growth and its activation has been described in nearly 70% of haematological and 
solid tumours  (Frank 1999). Studies have found STAT3 to be constitutively 
activated in human cutaneous T cell lymphoma and diffuse large B cell lymphoma 
(Sommer, Clemmensen et al. 2004; Ding, Yu et al. 2008; Wu, Song et al. 2011). 
STAT3 is an important downstream target of  IL-6. It has been demonstrated that 
the Il-6 mediated T cell survival is impaired in T cell specific STAT3 deficient mice 
(Takeda, Kaisho et al. 1998). In the Egr2-/-Egr3-/- model, we also demonstrated, in 
vivo, an increase in IL-6 expression as well as an increased STAT3 expression, 
coinciding with the findings of Takeda K. et al., 1998. 
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4.2 Conclusion 
Our work has confirmed a role for Egr2 and/or Egr3 in the control of 
inflammation and lymphocyte homeostasis. The study revealed hitherto unknown 
roles of Egr2 and/or Egr3 in regulating the expression of tumour suppressor genes, 
Ikaros, Aiolos and FOXO3, controlling the formation of lymphoma. 
Based on our findings presented here, I have proposed two possible 
pathways for the development of lymphoma in defective Egr2 and Egr3 mice. 
Firstly, the defect of Egr2 and 3 results in the downregulation of important tumour 
suppressor genes, Ikaros and Aiolos, as well as of FOXO3. Secondly, the chronic 
inflammation in the mice provides the microenvironment for the tumour growth by 
activating STAT3 oncogenes (Shacter and Weitzman 2002; Rakoff-Nahoum 2006). 
Defects in Ikaros and Aiolos may suppress the target genes involved in cell 
proliferation; however we have not studied any of the Ikaros or Aiolos target genes 
in our model. FOXO3 is known to aid DNA repair by interacting with ATM. Defects in 
these tumour suppressor genes allow the cells to proliferate rapidly and 
continuously, without crucial controls in place. In parallel, Egr2 and/or Egr3 are 
unable to control oncogene STAT3, by unable to bind to their suppressors SOCS3, 
hence activating their target genes, such as CDC25B. This leads to lymphoma 
development. The inflammation caused by Egr2 and 3 defect increases the 
cytokines, in the microenvironment, hence increasing the availability of growth 
factors for the tumours to expand. This has been illustrated in Figure 4.1. 
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Figure 4.1: Proposed role of Egr2 and/Egr3 in preventing lymphoma development. 
This figure demonstrates that the absence of Egr2 and Egr3 in lymphocytes is unable to 
activate the expression of Ikaros, Aiolos and FOXO3 genes, which results in the 
dysregulations of the tumour suppressor functions of these genes. Similarly Egr2 and Egr3 
are unable to bind to and activate the expression of SOCS3 gene, which is important for 
inhibiting the STAT3 oncogene. This results in the activation of oncogene function. Both the 
evasion of growth suppressors and activation of oncogenes are key hallmarks of cancer 
development. 
 
To summarise our model Egr2 and Egr3 act as tumour suppressor genes. 
They retard proliferation and prevent tumourgenesis by positively regulating other 
transcription factors and inhibiting oncogenes. Currently there has already been 
research on possible STAT3 inhibitors for cancer therapy. The novelty of the 
findings in this thesis provides new insights of cancer therapy. Here we put forward 
that Egr2 and Egr3 can be investigated as potential cancer therapy targets. 
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4.3 Future Work 
The ultimate aim of tumour suppressor genes is to repress the effect of cell 
cycle or promote apoptosis, which can be performed in a number of ways, such as 
by repressing gene that are essential for promoting cell growth or by coupling the 
cell cycle DNA damage. We have shown that Egr2 and/or Egr3 act as a tumour 
suppressor gene by regulating the expression of other transcription factors; Ikaros, 
Aiolos and FOXO3. The absence of Egr2 and/or Egr3 results in a defect expression of 
these genes, which may result in lymphoma development.  
To date the exact mechanism and key target genes of Ikaros, Aiolos and 
FOXO3 is still not clear. It is therefore important in future development to identify 
the exact pathway/mechanism of how these transcription factors function with the 
presence of Egr family proteins and what target genes are activated or suppressed 
to prevent lymphoma development.  
Proposal of using ChIP-sequencing to systemically investigate all possible 
genes involved in tumour development in relation to Egr2 function. 
Many lymphomas are a result of chromosome deletions. These deletions are 
thought to contain the tumour suppressor genes within the lost region. However, 
most loss of function mutations that occur in the tumour suppressor genes are 
recessive mutations hence both of the cells tumour suppressor genes must be 
mutated or lost (‘two-hit’ theory) for cancer to progress. Here in this study 
chromosome deletion has not been investigated, which should be considered for 
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further investigation to support the function of Egr2 and or Egr3 as tumour 
suppressor genes. 
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Appendix 
Genotype 
Age 
(Months) 
Gender CD3 B220 Metastasis 
Egr2-/- 12+ Female + - NO 
Egr2-/- 12+ Female + - NO 
Egr2-/- 12+ Female - + NO 
Egr2-/- 8 Female + - YES 
Egr2-/- 8 Female + - YES 
Egr2-/- 10 Male  + YES 
Egr2-/- 8 Female + - YES 
Egr2-/- 12 Female - + YES 
Egr2-/-Egr3-/+ 7 Female - + YES 
Egr2-/- 12+ Female - + YES 
Egr2-/-Egr3-/- 5 Male - + YES 
Egr2-/-Egr3-/+ 6 Female - + YES 
Egr2-/-Egr3-/+ 6 Male - + YES 
Egr2-/-Egr3-/- 4 Female - + YES 
Egr2-/- 12 Female - + YES 
Egr2-/-Egr3-/- 5 Female + - YES 
Egr2-/-Egr3-/+ 5 Female + - YES 
Table A.1 Summary of tumour development in Egr2-/-Egr3-/- mice models 
Note: around 80% of the tumours were characterised as small cell lymphoma.* 
